Low energy immune stimulation for treating cancer and metastasis

Low-energy focused ultrasound therapy induces immunogenic responses in tumors, overcoming immune evasion and enhancing treatment efficacy by stimulating an immune response and sensitizing cancer cells, thus improving control of primary tumors and metastases.

JP2024160237APending Publication Date: 2024-11-13MONTEFIORE MEDICAL CENT INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024114274
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-12-08
Filing Date
2024-07-17
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Traditional cancer treatments like surgery, chemotherapy, and radiation may not sufficiently suppress cancer, and immunotherapy can be less effective due to tumor microenvironments that evade immune response, while existing ultrasound methods may disrupt the tumor microenvironment and reduce immune system effectiveness.

Method used

A low-energy, non-ablative focused ultrasound (LOFU) therapy that induces mild mechanical and thermal stress in tumors, increasing heat shock protein expression and immunogenic responses, combined with other treatments to stimulate an immune response against cancer.

Benefits of technology

LOFU reverses tumor-induced tolerance, enhances cytokine production in CD4+ T cells, and synergizes with immunotherapy and radiation to control primary tumors and metastases, sensitizing cancer cells to chemotherapy and improving treatment outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160237000001_ABST
    Figure 2024160237000001_ABST
Patent Text Reader

Abstract

To provide systems, devices, and methods for treating cancer and metastasis by using low energy immune stimulation.SOLUTION: Low energy immune stimulation includes administering immune stimulation energy. The low energy immune stimulation can be combined with an adjunct therapy.SELECTED DRAWING: Figure 25
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] <CROSS REFERENCE TO RELATED APPLICATIONS> This application claims the benefit of U.S. Provisional Patent Application No. 62 / 584,064, filed November 9, 2017, and U.S. Provisional Patent Application No. 62 / 596,715, filed December 8, 2017, which are incorporated herein by reference. The subject matter of this application is related to PCT / US2016 / 035440, the entire disclosure of which is incorporated herein by reference.

[0002] <Statement on government support> This invention was made with Government support under RO1EB009040 awarded by the National Institute of Biotechnology and Biotechnology (NIBIB). The Government has certain rights in this invention. [Background technology]

[0003] Cancer is a disease in which genetically mutated cells grow uncontrollably, drain nutrients, and destroy the function of healthy tissues. Conventional cancer treatments, such as surgery, chemotherapy, and radiation, can eradicate cancer cells and the tumors in which they reside, but may not be useful in fully suppressing cancer. The use of immunotherapy has been proposed, which engages cells of the immune system to seek out and eliminate cancer cells, but this approach may, at least in some instances, produce less-than-ideal results. For example, tumors may generate microenvironments that are privileged sites that can evade immunotherapy. Furthermore, the presentation of antigens by cancer cells may be less-than-ideal in at least some respects.

[0004] Ultrasound has been proposed in combination with other therapies for the treatment of cancer, but the previous ultrasound methods and devices may be less than ideal in at least some respects.For example, high intensity focused ultrasound may take longer than ideal to treat tumors, and instantaneously destroys tumor microenvironment by a process called coagulation necrosis, thereby preventing immune cell infiltration in tumors and taking up and presenting tumor-associated antigens (TAA).Therefore, it would be useful to be able to use other types of auxiliary sub-ablative energy to treat cancer.

[0005] In light of the above, there is a need for improved methods and devices for treating cancer. Ideally, the methods and devices will generate an immune response against the cancer such that the patient's immune system generates an in situ vaccine to treat the cancer. The methods and devices can be configured to treat cancer with a sub-ablative dose of energy to generate an immunogenic response when combined with other therapies. Summary of the Invention

[0006] In some embodiments, an acoustic stimulation therapy system is disclosed herein, the system comprising: a processor; and one or more ultrasound transducers coupled to the processor, the ultrasound transducers configured to generate a frequency waveform of the one or more ultrasound beams in the range of 10 to 900 W / cm. 2 The spatial peak time-averaged acoustic power intensity (I spta ) and at least 0.5 cm 3 and a probe coupled to the processor, the probe configured to monitor a patient. In some embodiments, the processor and the ultrasound transducer are configured to generate one or more ultrasound beams having a beam volume of at least about 0.5 cm per second. 3In some embodiments, the scanning speed is about 0.5 cm per second of the total volume of tissue being scanned. 3 ~about 50cm 3 In some embodiments, the entire volume of tissue is scanned. In some embodiments, the total volume of tissue is at least about 2 cm. 3 In some embodiments, the total volume of tissue is about 0.5 cm 3 ~About 1000cm 3 In some embodiments, the total volume of tissue is within the range of about 1 cm 3 ~about 500cm 3 In some embodiments, the total volume of tissue is within the range of about 1 cm 3 ~about 250cm 3 In some embodiments, the intensity is in the range of about 20 W / cm 2 ~about 500W / cm 2In some embodiments, the processor is configured with instructions for overlapping the multiple locations. In some embodiments, the processor is configured with instructions for moving the ultrasonic transducer from a first location corresponding to a first volumetric region to a second location corresponding to a second volumetric region while the ultrasonic transducer transmits the ultrasonic beam. In some embodiments, the system further includes a linkage coupled to the one or more ultrasonic transducers, the processor is coupled to the linkage and configured with instructions for moving the one or more ultrasonic transducers to the multiple locations. In some embodiments, the linkage comprises a robotic arm including multiple joints, each of the multiple joints coupled to an actuator for controlling an angle of the joint, and the processor is configured with instructions for determining multiple angles of the multiple joints to direct the ultrasonic beam to the multiple locations. In some embodiments, the robotic arm comprises multiple fingers, each of the multiple fingers coupled to a transducer mounted thereon, each of the multiple fingers configured to control an angle of a transducer of the ultrasonic beam from the transducer mounted on the finger to direct the ultrasonic beam to the target location. In some embodiments, the processor is configured to control an orientation of the ultrasound transducer at each of a plurality of positions to align the ultrasound transducer with a surface of the patient's skin at each of the plurality of positions. In some embodiments, the processor is configured to control an orientation of the ultrasound transducer at each of a plurality of positions to align the ultrasound transducer with a surface of the patient's skin at each of the plurality of positions, optionally where each of the plurality of positions corresponds to a three-dimensional position and a three-dimensional orientation to position the transducer in six degrees of freedom.In some embodiments, the system further includes a user input for a user to specify an adjunctive therapy to be combined with the ultrasound treatment, wherein the processor is configured with instructions to record a treatment time of the ultrasound beam to the tissue and output a time for the adjunctive therapy, optionally the adjunctive therapy is selected from the group consisting of radiation therapy, chemotherapy, immunotherapy, irreversible electroporation (IRE), microwave therapy, low intensity focused ultrasound (LOFU), and high intensity focused ultrasound (HIFU), and optionally the output time includes a time frame for the adjunctive therapy. In some embodiments, the processor is configured with instructions to provide a user interface to the user, the user interface including an image of the patient's tumor and a location of the input treatment. In some embodiments, the processor is configured to perform tissue elastography of the entire tissue volume. In some embodiments, the processor is configured to receive a diffusion parameter as an input. In some embodiments, the probe is an imaging probe. In some embodiments, the probe is a thermometer. In some embodiments, the probe is a thermocouple. In some embodiments, the probe is a fiber optic temperature probe. In some embodiments, the processor is configured to provide a temperature readout. In some embodiments, the processor is configured to generate a temperature alarm. In some embodiments, the probe includes a separate transducer that measures ultrasound. In some embodiments, the probe uses elastography to monitor the effect of treatment on the tissue. In some embodiments, the system further comprises a cooling system. In some embodiments, the adjunctive therapy is radiation therapy. In some embodiments, the radiation therapy is sub-ablative. In some embodiments, the adjunctive therapy is IRE. In some embodiments, the IRE is administered for a period of about 30 seconds to about 180 seconds. In some embodiments, the adjunctive therapy is microwave therapy.In some embodiments, the microwave therapy is administered for a period of about 1 second to about 60 seconds and the power is about 1 W to about 10 W. In some embodiments, the adjunctive therapy is LOFU. In some embodiments, the LOFU is about 1 to 1,000 W / cm. 2 The spatial peak time-averaged acoustic power intensity (I spta In some embodiments, the LOFU has an acoustic power of about 3 W to 32 W. In some embodiments, the LOFU is administered for a period of about 0.5 seconds to about 5 seconds. In some embodiments, the adjunctive therapy is HIFU. In some embodiments, the HIFU has an acoustic power of about 1,000 to 2,000 W / cm. 2 The spatial peak time-averaged acoustic power intensity (I spta). In some embodiments, the HIFU has an acoustic power of about 1 W to 20 W. In some embodiments, the HIFU is administered for a period of about 1 second to about 10 seconds. In some embodiments, the adjunctive therapy is chemotherapy. In some embodiments, the chemotherapy comprises administering a chemotherapeutic agent. In some embodiments, the chemotherapeutic agent is a proteasome inhibitor, a PI3 kinase inhibitor, an autophagy inhibitor, an mTOT inhibitor, a PPARγ agonist, a Cox-2 inhibitor, a calcium channel inhibitor, an ER stress inducer, a CHOP modulator, a nucleoside analog, an eIF2α phosphatase inhibitor, a protein ligand, or an HSP90 inhibitor. In some embodiments, the chemotherapeutic agent is bortezomib, 3-methyladenine, polyphenol (green tea) epigallocatechin gallate, genistein, curcumin, resveratrol, 15,16-dihydrodanshen I (Tanshen root), chloroquine, rapamycin, temsirolimus, 4-O-carboxymethyl ascochlorin, celecoxib, verapamil, ritonavir, 3-thia fatty acid, tetradecylthioacetic acid, nelfinavir, cisplatin, gemcitabine, salubrinal, cycloheximide, TRAIL, 4-phenylbutyric acid, geldanamycin, 17-allyamino-17-demethoxy-geldanamycin (17AAG), 17-dimethylamino-ethylamino-17-demethoxygeldanamycin (17DMAG), or vacuolin. In some embodiments, the chemotherapeutic agent is an HSP90 inhibitor. In some embodiments, the chemotherapeutic agent is 17-allylamino-17-demethoxy-geldanamycin (17AAG). In some embodiments, the adjunctive therapy is an immunotherapy. In some embodiments, the immunotherapy is selected from the group consisting of dendritic cell targeted therapy, effector T cell targeting, and immune checkpoint inhibition.In some embodiments, the dendritic cell targeted therapy comprises a dendritic cell targeted therapy immunotherapeutic agent selected from the group consisting of Flt3L, CD40L, GM-CSF, RIG1 helicase activator, anti-CD40, NKG2D ligand, anti-CSF1R, anti-TLR, TLR ligand, INF-α, and TNF-β. In some embodiments, the effector T cell target comprises a T cell targeted immunotherapeutic agent selected from the group consisting of anti-OX40, 4-1BBL, anti-foxp40 TGF-β inhibitor, anti-CD137, artificial immune synapse for T cell activation, anti-CD47, anti-CD27, and anti-GD2. In some embodiments, the immune checkpoint inhibition comprises an immune checkpoint immunotherapeutic selected from the group consisting of anti-CTL4, anti-PD1, anti-VISTA, tim3, an IDO inhibitor, norharmane, rosmarinic acid, a COX-2 inhibitor, 1-methyltryptophan, epacadostat, and navoximod.

[0007] In some embodiments, disclosed herein are methods of treating a patient, the methods comprising: administering an immune stimulatory energy selected from the group consisting of irreversible electroporation (IRE), microwave, low intensity focused ultrasound (LOFU), high intensity focused ultrasound (HIFU), radiofrequency energy, and cryotherapy; and administering an immunotherapy selected from the group consisting of dendritic cell targeted therapy, effector T cell targeting, and immune checkpoint inhibition. In some embodiments, the dendritic cell targeted therapy comprises an immunotherapeutic agent of the dendritic cell targeted therapy selected from the group consisting of Flt3L, CD40L, GM-CSF, RIG1 helicase activator, anti-CD40, NKG2D ligand, anti-CSF1R, anti-TLR, TLR ligand, INF-α, and TNF-β. In some embodiments, the effector T cell targeting comprises a T cell targeting immunotherapeutic selected from the group consisting of anti-OX40, 4-1BBL, anti-foxp40 TGF-β inhibitor, anti-CD137, artificial immune synapse for T cell activation, anti-CD47, anti-CD27, and anti-GD2. In some embodiments, the immune checkpoint inhibition comprises an immune checkpoint immunotherapeutic selected from the group consisting of anti-CTL4, anti-PD1, anti-VISTA, tim3, IDO inhibitors, norharmane, rosmarinic acid, COX-2 inhibitors, 1-methyltryptophan, epacadostat, and naboximide.

[0008] <Incorporation by reference> All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. [Brief description of the drawings]

[0009] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments in which the principles of the invention are utilized, and the accompanying drawings in which: [Figure 1] Melanoma tumors suppress CD4+ T cell cytokine production. AB: 3x105 B16-F1 melanoma cells were administered to the lumbar flank of C57Bl / 6 mice. Tumors were allowed to grow to a size of 7-8 mm3. CD4+ T cells were isolated from tumor DLN and distal contralateral NDLN and stimulated with anti-CD3 and anti-CD28 antibodies. IL-2 and IFNγ were measured by ELISA. CD4+ T cells from tumor-free mice served as control. CD: OTII mice were administered 3x105 B16-Fl-OVA melanoma cells as described. T cells were stimulated with OVA323-339 peptide-loaded splenocytes and IL-2 and IFNγ production was measured by ELISA. EF: Tumors were induced in Tyrp1 mice with B16-F1 cells as described above. Isolated CD4+ T cells were stimulated with anti-CD3 and anti-CD28 antibodies, and IL-2 and IFNγ production was measured by ELISA. Graphs show the mean + SEM from 4 (AB) or 3 (CF) independent experiments. Results are shown as the mean + SEM from 3-5 mice per experiment. Data were analyzed using ANOVA with Tukey post-test (***P<0.01; **P<0.01; *P<0.05). [Diagram 2]Treatment of melanoma tumors with LOFU overcomes tumor-induced CD4+ T cell tolerance. AB: Tumors were induced in C57Bl / 6 mice by subcutaneous injection. 3x105 B16-F1 melanoma cells were injected into the lumbar flank. Tumors were left untreated or treated with LOFU. 36 hours after FUS treatment, CD4+ T cells were isolated from tumor DLN or NDLN and stimulated with anti-CD3 and anti-CD28 antibodies. IL-2 and IFNγ production was assessed by ELISA. Results (total cytokine production and ratio of cytokine levels produced by T cells from NDLN and DLN in each group) are presented as mean + SEM from three different mice per condition. Differences between cytokine production of DLN T cells in untreated or treated mice were analyzed using a two-tailed test (*P<0.05). C: Tumors were induced in mice by administration of 3x105 B16 melanoma cells. After tumor development, total RNA samples were extracted from CD4+ T cells isolated from DLN and NDLN of tumor-bearing and tumor-free control mice. Expression of anergy-related genes was measured by quantitative RT-PCR. Results are shown as fold induction of gene expression in resident T cells of DLN or NDLN in tumor-bearing mice compared with T cells isolated from tumor-free mice. Data represent the mean + SEM from three independent experiments. D: B16-F1 melanoma tumors were induced in Tyrp1 mice and then left untreated or treated with LOFU. Expression of various anergy-related genes was measured by RT-PCR in CD4+ T cells isolated from DLN and NDLN. Expression of anergy-related genes is expressed as fold induction (mean + SEM from five independent experiments) over values ​​obtained in T cells from tumor-free Tyrp1 mice. [Diagram 3]Lysates from LOFU-treated B16-F1 melanoma tumors can reverse the hyporesponsive state of anergic T cells. A: Naive CD4+ T cells were isolated from spleens and lymph nodes of Tyrp1 mice and differentiated into TH1 cells. Anergy was then induced by leaving the cells untreated or by treating them with anti-CD3 alone for 16 h. The cells were then rested for 72 h in the strict absence of IL-2 and restimulated with anti-CD3 and anti-CD28 antibodies. IL-2 levels were measured by ELISA. Results are shown as mean + SEM from two independent experiments. B: CD11c+ dendritic cells were isolated from the spleens of tumor-free Tyrp1 mice. Anergic TH1 cells generated from CD4+ T cells from Tyrp1 mice described in (A) were co-cultured with dendritic cells and tumor lysates from untreated or LOFU-treated B16-F1 melanoma tumors. Supernatants were collected after 24 hours and analyzed for IL-2 by ELISA. Results are shown as mean + SEM from two independent experiments with three independent sets of tumor lysates used in each experiment. Data were analyzed using analysis of variance with Tukey's test (**P<0.01). [Figure 4]FUS treatment induces changes in the expression and cellular distribution of Hsp70 and calreticulin in B16-F1 melanoma cells. A: Total DLN-resident cells from untreated and LOFU-treated B16-F1 melanoma-bearing mice were isolated and immunostained for CD11c to gate on dendritic cells. Surface expression of B7.1, B7.2, and MHCII was then assessed by flow cytometry. Appropriate isotype controls were used for each primary antibody. Representative histograms are shown. B: Representative FACS dot plots of B16 tumor cell suspensions obtained from untreated or LOFU-treated mice were stained with viability markers (live / dead Mk). Relative quantification of dead cells is reported. Boxes and arrows indicate dead cells (live / dead MK+). C: Fluorescent immunostaining of B16-F1 tumor tissue isolated from untreated or LOFU-treated mice. Tissue sections were stained with antibodies to detect calreticulin or Hsp70 and TRP1. Nuclei were stained with DAPI. Magnification 60x. D: Cells from tumors of LOFU-treated and untreated mice were stained for CD45 and for TRP1 expression. CD45-TRP1+B16 cells were then analyzed for Hsp70 expression. Representative histograms are shown. Gates and arrows indicate the populations selected for analysis. [Diagram 5]FUS treatment of melanoma tumors enhances dendritic cell-mediated stimulation of CD4+ T cells. A: CD11c+ splenic dendritic cells were purified from C57Bl / 6 mice and co-cultured with responder naive CD4+ T cells isolated from OT-II mice. B16-F1-OVA melanoma tumor lysates were prepared from untreated or LOFU-treated tumor-bearing mice and added to the respective cultures to drive dendritic cell-mediated T cell stimulation. In separate samples, exogenous OVA323-339 peptide was also added together with the tumor lysates. Supernatants were collected 24 hours later and IL-2 production was assessed by ELISA. Results are presented as mean + SEM from four independent experiments and analyzed by one-way ANOVA followed by Tukey's test (*P<0.05; ***P<0.001; ns, not significant). B: B16-F1 melanoma tumors were left untreated or treated with LOFU. Tumor DLN were isolated and depleted of T cells. DLN cells were then co-cultured with naive Tyrp1 CD4+ T cells and stimulated with B16 melanoma tumor lysates obtained from in vitro cultures. Supernatants were collected 24 h later and analyzed for IL-2 levels by ELISA. Data are presented as mean + SEM from three independent experiments. Differences between cytokine production in cultures using DLN cells from untreated or LOFU-treated mice were analyzed using two-tailed t-tests (*P<0.05). [Figure 6]LOFU inhibits constitutive STAT3 activation in human hepatocellular carcinoma cell lines. Three human HCC cell lines, HepG2, Hep3B, and Huh7, were found to have constitutive activation of STAT3, and LOFU significantly inhibited STAT3 activation in all three HCC cell lines (A). The response to LOFU in these three cell lines showed different patterns, with Hep3B responding as early as 15 min, and HepG2 and Huh7 responding at 1 h. This result further demonstrated the effect of LOFU on STAT3 deactivation and provided evidence for using LOFU in HCC in addition to prostate cancer. LOFU was shown to downregulate STAT3 activity, which is responsible for the radioresistance of many cancer cells, and therefore LOFU may serve as a radiosensitizer for cancer radiotherapy. Cancer cells were first treated with LOFU and exposed to radiation (5 Gy) 1 h later. The cells were incubated for 96 h, and the total number of cells was counted by trypan blue. In addition, a clonogenic assay was performed and the number of colonies was counted 10 days after treatment. Compared with LOFU and radiation alone, the combination of LOFU and radiation reduced the number of cells (B) and colonies (D). In addition, the addition of STAT3 inhibitor WP1066 before LOFU treatment had a superior effect on inducing cell death (C). LOFU and WP1066 showed similar effects on cell proliferation, which was consistent with the results of STAT3 inhibition by both drugs. [Figure 7]FUS followed by hypofractionated IGRT resulted in a reduction in T cell-mediated long-term primary tumor control and distant metastases. A: C57Bl / 6 mice bearing subcutaneous dorsal right hind limb tumors of 50 mm3 were separated into one of four treatment groups: untreated, LOFU, hypofractionated IGRT, or LOGU+IGRT, and tumor growth was monitored for 62 days or until primary tumors grew to >300 mm3. Graphs show mean ± SEM of tumor volumes from one of two representative experiments (3–5 mice per group). Data were analyzed by one-way ANOVA followed by Bonferroni correction (before day 29) or two-tailed Student's t test (after day 29). Significant differences (defined as P < 0.05) between untreated or LOFU-treated mice and IGRT or LOFU+IGRT occurred from day 25 onwards, and between IGRT-treated and LOFU+IGRT-treated mice from day 35 onwards. Individual graphs showing the distribution of tumor size on specific days are also shown in B. Experiments similar to those described in A were performed in BALB / c nude mice. No significant differences were observed between the different groups at any time point. C: C57Bl / 6 mice were monitored for progression / recurrence of the primary tumor, defined as either a recurrence reaching a volume of 150 mm3 or the progression of local metastases to the popliteal or inguinal lymph nodes. In addition, animals that died naturally were scored as having recurrence or progression of disease. Recurrence-free survival data were analyzed using the Mantel-Cox test. D: Lungs were collected from animals that died naturally, had a very large tumor burden necessitating euthanasia, or were sacrificed at the end of a 2-month long experiment. Lung metastases were then measured. Lungs that had coalesced into plaques or had more than 250 nodules were considered too numerous to count and were assigned a maximum value of 250. Representative specimens are shown for each treatment group. Results are presented as mean ± + SEM, n = 3-5 mice per group, and analyzed by Kruskal-Wallis test followed by Dunn's posttest. *P<0.05. [Figure 8]LOFU and RT treatment of mouse prostate and breast cancer models. Two treatments with LOFU (5W, 100%) and / or radiation (10Gy) were performed on two days with a 24-hour interval between the two treatments (A). Due to the high intensity of this LOFU treatment, a 1-day interval was allowed between the two treatments to allow the wounds to heal before the second treatment. For this tumor, a radiation dose of 10Gyx2 was able to significantly delay tumor growth without complete healing (top row of 8B). The median time for the tumor to reach 5 times its initial volume (V0) was 47 days compared to 25 days for untreated mice. The addition of LOFU before radiation therapy cured the primary tumor in about 46.4% of treated mice (top of B & left of C). The addition of LOFU resulted in some mild skin burns covering most of the tumor surface. These burns healed spontaneously within 1-2 weeks after treatment. In wild-type mice, the ability to mount an immune response against a foreign antigen, for example, human PSA in this case, did not mimic human prostate cancer, which has a low mutational burden but is full of self-antigens. PSA-Tg transgenic mice, the model that best mimics the human disease of prostate cancer, received combination therapy with LOFU and RT, showed a reduction in primary tumors of 57.1 (middle row of B & middle of C). These results indicated that combination therapy with LOFU and RT could overcome resistance to PSA or generate enough neoantigens to make resistance to PSA irrelevant. To confirm that the efficacy of LOFU and TR was mediated by T cells, the same experiment was performed in athymic nude mice. Radiation resulted in a delay in tumor growth of primary tumors, but the addition of LOFU did not provide any benefit (bottom row of B & right of C). These results indicate that T cells are required to cure primary tumors using a combination of LOFU and RT. A triple-negative breast cancer mouse model (4T1) was used to determine the efficacy of combined LOFU and RT treatment. Seven days after tumor inoculation with 2x105 cells, LOFU (5W, 50% duty cycle) and / or 20Gy radiation was administered on three consecutive days (Figure 8D).Both radiation alone and the combination of LOFU and radiation resulted in cure of the primary tumor, but the combination therapy significantly accelerated the time to cure of the primary tumor by a median time of 1 week. [Figure 9] LOFU induces UPR. A: LOFU increases the expression of Bip / Grp78 and EDEM mRNA. Real-time PCR analysis of RNA isolated from LOFU-treated Rill tumors showed a 29.73 ± 0.56-fold increase in Bip / Grp78 and a 9.27 ± 1.18-fold increase in EDEM mRNA levels compared to untreated controls. B: LOFU increases the expression of IRE1α mRNA by 2.8 ± 0.4-fold. Real-time PCR analysis shows that the increase in IRE1α expression induced by LOFU was not altered by 17AAG treatment. C: LOFU caused splicing of XBP1 mRNA. 17AAG treatment inhibits the splicing of XBP1. XBP1s, XBP1h, and XBP1u represent the spliced, hybrid, and unspliced ​​forms of XBP1, respectively. DG: LOFU+17AAG combination therapy prolongs ER stress in RM1 tumor cells. Western blot and bar graphs show that protein expression of ERP78 (D&E), ERP57 (D&F), and ERp44 (D&G) was induced in the combination therapy group. [Figure 10]LOFU+17AAG activates the pro-apoptotic pathway of UPR and induces apoptosis in tumor cells. A&B: Western blot of pPERK (A) and peIF2α (B). LOFU+17AAG activates PERK by phosphorylation of PERK (pPERK), which further induces phosphorylation of eIF2α (peIF2α). C: Real-time PCR analysis of CHOP mRNA. There was a 25±1.3-fold increase in CHOP transcripts in the LOFU+17AAG-treated group compared to the control. D: Real-time PCR array of RNA isolated from tumors treated with LOFU+17AAG. Heat map analysis showed that the LOFU+17AAG-treated group had several-fold increased transcript levels of apoptotic genes compared to the untreated control or LOFU group. E: TUNEL staining. Immunohistochemical staining showed predominantly tunel-positive cells in the LOFU+17AAG-treated group compared to the control or LOFU group. Note that 17AAG alone further induced apoptosis in tumor tissues that were augmented by LOFU. [Figure 11] LOFU+17AAG treatment inhibits chaperone-mediated autophagy (CMA) in RM1 tumor cells. (A&B) Immunoblot analysis showed several-fold downregulation of SMA marker LAMP2a expression levels in the combination therapy group. Treatment with either LOFU or 17AAG upregulates LAMP2a expression levels. (A&C) Combination treatment of LOFU and 17AAG did not alter the expression levels of beclin, a macroautophagy marker. [Figure 12]Tumor growth delay in mouse and human prostate tumors after LOFU+17AAG treatment. A: Treatment scheme. Palpable tumors were treated with LOFU every 3-4 days for five fractions administered over a 2-week period. Animals received 17AAG three times a week during this time. Tumors were harvested 24 hours after the last fraction of LOFU. B: RM1 tumors. In C57Bl6 mice, LOFU+17AAG combination therapy significantly reduced the growth of RM1 tumors compared to controls (p<0.004). Note that either LOFU or 17AAG alone failed to significantly control tumors. LOFU sensitized the effects of low doses (25 mg / kg body weight) of 17AAG. C: PC3 tumors. In BalbC nu / nu mice, LOFU+17AAG combination therapy showed a significant reduction in the growth of PC3 tumors (p<0.007). [Figure 13] LOFU+17AAG treatment reduced the expression of prostate cancer stem cell markers in RM1 cells. Flow cytometry of isolated RM1 tumor cells showed a significant decrease in cell surface expression of SCA1 (A&B), CD44 (A&C), CD133 (A&D), and α2131 integrin (A&E) on RM1 tumor cells after LOFU+17AAG treatment. (F) qRT-PCR array and subsequent heat map analysis showed that the LOFU+17AAG combination therapy group downregulated the mRNA levels of stem cell transcription factors. [Figure 14]Pretreatment with LOFU followed by treatment with HIFU induced tumor-specific T cell responses. Pretreatment with non-ablative LOFU allowed tumor cells to process misfolded proteins, and subsequent treatment with HIFU 1 day later allowed HSP-peptide complexes to be released from dead tumor cells for DC uptake and induction of T cell immunity. Palpable OVA-expressing RM1-OT tumors were treated sequentially with LOFU followed by HIFU 1 day apart, and animals were sacrificed on days 3, 7, and 14 after LOFU treatment. Meanwhile, tumor-specific T cell responses were not detected in one cycle of LOFU and HIFU treatment, but there was a modest increase in the total number of IFN-γ-producing cells (stimulated by PMA and ionomycin) on day 3 (110±5 / 2.5×105 cells LOFU and 66±16 / 2.5×105 cells HIFU vs. untreated, p<0.05, FIG. 14A), indicating that LOFU and HIFU treatment may tilt the immune response toward a Th1 phenotype. However, the number of IFN-γ-secreting cells decreased to pretreatment levels on days 7 and 14 without any statistical difference. Thus, repeated treatment of tumors with LOFU and HIFU promotes the release of HSPs and tumor antigens for periodic immunization and simulates a vaccination schedule for the induction of tumor-specific immune responses. Palpable RM1-OT tumors were treated three times with weekly cycles of consecutive LOFU and HIFU administered 1 day apart, and animals were sacrificed one week after the last HIFU treatment. The frequency of tumor-specific T cells in splenocytes was analyzed by IFN-γ ELISPOT assay to detect the cytotoxic function of these tumor-reactive T cells. When splenocytes from LOFU- and HIFU-treated mice were co-cultured with irradiated RM1-OT cells, the number of IFN-γ-secreting RM1-OT-reactive T cells increased (432 ± 65 cells per 2.5 × 105 splenocytes after LOFU + HIFU vs. 15 ± 6 cells per 2.5 × 105 splenocytes after HIFU only; Fig. 14B). The frequency of tumor-specific IFN-γ-releasing T cells in LOFU- and HIFU-treated mice was 0.17 ± 0.03%.These tumor-reactive splenocytes were found to specifically recognize both the OVA-derived MHC class I-restricted peptide, OVA257-264 (149±28 cells per 2.5×105 total splenocytes) and the MHC class II-restricted peptide, OVA323-339 (132±32 cells per 2.5×105 total splenocytes) when co-cultured with these peptides. In contrast, no significant immune response was detected in mice treated with either LOFU or HIFU alone (15±6 cells per 2.5×105 total splenocytes in both groups). These results indicate that the combined therapy of LOFU and HIFU can induce both CD4 and CD8 T cell responses against OVA, a surrogate cytoplasmic tumor antigen. HIFU treatment alone induced cell death and release of HSPs in tumor tissues but did not induce significant antitumor cell-mediated immunity. Tumor-specific cytotoxic T lymphocytes (CTLs) were assessed by CD107a recruitment assay, measuring the presence of cell surface CD107a on splenocytes after culture with irradiated RM1-OT cells. CD107a is a membrane protein of perforin / granzyme B vesicles that becomes transiently recruited to the cell surface during the cytotoxic degranulation process by CTLs. Although CTLs were present in all treatment groups, tumor-specific CD107a+ T cells were highest in mice treated with LOFU and HIFU (27.88±4.80% in LOFU and HIFU treated mice vs. 7.5±1.2% in untreated mice, p<0.05; Fig. 14C). The percentage of CD8+ T cells that were reactive to a surrogate tumor antigen (OVA) was quantified by H-2b / OVA257-264 tetramer staining (Fig. 14D). Although untreated or single treatment cohorts had negligible OVA-reactive CD8 T cells, these cells increased after LOFU and HIFU treatment (0.12% LOFU+HIFU vs. <0.01% untreated), further confirming the presence of tumor-specific T cells in vivo. Finally, to examine whether pretreatment with non-ablative LOFU increases the therapeutic effect of HIFU, the time interval between HIFU exposures was kept the same between treatment groups of tumor-bearing mice.Tumor sizes in the various groups were not significantly different after one cycle of ultrasound therapy, but growth retardation was observed after two cycles (E, lower panel). As expected, LOFU treatment alone did not change tumor growth rates compared to untreated controls (p>0.05). HIFU alone significantly inhibited tumor growth compared to LOFU and untreated cohorts (p<0.05). Pretreatment with LOFU significantly enhanced the tumoricidal effect of HIFU treatment, as shown by the relative mouse photographs (E, upper panel) (LOFU and HIFU vs. HIFU, p<0.01; LOFU and HIFU vs. LOFU or no treatment (NT), p<0.001). [Figure 15]Combined treatment of LOFU and RT enhances antitumor cytotoxic T cell immunity and immune memory in a mouse model of tumor reloading. To determine the impact of combination therapy on CD8+ T cell responses, tumor antigen-specific T cells were analyzed after treatment with PSA-specific MHC class I pentamers. PSA-specific, activated CD62L-CD8+ T cells were increased across all treatment groups, with LOFU+RT having the highest percentage of CD62L- / pentamer+CD8 T cells (1.557±0.127%) compared to the LOFU-only (0.497±0.064%) and RT-only (0.923±0.387%) groups (Figure 15A). LDH release assays, which indicate cell death, also confirmed that splenocytes from PSA transgenic mice treated with the combination therapy increased cell death in tumors (NT: 4.186±3.1%, LOFU: 5.1±4.3%, RT: 2.91±1.7%, LOFU+RT: 11.613±3.98%; Fig. 15B). To determine whether the combination of LOFU and RT resulted in immune memory, mice cured of primary tumors after LOFU+RT treatment were rechallenged with TPSA23 cells on the opposite flank and tumor growth profiles were measured up to 60 days after inoculation. Fig. 15C, D, and E show tumor growth in individual mice in each treatment group. At day 45 post-inoculation, seven of eight PSA transgenic mice showed significant growth retardation (naive: 307.6 mm3, WT: 184.8 mm3, PSA: 128.6 mm3, p=0.10), with only one mouse showing a complete lack of tumor memory. By day 56 post-inoculation, there was complete tumor growth inhibition in two of eight PSA transgenic mice (Figure 15E). The rechallenge response in WT mice (Figure 15D) was different, with only one of four mice showing tumor growth inhibition at day 43 post-inoculation and sustaining that tumor inhibition response until the end of the experiment. On day 56, WT mice cured of primary tumors by the combination of LOFU and RT had a 52% tumor growth delay and PSA transgenic mice cured of primary tumors by the combination of LOFU+RT had a 74% tumor growth delay compared to naive mice (Figure 15F), indicating immune memory generated by LOFU+RT treatment of previously cured tumors.Both groups of C57 / BL6 (WT) and PSA transgenic mice (C57 / BL6 background) cured of primary tumors showed tumor growth delay after rechallenge, but only PSA transgenic mice showed a statistically significant reduction in tumor volume compared to the naive group (p=0.0043, Mann-Whitney U test). Although there was no statistically significant difference between the rechallenge tumor volumes of wild-type rechallenged mice and naive or PSA transgenic mice, one out of four mice did not show immune memory and three out of four mice had statistically significant growth delay compared to untreated mice (p=0.04). These experiments indicate that the combination therapy of LOFU and RT not only resulted in primary tumor cure but also enhanced immune memory resulting in significant inhibition of secondary tumor growth. [Figure 16A]Augmentation of hormone-based chemotherapy by LOFU. Clonogenicity is important with respect to cancer progression, especially when considering the formation of metastases. Clonogenicity refers to the ability of a single cell to produce eight successful generations. Clonogenic assays were performed in combination with 5 μM abiraterone (AbA), an antiandrogen treatment. No significant difference in viability between LOFU alone and abiraterone alone was shown (16A). However, as shown in the representative pictures below, colonies formed under abiraterone treatment were on average smaller than those formed with LoFU treatment (16B). The combination treatment resulted in a significant decrease in viability in both TRAMPC2 and TPSA23 cell lines compared to the individual treatments. Proliferation assays of abiraterone alone or in combination with LOFU were performed on TPSA23 and its parental cell line TRAMPC2, using crystal violet signal as output of cell proliferation. Low doses of abiraterone (5 μM) significantly inhibited proliferation of both cell lines beyond 48 hours of incubation compared to no treatment (TRAMPC2: p=0.0003; TPSA23: p=0.04; unpaired two-tailed T-test). High doses of abiraterone (10 μM) eliminated the proliferation capacity of both cell lines. When LOFU was used in addition to 5 μM abiraterone, proliferation capacity was eliminated to the same extent as 10 μM abiraterone. The reduction in proliferation capacity was statistically significant between LOFU and either dose of abiraterone compared to monotherapy (p<0.005, unpaired two-tailed T-test). Apalutamide (an androgen receptor antagonist that binds LOFU) had an enhanced effect on the clonogenicity of TPSA23 tumor cells similar to abiraterone treatment. LOFU in combination with a low dose of apalutamide (5 μM) resulted in significantly fewer colonies than apalutamide or LOFU alone, with efficacy similar to that of doubling the dose of apalutamide (16D). A high dose of apalutamide (10 μM) resulted in a significant reduction in clonogenicity, but the combination was even more effective. Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G).Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). The combination of LOFU, Aba, and 17AAG had a synergistic effect on reducing the number of remaining prostate cancer cells. Letrozole and 4-hydroxytamoxifen (4-HT) both target the estrogen receptor and are used to treat breast cancer. Figure 16G involved the viability of MCF7 human breast cancer cell lines when treated alone or in combination with LOFU, letrozole, and 4-HT. Finally, the in vivo mouse model of TPSA23 was treated with two doses of LOFU (5W, 100%) over a period of 3 days. Abiraterone was given by oral gavage (0.5 mg / mouse / day) daily for 14 consecutive days. Combination therapy resulted in a significant reduction in tumor growth delay in 3 out of 5 mice and primary tumor cure in 40% (2 out of 5) of treated mice (16H). At day 45 post-inoculation, LoFU alone had a 66% tumor growth delay compared to untreated, and the combination of LOFU and abiraterone resulted in 100% tumor growth delay versus either untreated or LOFU alone. [Figure 16B]Augmentation of hormone-based chemotherapy by LOFU. Clonogenicity is important with respect to cancer progression, especially when considering the formation of metastases. Clonogenicity refers to the ability of a single cell to produce eight successful generations. Clonogenic assays were performed in combination with 5 μM abiraterone (AbA), an antiandrogen treatment. No significant difference in viability between LOFU alone and abiraterone alone was shown (16A). However, as shown in the representative pictures below, colonies formed under abiraterone treatment were on average smaller than those formed with LoFU treatment (16B). The combination treatment resulted in a significant decrease in viability in both TRAMPC2 and TPSA23 cell lines compared to the individual treatments. Proliferation assays of abiraterone alone or in combination with LOFU were performed on TPSA23 and its parental cell line TRAMPC2, using crystal violet signal as output of cell proliferation. Low doses of abiraterone (5 μM) significantly inhibited proliferation of both cell lines beyond 48 hours of incubation compared to no treatment (TRAMPC2: p=0.0003; TPSA23: p=0.04; unpaired two-tailed T-test). High doses of abiraterone (10 μM) eliminated the proliferation capacity of both cell lines. When LOFU was used in addition to 5 μM abiraterone, proliferation capacity was eliminated to the same extent as 10 μM abiraterone. The reduction in proliferation capacity was statistically significant between LOFU and either dose of abiraterone compared to monotherapy (p<0.005, unpaired two-tailed T-test). Apalutamide (an androgen receptor antagonist that binds LOFU) had an enhanced effect on the clonogenicity of TPSA23 tumor cells similar to abiraterone treatment. LOFU in combination with a low dose of apalutamide (5 μM) resulted in significantly fewer colonies than apalutamide or LOFU alone, with efficacy similar to that of doubling the dose of apalutamide (16D). A high dose of apalutamide (10 μM) resulted in a significant reduction in clonogenicity, but the combination was even more effective. Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G).Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). The combination of LOFU, Aba, and 17AAG had a synergistic effect on reducing the number of remaining prostate cancer cells. Letrozole and 4-hydroxytamoxifen (4-HT) both target the estrogen receptor and are used to treat breast cancer. Figure 16G involved the viability of MCF7 human breast cancer cell lines when treated alone or in combination with LOFU, letrozole, and 4-HT. Finally, the in vivo mouse model of TPSA23 was treated with two doses of LOFU (5W, 100%) over a period of 3 days. Abiraterone was given by oral gavage (0.5 mg / mouse / day) daily for 14 consecutive days. Combination therapy resulted in a significant reduction in tumor growth delay in 3 out of 5 mice and primary tumor cure in 40% (2 out of 5) of treated mice (16H). At day 45 post-inoculation, LoFU alone had a 66% tumor growth delay compared to untreated, and the combination of LOFU and abiraterone resulted in 100% tumor growth delay versus either untreated or LOFU alone. [Figure 16C]Augmentation of hormone-based chemotherapy by LOFU. Clonogenicity is important with respect to cancer progression, especially when considering the formation of metastases. Clonogenicity refers to the ability of a single cell to produce eight successful generations. Clonogenic assays were performed in combination with 5 μM abiraterone (AbA), an antiandrogen treatment. No significant difference in viability between LOFU alone and abiraterone alone was shown (16A). However, as shown in the representative pictures below, colonies formed under abiraterone treatment were on average smaller than those formed with LoFU treatment (16B). The combination treatment resulted in a significant decrease in viability in both TRAMPC2 and TPSA23 cell lines compared to the individual treatments. Proliferation assays of abiraterone alone or in combination with LOFU were performed on TPSA23 and its parental cell line TRAMPC2, using crystal violet signal as output of cell proliferation. Low doses of abiraterone (5 μM) significantly inhibited proliferation of both cell lines beyond 48 hours of incubation compared to no treatment (TRAMPC2: p=0.0003; TPSA23: p=0.04; unpaired two-tailed T-test). High doses of abiraterone (10 μM) eliminated the proliferation capacity of both cell lines. When LOFU was used in addition to 5 μM abiraterone, proliferation capacity was eliminated to the same extent as 10 μM abiraterone. The reduction in proliferation capacity was statistically significant between LOFU and either dose of abiraterone compared to monotherapy (p<0.005, unpaired two-tailed T-test). Apalutamide (an androgen receptor antagonist that binds LOFU) had an enhanced effect on the clonogenicity of TPSA23 tumor cells similar to abiraterone treatment. LOFU in combination with a low dose of apalutamide (5 μM) resulted in significantly fewer colonies than apalutamide or LOFU alone, with efficacy similar to that of doubling the dose of apalutamide (16D). A high dose of apalutamide (10 μM) resulted in a significant reduction in clonogenicity, but the combination was even more effective. Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G).Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). The combination of LOFU, Aba, and 17AAG had a synergistic effect on reducing the number of remaining prostate cancer cells. Letrozole and 4-hydroxytamoxifen (4-HT) both target the estrogen receptor and are used to treat breast cancer. Figure 16G involved the viability of MCF7 human breast cancer cell lines when treated alone or in combination with LOFU, letrozole, and 4-HT. Finally, the in vivo mouse model of TPSA23 was treated with two doses of LOFU (5W, 100%) over a period of 3 days. Abiraterone was given by oral gavage (0.5 mg / mouse / day) daily for 14 consecutive days. Combination therapy resulted in a significant reduction in tumor growth delay in 3 out of 5 mice and primary tumor cure in 40% (2 out of 5) of treated mice (16H). At day 45 post-inoculation, LoFU alone had a 66% tumor growth delay compared to untreated, and the combination of LOFU and abiraterone resulted in 100% tumor growth delay versus either untreated or LOFU alone. [Figure 16D]Augmentation of hormone-based chemotherapy by LOFU. Clonogenicity is important with respect to cancer progression, especially when considering the formation of metastases. Clonogenicity refers to the ability of a single cell to produce eight successful generations. Clonogenic assays were performed in combination with 5 μM abiraterone (AbA), an antiandrogen treatment. No significant difference in viability between LOFU alone and abiraterone alone was shown (16A). However, as shown in the representative pictures below, colonies formed under abiraterone treatment were on average smaller than those formed with LoFU treatment (16B). The combination treatment resulted in a significant decrease in viability in both TRAMPC2 and TPSA23 cell lines compared to the individual treatments. Proliferation assays of abiraterone alone or in combination with LOFU were performed on TPSA23 and its parental cell line TRAMPC2, using crystal violet signal as output of cell proliferation. Low doses of abiraterone (5 μM) significantly inhibited proliferation of both cell lines beyond 48 hours of incubation compared to no treatment (TRAMPC2: p=0.0003; TPSA23: p=0.04; unpaired two-tailed T-test). High doses of abiraterone (10 μM) eliminated the proliferation capacity of both cell lines. When LOFU was used in addition to 5 μM abiraterone, proliferation capacity was eliminated to the same extent as 10 μM abiraterone. The reduction in proliferation capacity was statistically significant between LOFU and either dose of abiraterone compared to monotherapy (p<0.005, unpaired two-tailed T-test). Apalutamide (an androgen receptor antagonist that binds LOFU) had an enhanced effect on the clonogenicity of TPSA23 tumor cells similar to abiraterone treatment. LOFU in combination with a low dose of apalutamide (5 μM) resulted in significantly fewer colonies than apalutamide or LOFU alone, with efficacy similar to that of doubling the dose of apalutamide (16D). A high dose of apalutamide (10 μM) resulted in a significant reduction in clonogenicity, but the combination was even more effective. Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G).Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). The combination of LOFU, Aba, and 17AAG had a synergistic effect on reducing the number of remaining prostate cancer cells. Letrozole and 4-hydroxytamoxifen (4-HT) both target the estrogen receptor and are used to treat breast cancer. Figure 16G involved the viability of MCF7 human breast cancer cell lines when treated alone or in combination with LOFU, letrozole, and 4-HT. Finally, the in vivo mouse model of TPSA23 was treated with two doses of LOFU (5W, 100%) over a period of 3 days. Abiraterone was given by oral gavage (0.5 mg / mouse / day) daily for 14 consecutive days. Combination therapy resulted in a significant reduction in tumor growth delay in 3 out of 5 mice and primary tumor cure in 40% (2 out of 5) of treated mice (16H). At day 45 post-inoculation, LoFU alone had a 66% tumor growth delay compared to untreated, and the combination of LOFU and abiraterone resulted in 100% tumor growth delay versus either untreated or LOFU alone. [Figure 16E]Augmentation of hormone-based chemotherapy by LOFU. Clonogenicity is important with respect to cancer progression, especially when considering the formation of metastases. Clonogenicity refers to the ability of a single cell to produce eight successful generations. Clonogenic assays were performed in combination with 5 μM abiraterone (AbA), an antiandrogen treatment. No significant difference in viability between LOFU alone and abiraterone alone was shown (16A). However, as shown in the representative pictures below, colonies formed under abiraterone treatment were on average smaller than those formed with LoFU treatment (16B). The combination treatment resulted in a significant decrease in viability in both TRAMPC2 and TPSA23 cell lines compared to the individual treatments. Proliferation assays of abiraterone alone or in combination with LOFU were performed on TPSA23 and its parental cell line TRAMPC2, using crystal violet signal as output of cell proliferation. Low doses of abiraterone (5 μM) significantly inhibited proliferation of both cell lines beyond 48 hours of incubation compared to no treatment (TRAMPC2: p=0.0003; TPSA23: p=0.04; unpaired two-tailed T-test). High doses of abiraterone (10 μM) eliminated the proliferation capacity of both cell lines. When LOFU was used in addition to 5 μM abiraterone, proliferation capacity was eliminated to the same extent as 10 μM abiraterone. The reduction in proliferation capacity was statistically significant between LOFU and either dose of abiraterone compared to monotherapy (p<0.005, unpaired two-tailed T-test). Apalutamide (an androgen receptor antagonist that binds LOFU) had an enhanced effect on the clonogenicity of TPSA23 tumor cells similar to abiraterone treatment. LOFU in combination with a low dose of apalutamide (5 μM) resulted in significantly fewer colonies than apalutamide or LOFU alone, with efficacy similar to that of doubling the dose of apalutamide (16D). A high dose of apalutamide (10 μM) resulted in a significant reduction in clonogenicity, but the combination was even more effective. Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G).Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). The combination of LOFU, Aba, and 17AAG had a synergistic effect on reducing the number of remaining prostate cancer cells. Letrozole and 4-hydroxytamoxifen (4-HT) both target the estrogen receptor and are used to treat breast cancer. Figure 16G involved the viability of MCF7 human breast cancer cell lines when treated alone or in combination with LOFU, letrozole, and 4-HT. Finally, the in vivo mouse model of TPSA23 was treated with two doses of LOFU (5W, 100%) over a period of 3 days. Abiraterone was given by oral gavage (0.5 mg / mouse / day) daily for 14 consecutive days. Combination therapy resulted in a significant reduction in tumor growth delay in 3 out of 5 mice and primary tumor cure in 40% (2 out of 5) of treated mice (16H). At day 45 post-inoculation, LoFU alone had a 66% tumor growth delay compared to untreated, and the combination of LOFU and abiraterone resulted in 100% tumor growth delay versus either untreated or LOFU alone. [Figure 16F]Augmentation of hormone-based chemotherapy by LOFU. Clonogenicity is important with respect to cancer progression, especially when considering the formation of metastases. Clonogenicity refers to the ability of a single cell to produce eight successful generations. Clonogenic assays were performed in combination with 5 μM abiraterone (AbA), an antiandrogen treatment. No significant difference in viability between LOFU alone and abiraterone alone was shown (16A). However, as shown in the representative pictures below, colonies formed under abiraterone treatment were on average smaller than those formed with LoFU treatment (16B). The combination treatment resulted in a significant decrease in viability in both TRAMPC2 and TPSA23 cell lines compared to the individual treatments. Proliferation assays of abiraterone alone or in combination with LOFU were performed on TPSA23 and its parental cell line TRAMPC2, using crystal violet signal as output of cell proliferation. Low doses of abiraterone (5 μM) significantly inhibited proliferation of both cell lines beyond 48 hours of incubation compared to no treatment (TRAMPC2: p=0.0003; TPSA23: p=0.04; unpaired two-tailed T-test). High doses of abiraterone (10 μM) eliminated the proliferation capacity of both cell lines. When LOFU was used in addition to 5 μM abiraterone, proliferation capacity was eliminated to the same extent as 10 μM abiraterone. The reduction in proliferation capacity was statistically significant between LOFU and either dose of abiraterone compared to monotherapy (p<0.005, unpaired two-tailed T-test). Apalutamide (an androgen receptor antagonist that binds LOFU) had an enhanced effect on the clonogenicity of TPSA23 tumor cells similar to abiraterone treatment. LOFU in combination with a low dose of apalutamide (5 μM) resulted in significantly fewer colonies than apalutamide or LOFU alone, with efficacy similar to that of doubling the dose of apalutamide (16D). A high dose of apalutamide (10 μM) resulted in a significant reduction in clonogenicity, but the combination was even more effective. Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G).Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). The combination of LOFU, Aba, and 17AAG had a synergistic effect on reducing the number of remaining prostate cancer cells. Letrozole and 4-hydroxytamoxifen (4-HT) both target the estrogen receptor and are used to treat breast cancer. Figure 16G involved the viability of MCF7 human breast cancer cell lines when treated alone or in combination with LOFU, letrozole, and 4-HT. Finally, the in vivo mouse model of TPSA23 was treated with two doses of LOFU (5W, 100%) over a period of 3 days. Abiraterone was given by oral gavage (0.5 mg / mouse / day) daily for 14 consecutive days. Combination therapy resulted in a significant reduction in tumor growth delay in 3 out of 5 mice and primary tumor cure in 40% (2 out of 5) of treated mice (16H). At day 45 post-inoculation, LoFU alone had a 66% tumor growth delay compared to untreated, and the combination of LOFU and abiraterone resulted in 100% tumor growth delay versus either untreated or LOFU alone. [Figure 16G]Augmentation of hormone-based chemotherapy by LOFU. Clonogenicity is important with respect to cancer progression, especially when considering the formation of metastases. Clonogenicity refers to the ability of a single cell to produce eight successful generations. Clonogenic assays were performed in combination with 5 μM abiraterone (AbA), an antiandrogen treatment. No significant difference in viability between LOFU alone and abiraterone alone was shown (16A). However, as shown in the representative pictures below, colonies formed under abiraterone treatment were on average smaller than those formed with LoFU treatment (16B). The combination treatment resulted in a significant decrease in viability in both TRAMPC2 and TPSA23 cell lines compared to the individual treatments. Proliferation assays of abiraterone alone or in combination with LOFU were performed on TPSA23 and its parental cell line TRAMPC2, using crystal violet signal as output of cell proliferation. Low doses of abiraterone (5 μM) significantly inhibited proliferation of both cell lines beyond 48 hours of incubation compared to no treatment (TRAMPC2: p=0.0003; TPSA23: p=0.04; unpaired two-tailed T-test). High doses of abiraterone (10 μM) eliminated the proliferation capacity of both cell lines. When LOFU was used in addition to 5 μM abiraterone, proliferation capacity was eliminated to the same extent as 10 μM abiraterone. The reduction in proliferation capacity was statistically significant between LOFU and either dose of abiraterone compared to monotherapy (p<0.005, unpaired two-tailed T-test). Apalutamide (an androgen receptor antagonist that binds LOFU) had an enhanced effect on the clonogenicity of TPSA23 tumor cells similar to abiraterone treatment. LOFU in combination with a low dose of apalutamide (5 μM) resulted in significantly fewer colonies than apalutamide or LOFU alone, with efficacy similar to that of doubling the dose of apalutamide (16D). A high dose of apalutamide (10 μM) resulted in a significant reduction in clonogenicity, but the combination was even more effective. Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G).Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). The combination of LOFU, Aba, and 17AAG had a synergistic effect on reducing the number of remaining prostate cancer cells. Letrozole and 4-hydroxytamoxifen (4-HT) both target the estrogen receptor and are used to treat breast cancer. Figure 16G involved the viability of MCF7 human breast cancer cell lines when treated alone or in combination with LOFU, letrozole, and 4-HT. Finally, the in vivo mouse model of TPSA23 was treated with two doses of LOFU (5W, 100%) over a period of 3 days. Abiraterone was given by oral gavage (0.5 mg / mouse / day) daily for 14 consecutive days. Combination therapy resulted in a significant reduction in tumor growth delay in 3 out of 5 mice and primary tumor cure in 40% (2 out of 5) of treated mice (16H). At day 45 post-inoculation, LoFU alone had a 66% tumor growth delay compared to untreated, and the combination of LOFU and abiraterone resulted in 100% tumor growth delay versus either untreated or LOFU alone. [Figure 16H]Augmentation of hormone-based chemotherapy by LOFU. Clonogenicity is important with respect to cancer progression, especially when considering the formation of metastases. Clonogenicity refers to the ability of a single cell to produce eight successful generations. Clonogenic assays were performed in combination with 5 μM abiraterone (AbA), an antiandrogen treatment. No significant difference in viability between LOFU alone and abiraterone alone was shown (16A). However, as shown in the representative pictures below, colonies formed under abiraterone treatment were on average smaller than those formed with LoFU treatment (16B). The combination treatment resulted in a significant decrease in viability in both TRAMPC2 and TPSA23 cell lines compared to the individual treatments. Proliferation assays of abiraterone alone or in combination with LOFU were performed on TPSA23 and its parental cell line TRAMPC2, using crystal violet signal as output of cell proliferation. Low doses of abiraterone (5 μM) significantly inhibited proliferation of both cell lines beyond 48 hours of incubation compared to no treatment (TRAMPC2: p=0.0003; TPSA23: p=0.04; unpaired two-tailed T-test). High doses of abiraterone (10 μM) eliminated the proliferation capacity of both cell lines. When LOFU was used in addition to 5 μM abiraterone, proliferation capacity was eliminated to the same extent as 10 μM abiraterone. The reduction in proliferation capacity was statistically significant between LOFU and either dose of abiraterone compared to monotherapy (p<0.005, unpaired two-tailed T-test). Apalutamide (an androgen receptor antagonist that binds LOFU) had an enhanced effect on the clonogenicity of TPSA23 tumor cells similar to abiraterone treatment. LOFU in combination with a low dose of apalutamide (5 μM) resulted in significantly fewer colonies than apalutamide or LOFU alone, with efficacy similar to that of doubling the dose of apalutamide (16D). A high dose of apalutamide (10 μM) resulted in a significant reduction in clonogenicity, but the combination was even more effective. Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G).Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). Similar results were observed in mouse prostate cancer (16E-16F) and human breast cancer cell lines (16G). The combination of LOFU, Aba, and 17AAG had a synergistic effect on reducing the number of remaining prostate cancer cells. Letrozole and 4-hydroxytamoxifen (4-HT) both target the estrogen receptor and are used to treat breast cancer. Figure 16G involved the viability of MCF7 human breast cancer cell lines when treated alone or in combination with LOFU, letrozole, and 4-HT. Finally, the in vivo mouse model of TPSA23 was treated with two doses of LOFU (5W, 100%) over a period of 3 days. Abiraterone was given by oral gavage (0.5 mg / mouse / day) daily for 14 consecutive days. Combination therapy resulted in a significant reduction in tumor growth delay in 3 out of 5 mice and primary tumor cure in 40% (2 out of 5) of treated mice (16H). At day 45 post-inoculation, LoFU alone had a 66% tumor growth delay compared to untreated, and the combination of LOFU and abiraterone resulted in 100% tumor growth delay versus either untreated or LOFU alone. [Figure 17] FIG. 1 is a block diagram of an APT device according to some embodiments of the present invention. [Figure 18] FIG. 1 is a block diagram of an APT device according to some embodiments of the present invention. [Figure 19] FIG. 1 is a block diagram of an APT device according to some embodiments of the present invention. [Figure 20] FIG. 1 is a block diagram of an APT device according to some embodiments of the present invention including an integrated ultrasound imaging device. [Figure 21] FIG. 1 is a block diagram of an APT device according to some embodiments of the present invention including an integrated ultrasound imaging device. [Figure 22] FIG. 1 is a block diagram of an APT device according to some embodiments of the present invention including an integrated ultrasound imaging device. [Figure 23]1 is a perspective view of a transducer according to some embodiments of the present invention. [Figure 24] 1 illustrates a positioning device according to some embodiments of the present invention. [Diagram 25] 1 illustrates an ultrasound transducer mounted on a robotic arm according to some embodiments. [Figure 26] 1 illustrates a graphical user interface representing a CT segmentation (image), according to some embodiments. [Figure 27] FIG. 2 illustrates a block diagram of a hardware architecture according to some embodiments. [Figure 28] FIG. 1 illustrates a block diagram of a software architecture treatment plan, according to some embodiments. [Figure 29] FIG. 1 illustrates a block diagram of a software architecture action execution according to some embodiments. [Diagram 30] 1 illustrates translational motion of a robot and a procedure, according to some embodiments. [Diagram 31] 1 illustrates a multi-beam treatment head that increases the dosage of a focal zone relative to surrounding tissue, according to some embodiments. [Diagram 32] 1 illustrates an exemplary digital processing device, according to some embodiments. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] Described herein are ultrasound (US) therapies that deliver reduced levels of energy to treatment zones compared to configurations of high intensity focused ultrasound (HIFU), e.g., adjunctive ablation levels. Ultrasound can easily penetrate into and throughout tumors, localize with millimeter precision, and provide external operator control of toxicity. In some instances, US may be utilized as an imaging method. Such characteristics can be compared to other energy-based modalities, e.g., RF ablation and electroporation, which do not offer imaging capabilities. Furthermore, advantageously, US does not include the inherent toxicity of ionizing radiation, which typically includes a lifetime maximum tolerated dose (MTD) that limits the total dose. In other instances, the toxicity of US can be tuned by varying the intensity and duration between non-toxic imaging and the ablative toxicity of HIFU. These treatments may utilize ultrasound treatment parameters and regimens that function in part through protein denaturation, disruption of ER processes in cancer cells, and the resulting production and display of immunogenic DAMPs on cancer cells and within the tumor microenvironment.

[0011] In a typical embodiment, treatment of a specific lesion volume is at a constant power of 1 MHz for a short period (e.g., 1.5 seconds), raising the temperature of the tumor tissue to less than about 45°C. This ultrasound treatment, generated using a concave transducer to focus the ultrasound at the treatment zone and referred to herein as "low-energy non-ablative focused ultrasound" (LOFU), generates mild mechanical and thermal stress in tumor cells but avoids tissue-damaging cavitation and coagulation necrosis. A non-ablative "sonic" stress response is induced in tumors, increasing the expression of heat shock proteins without actually killing them. LOFU has the potential to release immune modulators, including heat shock proteins, and can be effective in inducing tumor-specific immune activation. Using a murine B16 melanoma tumor model, it is disclosed that LOFU treatment reverses tumor-induced resistance and increases effector cytokine production in tumor antigen-specific CD4+ T cells, which appears to be caused by the release of immunogenic molecules by tumor cells. Furthermore, the combination of LOFU with ablative hypofractionated cone-beam computed tomography (CT) image-guided radiation therapy (IGRT) results in synergistic control of primary tumors, as well as a reduction in spontaneous lung metastases and prolonged recurrence-free survival in immunocompetent mice. In addition, LOFU has been shown to sensitize cancer cells (prostate cancer in the example) to chemotherapeutic agents.

[0012] In some embodiments, the tumor-focused energy can be combined with bioactive agents including immune cell growth factors and agents that target the PD-1 axis, CSF-1R, Tie2, and STING pathways. In some embodiments, the energy can be combined with chemotherapy known to generate immunogenic patterns within a typical tumor microenvironment (TME). In some embodiments, the energy can be combined with bioactive molecules that reduce physical barriers in tumors, including cell-free protein network density.

[0013] In an exemplary embodiment, the LOFU (also referred to herein as "acoustic stimulation therapy") is between 10 and 1000 W / cm in the treatment zone. 2 The spatial peak time-averaged intensity (I spta ), the ultrasound is administered continuously for a time period ranging from 0.5 to 5 seconds, the frequency is in the range of 0.01 to 10 MHz, and the mechanical index is less than 4. The mechanical index (MI) is the rarefaction pressure in MPa over the square root of the central frequency in MHz. The energy and intensity of the administered ultrasound are intended to lie between those ultrasound energies and intensities that cause either a primarily ablative effect or a primarily diagnostic effect.

[0014] As explained in more detail below, the various treatment methods discussed herein provide a radiation intensity of 10-1000 W / cm2 at the treatment zone. 2 The spatial peak time-averaged intensity (I spta The ultrasound may be administered using a LOFU or acoustic stimulation therapy device including a transducer that produces an acoustic power of 100 W / cm2. The ultrasound is administered continuously for a time ranging from 0.5 to 5 seconds or pulsed with a pulse width of 1 to 100 milliseconds and at a frequency ranging from 0.01 to 10 MHz. In some embodiments, the frequency ranges from 0.05 to 5 MHz. In some embodiments, the frequency ranges from 0.1 to 2 MHz. In some embodiments, the minimum diameter of any ultrasound beam at the treatment zone is about 1 cm. In one embodiment, the LOFU is administered at the area of ​​treatment with a power of 10 to 100 W / cm2. 2 I spta In one embodiment, the LOFU is administered at 100-200 W / cm in the area of ​​treatment. 2 I spta In one embodiment, the LOFU is 200-300 W / cm2 in the area of ​​treatment. 2 I spta In one embodiment, the LOFU is 300-400 W / cm2 in the area of ​​treatment. 2 I spta In one embodiment, the LOFU is 400-500 W / cm2 in the area of ​​treatment.2 I spta In one embodiment, the LOFU is 500-600 W / cm2 in the area of ​​treatment. 2 I spta In one embodiment, the LOFU is 600-700 W / cm2 in the area of ​​treatment. 2 I spta In one embodiment, the LOFU is 700-800 W / cm2 in the area of ​​treatment. 2 I spta In one embodiment, the LOFU is 800-900 W / cm2 in the area of ​​treatment. 2 I spta In one embodiment, the LOFU is 900-1000 W / cm2 in the area of ​​treatment. 2 I spta In one embodiment, the ultrasound is administered for a time ranging from 0.5 to 1 seconds. In one embodiment, the ultrasound is administered for a time ranging from 1 to 2 seconds. In one embodiment, the ultrasound is administered for a time ranging from 2 to 3 seconds. In one embodiment, the ultrasound is administered for a time ranging from 3 to 4 seconds. In one embodiment, the ultrasound is administered for a time ranging from 4 to 5 seconds. In one embodiment, the ultrasound is administered at a frequency of 0.01 to 1 MHz. In one embodiment, the ultrasound is administered at a frequency of 1 to 2 MHz. In one embodiment, the ultrasound is administered at a frequency of 2 to 3 MHz. In one embodiment, the ultrasound is administered at a frequency of 3 to 4 MHz. In one embodiment, the ultrasound is administered at a frequency of 4 to 5 MHz. In one embodiment, the ultrasound is administered at a frequency of 5 to 6 MHz. In one embodiment, the ultrasound is administered at a frequency of 6 to 7 MHz. In one embodiment, the ultrasound is administered at a frequency of 7 to 8 MHz. In one embodiment, the ultrasound is administered at a frequency of 8 to 9 MHz. In one embodiment, the ultrasound is administered at a frequency of 9 to 10 MHz. In one embodiment, the ultrasound is administered at a frequency greater than 10 MHz.

[0015] A method for enhancing the efficacy of chemotherapy in a subject is provided, the method comprising administering to the subject (i) an amount of low intensity focused ultrasound (LOFU) and (ii) an amount of a chemotherapeutic agent, wherein the chemotherapeutic agent induces endoplasmic reticulum (ER) stress and / or unfolded protein response (UPR) in tumor cells, wherein the amounts of (i) and (ii) are sufficient to enhance the efficacy of the chemotherapy.

[0016] Further provided is a method of increasing the effectiveness of chemotherapy in a predetermined volume of tissue of a subject that is smaller than the entire subject, the method comprising the steps of (i) administering to the subject an amount of a chemotherapeutic agent, wherein the chemotherapeutic agent induces endoplasmic reticulum (ER) stress and / or unfolded protein response (UPR) in tumor cells, and (ii) administering an amount of low intensity focused ultrasound (LOFU) to the predetermined volume of tissue of the subject, wherein both amounts (i) and (ii) are sufficient to increase the effectiveness of chemotherapy in the predetermined volume of tissue.

[0017] A method is provided for treating a tumor in a subject that is resistant to a chemotherapeutic agent, the method comprising: receiving an identification of the subject as having a tumor that is resistant to a specified chemotherapeutic agent; and administering (i) an amount of low intensity focused ultrasound (LOFU) and (ii) an amount of the specified chemotherapeutic agent, where both amounts (i) and (ii) are sufficient to treat the tumor.

[0018] Further provided is a method of treating a chemotherapy-resistant tumor in a subject, the tumor having become chemotherapy-resistant to a previously administered chemotherapy agent, the method comprising administering to the subject: (i) an amount of low intensity focused ultrasound (LOFU) and (ii) an amount of a chemotherapy agent, wherein both amounts (i) and (ii) are sufficient to treat the chemotherapy-resistant tumor.

[0019] In an embodiment of the method, the chemotherapeutic agent induces endoplasmic reticulum (ER) stress and / or unfolded protein response (UPR) in the tumor cells.

[0020] In an embodiment of the method, a chemotherapeutic agent has previously been administered to the subject multiple times, where the tumor was diagnosed as resistant to the chemotherapeutic agent after the first administration of the chemotherapeutic agent.

[0021] In embodiments of the methods relating to chemoresistance, the methods may further include receiving an identification of the subject as having a tumor that is chemoresistant to a previously administered chemotherapeutic agent.

[0022] In an embodiment of the method, the chemotherapeutic agent triggers the UPR in the tumor cells.

[0023] In an embodiment of the method, the chemotherapeutic agent induces ER stress in the tumor cells.

[0024] In an embodiment of the method, the amounts of (i) and (ii) together are sufficient to induce or increase apoptosis of the tumor cell.

[0025] In an embodiment of the method, the amount of chemotherapeutic agent alone administered is a sub-therapeutic dose for treatment of the tumor, without an increase in efficacy.

[0026] In an embodiment of the method, the administered LOFU is directed to the location of the tumor in the subject.

[0027] In method embodiments, low intensity focused ultrasound (LOFU) is administered to the subject prior to or simultaneously with chemotherapy or radiation therapy or immunotherapy. In method embodiments, LOFU is administered to the subject prior to radiation therapy being administered. In method embodiments, LOFU is administered to the subject prior to chemotherapy being administered. In method embodiments, LOFU is administered to the subject prior to immunotherapy being administered. In method embodiments, LOFU is administered to the subject simultaneously with radiation therapy being administered. In method embodiments, LOFU is administered to the subject simultaneously with chemotherapy being administered. In method embodiments, LOFU is administered to the subject simultaneously with immunotherapy being administered.

[0028] In an embodiment of the method, the chemotherapeutic agent is an HSP90 inhibitor. In one embodiment, the HSP90 inhibitor is 17AAG (tanespimycin or 17-N-allylamino-17-demethoxygeldanamycinan). In one embodiment, the chemotherapeutic agent is an HSP90 inhibitor. An example of an HSP90 inhibitor is 17AAG (tanespimycin or 17-N-allylamino-17-demethoxygeldanamycinan). In one embodiment, the chemotherapeutic agent is an alkylating agent. In one embodiment, the chemotherapeutic agent is trabectedin. In one embodiment, the chemotherapeutic agent is a mustard gas derivative. In one embodiment, the chemotherapeutic agent is a metal salt. In one embodiment, the chemotherapeutic agent is a plant alkaloid. In one embodiment, the chemotherapeutic agent is an antitumor antibiotic. In one embodiment, the chemotherapeutic agent is an antimetabolite. In one embodiment, the chemotherapeutic agent is a topoisomerase inhibitor. In one embodiment, the chemotherapeutic agent is a proteasome inhibitor. In one embodiment, the chemotherapeutic agent is a chemotherapeutic NSAID. In one embodiment, the chemotherapeutic agent is tamoxifen. In one embodiment, the chemotherapeutic agent is a nonsteroidal antiandrogen (NSAA). In one embodiment, the chemotherapeutic agent is apalutamide. In one embodiment, the chemotherapeutic agent comprises hormone therapy. In one embodiment, the chemotherapeutic agent is one of the various antineoplastic agents listed herein below.

[0029] In a method embodiment, the LOFU is delivered by an ultrasound beam from an ultrasound device including a transducer, and the device and subject are positioned such that at least a portion of the tumor is located at the focal point of the transducer. In a method embodiment, the LOFU is delivered to at least a portion of the tumor, and the location of the tumor in the subject is monitored by an imaging technique. In one method embodiment, the imaging technique is magnetic resonance imaging. In one method embodiment, the imaging technique is computed tomography. In one method embodiment, the imaging technique is ultrasound imaging.

[0030] In one embodiment of the method, LOFU is administered at least once to multiple volumes within the tumor over a period of less than one hour.

[0031] In one embodiment of the method, the LOFU is non-ablative. In one embodiment of the method, the LOFU does not cause cavitation in the tissue to which it is applied.

[0032] In one embodiment of the method, the ultrasound component of the LOFU is administered at a frequency of 0.5 MHz to 1.5 MHz. In one embodiment of the method, the LOFU is administered for 1 to 3 seconds. In one embodiment of the method, the in situ intensity in the treatment zone is 250 W / cm at a tissue depth of 1 mm to 75 mm in the subject. 2 ~750W / cm 2 The LOFU is performed by an ultrasonic beam so that:

[0033] In one embodiment of the method, LOFU is administered throughout the entire tumor volume. In one embodiment of the method, the method delivers energy to the tumor in the range of 300-3000 Joules per cc of tumor. In one embodiment of the method, high intensity focused ultrasound (HIFU) is not administered to the subject. In one embodiment, HIFU is focused ultrasound that affects tissue temperature in a focal zone of about 80°C or higher. HIFU increases temperature to up to 60-85°C during exposure times of a few seconds on solid tissue and / or causes thermal ablation in the tissue. Thermal ablation is typically achieved with a frequency of 1 kW / cm at reported frequencies of 0.8-7 MHz. 2On the other hand, the LOFU is achieved at power intensities of, for example, 1-3 W / cm 2 and frequencies from 0.5 to 3 MHz (but see other LOFU ranges herein). LOFU can be focused ultrasound that is continuous (100% DC) or pulsed (<100% DC, some literature calls Low Intensity Pulsed Ultrasound or LIPUS) by adjusting the duty cycle. 2 Continuous LOFU at 100 Hz can increase the temperature in tissue by 0.1°C. In vivo experiments on muscle tissue have shown that ultrasonic treatment at a frequency of 1 MHz can increase the temperature by 0.5 W / cm. 2 at 0.04°C / min; 1.0W / cm 2 at 0.16°C / min; 1.5W / cm 2 0.33°C / min at 2.0W / cm 2 The graph shows that the temperature is increased at a rate of 0.38°C / min.

[0034] In one embodiment of the method, the effect of the amount of radiation therapy and the amount of LOFU is synergistic in treating the tumor.

[0035] In one embodiment of the method, the subject is a human.

[0036] In one embodiment of the method, the tumor is prostate, breast, nasopharynx, pharynx, lung, bone, brain, salivary gland, stomach, esophagus, testis, ovary, uterus, endometrium, liver, small intestine, appendix, colon, rectum, bladder, gallbladder, pancreas, kidney, bladder, cervix, vagina, vulva, prostate, thyroid, or skin, head and neck tumor, glioma, or soft tissue sarcoma. In one embodiment of the method, the tumor is prostate cancer.

[0037] In one embodiment of the method, the metastasis is a lung metastasis.

[0038] In one embodiment of the method, the LOFU is administered by an apparatus, the apparatus comprising: a control system for generating a frequency waveform; and a power waveform having a power of 1-1000 W / cm at the treatment area. 2 The spatial peak time-averaged acoustic power intensity (I spta), where the ultrasound is applied continuously to the treatment zone for a time period ranging from 0.5 to 5 seconds, the ultrasound frequency is in the range of 0.01 to 10 MHz, and the mechanical index of any beam is less than 4. In one embodiment of the method, each of the one or more transducers has a center frequency in the range of 0.05 to 5 MHz and a power waveform of 20 to 1000 W / cm. 2 In one embodiment of the method, each of the one or more transducers is configured to generate an ultrasound beam based on a frequency waveform having a center frequency in the range of 0.5-1.5 MHz and an acoustic output intensity of 20-1000 W / cm. 2 In one embodiment of the method, each transducer is configured to generate an ultrasound beam based on a frequency waveform having an acoustic output intensity of 250 W / cm2 or greater at the treatment zone. In one embodiment of the method, each transducer is configured to generate a cylindrical ultrasound wave having a -3 dB beam profile waist of 5 mm or greater at the treatment zone. In one embodiment of the method, one or more beams are mechanically moved during treatment. In one embodiment of the method, one or more transducers are operated sequentially or simultaneously to generate an average spatial peak of 250 W / cm2 or greater at the treatment zone during the treatment period. 2 In one embodiment of the method, the one or more transducers are configured to generate ultrasound waves having a frequency in the range of 10 kHz to 300 kHz. In one embodiment of the method, the one or more transducers are configured to generate ultrasound waves having a frequency in the range of 300 kHz to 3 MHz. In one embodiment of the method, one or more transducers operate at a frequency of 300 kHz to 3 MHz and one or more transducers operate at a frequency of 30 to 300 kHz. In one embodiment of the method, the two or more ultrasound transducers generate ultrasound beams through the treatment zone, each beam having a power of 10 to 500 W / cm. 2 In the intersection zone in the range of I sptaIn one embodiment of the method, the treatment time is less than 5 seconds per cubic centimeter of tumor. In one embodiment of the method, two transducers generate intersecting ultrasound beams within the treatment zone, each beam having an output of 50-500 W / cm. 2 In the intersection zone in the range of I spta In one embodiment of the method, three transducers generate ultrasound beams through the treatment zone, each beam having an intensity of 50-500 W / cm. 2 In the intersection zone in the range of I spta In one embodiment of the method, the one or more transducers generate ultrasound beams that are substantially in phase with each other in the treatment zone. In one embodiment of the method, two ultrasound beams emanating from separate ultrasound transducers are substantially in phase and intersect in the treatment zone, each beam having an intensity of 70-100 W / cm. 2 The ultrasound has an acoustic power spatial peak intensity in the crossing zone in the range of 1 to 5 seconds.

[0039] In one embodiment of the method, three ultrasound beams emitted from separate ultrasound transducers are substantially in phase and intersect within the treatment zone, each beam having an output of 50-70 W / cm 2 In one embodiment of the method, the ultrasound beams originating from the separate transducers each have an acoustic power spatial peak intensity at the treatment zone in the range of about 100-1000 W / cm2, and the ultrasound is administered for 1-5 seconds consecutively. 2 I in the range sptaIn one embodiment of the method, at least one transducer generates an ultrasound beam having a high intensity diameter substantially larger in size than the treatment zone and is oriented such that the treatment zone is entirely within the beam. In one embodiment of the method, a focused treatment zone is formed when two or more ultrasound beams intersect in a path, the focused treatment zone being about 1 cm or more perpendicular to the transmitted energy direction and about 1 cm or more parallel to the transmitted direction. In one embodiment of the method, the acoustic pressure applied to the treatment zone from each transducer is 0.1-10 MPa. In one embodiment of the method, the number of transducers providing the focused ultrasound treatment zone is between 1-1000. In one embodiment of the method, ultrasound from one or more transducers is applied continuously for the treatment time. In one embodiment of the method, ultrasound is generated with a duty cycle in the range of 1 on time unit:9 off time units. In one embodiment of the method, the transducers are configured to generate ultrasound of a single frequency tone or a multi-frequency chirp. In one embodiment of the method, the one or more transducers operate sequentially in time. In one embodiment of the method, the total energy delivered to the target tissue and a desired perimeter around the target tissue during the entire course of application is greater than the total energy delivered to the surrounding tissue. In one embodiment of the method, the one or more transducers are configured such that the frequency of the ultrasound is swept during application. In one embodiment of the method, the one or more transducers include a two-dimensional phased array. In one embodiment of the method, the one or more transducers include an annular array. In one embodiment of the method, the one or more transducers include a three-dimensional phased array. In one embodiment of the method, the one or more transducers are incorporated into one or more endoscopy devices. In one embodiment of the method, the one or more transducers are incorporated into a magnetic resonance imaging machine.

[0040] In one embodiment of the method, the one or more transducers are incorporated into a radiation therapy machine.

[0041] In one embodiment of the method, the one or more transducers are configured to generate ultrasound waves such that when ultrasound waves are applied to the treatment zone for about 2 seconds or less, the maximum temperature reached in the treatment zone is less than 45°C during treatment.

[0042] In one embodiment of the method, the one or more transducers are configured to generate ultrasound waves such that the maximum temperature reached in the treatment zone is less than 50°C during treatment when the ultrasound waves are applied to the treatment zone for about 2 seconds or less.

[0043] In one embodiment of the method, the one or more transducers are configured to generate ultrasound waves such that the maximum temperature reached in the treatment zone is less than 55°C during treatment when the ultrasound waves are applied to the treatment zone for about 2 seconds or less.

[0044] In one embodiment of the method, the LOFU and radiation therapy are administered by a system, the system comprising: a LOFU device, the LOFU device having a control system for generating a frequency waveform; and a radiation therapy device for generating a radiation dose of 1-1000 W / cm2 at the treatment area. 2 The spatial peak time-averaged acoustic power intensity (I spta ), where the ultrasound is applied continuously to the treatment zone for a time period in the range of 0.5 to 5 seconds, and the ultrasound frequency is in the range of 0.01 to 10 MHz; a radiation therapy machine; and a control system configured and operable to control the LOFU device and the radiation therapy machine such that a first amount of ultrasound and a second amount of radiation therapy are administered to the subject, where both the first amount and the second amount are sufficient to treat a tumor in the subject.

[0045] A method of treating a tumor in a subject is provided, the method comprising administering to the subject (i) an amount of low intensity focused ultrasound (LOFU) and (ii) an amount of chemotherapy or an amount of radiation therapy or an amount of immunotherapy, wherein both amounts (i) and (ii) are sufficient to treat the tumor.

[0046] In an embodiment of the method, an amount of LOFU and an amount of radiation therapy are administered to the subject. In another embodiment of the method, an amount of LOFU and an amount of radiation therapy are administered to the subject. In another embodiment of the method, an amount of LOFU and an amount of immunotherapy are administered to the subject.

[0047] A method of treating a tumor in a subject includes administering to the subject (i) an amount of low intensity focused ultrasound (LOFU) and (ii) an amount of a targeted anti-cancer therapy, where both amounts (i) and (ii) are sufficient to treat the tumor. In one embodiment, the targeted therapy comprises a mAb directed against Her2 or VEGFR. In one embodiment, the targeted therapy comprises a tyrosine kinase inhibitor.

[0048] Further provided is a method of inhibiting metastasis of a tumor in a subject, the method comprising administering to a subject having a tumor an amount of low intensity focused ultrasound (LOFU) and an amount of radiation therapy, both of which are sufficient to inhibit metastasis of the tumor in the subject.

[0049] In this method, the radiation therapy can be ablative hypofractionated radiation therapy.

[0050] Preferably, in this method, the LOFU is directed to the location of the tumor in the subject.

[0051] Further provided is a method of reducing the effective amount of anti-cancer chemotherapy required to treat a tumor in a subject, the method comprising administering to a subject receiving anti-cancer chemotherapy an amount of low intensity focused ultrasound (LOFU) sufficient to reduce the effective amount of anti-cancer chemotherapy required to treat the tumor.

[0052] In each embodiment of the method, LOFU is administered to the subject prior to or simultaneously with chemotherapy or radiotherapy or immunotherapy.

[0053] In one embodiment, LOFU is administered to a subject before radiation therapy is administered.

[0054] In the method of administering anti-cancer chemotherapy, in one embodiment, the anti-cancer chemotherapy comprises administering to the subject an HSP90 inhibitor. The HSP90 inhibitor can be 17AAG (tanespimycin or 17-N-allylamino-17-demethoxygeldanamycinan). In one embodiment, the chemotherapeutic agent is an alkylating agent. In one embodiment, the chemotherapeutic agent is trabectedin. In one embodiment, the chemotherapeutic agent is a mustard gas derivative. In one embodiment, the chemotherapeutic agent is a metal salt. In one embodiment, the chemotherapeutic agent is a plant alkaloid. In one embodiment, the chemotherapeutic agent is an antitumor antibiotic. In one embodiment, the chemotherapeutic agent is an antimetabolite. In one embodiment, the chemotherapeutic agent is a topoisomerase inhibitor. In one embodiment, the chemotherapeutic agent is a proteasome inhibitor. In one embodiment, the chemotherapeutic agent is a chemotherapeutic NSAID. In one embodiment, the chemotherapeutic agent is tamoxifen. In one embodiment, the chemotherapeutic agent is a nonsteroidal antiandrogen (NSAA). In one embodiment, the chemotherapeutic agent is apalutamide. In one embodiment, the chemotherapeutic agent comprises hormonal therapy. In one embodiment, the chemotherapeutic agent is one of the various anti-neoplastic agents listed below.

[0055] In one embodiment of the method, the LOFU is delivered by an ultrasound beam from an ultrasound machine that includes a transducer, the ultrasound machine and subject being positioned such that at least a portion of the tumor is located at the focal length of the transducer.

[0056] In one embodiment of the method, the LOFU is delivered to at least a portion of the tumor and the location of the tumor is monitored by imaging techniques. Magnetic resonance imaging can be such an imaging technique.

[0057] In the method, LOFU can be administered at least once at multiple points within the tumor over a period of less than one hour.

[0058] In one embodiment of the method, the LOFU is non-ablation.

[0059] In one embodiment of the method, LOFU is applied at a frequency between 0.5 MHz and 1.5 MHz.

[0060] In one embodiment of the method, the LOFU is administered for 1.5 to 3 seconds.

[0061] In one embodiment of the method, at the focus of the ultrasound beam, the in situ intensity is 250 W / cm 2 ~750W / cm 2 In one embodiment of the method, the LOFU is administered by an ultrasound beam such that at the focus of the ultrasound beam, the in situ intensity is 250 W / cm at a tissue depth of 1 mm to 75 mm in the subject. 2 ~750W / cm 2 In one embodiment of the method, the LOFU is administered by an ultrasound beam such that at the focus of the ultrasound beam, the in situ intensity is 350 W / cm at a tissue depth of 1 mm to 75 mm in the subject. 2 ~650W / cm 2 In one embodiment of the method, the LOFU is administered by an ultrasound beam such that at the focus of the ultrasound beam, the in situ intensity is 450 W / cm at a tissue depth of 1 mm to 75 mm in the subject. 2 ~550W / cm 2 The LOFU is performed by an ultrasonic beam so that:

[0062] LOFU can be performed over the entire tumor volume or over a portion of the tumor volume, hi a preferred embodiment, LOFU is performed over the entire tumor volume.

[0063] In one embodiment of the method, the LOFU delivers at least 500-5000 Joules of energy per cc of tumor tissue through the tumor. In one embodiment of the method, the LOFU delivers at least 1000-4000 Joules of energy per cc of tumor tissue. In one embodiment of the method, the LOFU delivers at least 2000-3000 Joules of energy per cc of tumor tissue through the tumor. In one embodiment, high intensity focused ultrasound (HIFU) is not administered to the subject. In one embodiment, high intensity focused ultrasound is not administered to the subject. In one embodiment, high intensity focused ultrasound is not administered to the tumor.

[0064] In one embodiment in which LOFU is administered to a subject prior to anti-cancer treatment, high intensity focused ultrasound is not administered to the subject after the LOFU is administered and before the anti-cancer treatment is administered.

[0065] In one embodiment, the anti-cancer therapeutic effect of the amount of radiation therapy and the amount of LOFU is synergistic.

[0066] In one embodiment, performing LOFU raises the temperature of the tissue / tumor to 40°C-45°C. In one embodiment, performing LOFU raises the temperature of the tissue / tumor to 40°C or less. In one embodiment, performing LOFU raises the temperature of the tissue / tumor to 45°C or less. In one embodiment, performing LOFU raises the temperature of the tissue / tumor to 50°C or less. HIFU generally raises the temperature of the tissue above this.

[0067] In one embodiment, the LOFU is applied for 0.5 to 3 seconds. In one embodiment, the LOFU is applied for 1.5 to 3 seconds. In one embodiment, the LOFU is applied with a 100% duty cycle. In one embodiment, the LOFU is applied with one of the following alternative embodiments: a 10, 20, 30, 40, 50, 60, 70, 80, or 90% duty cycle.

[0068] A method of sensitizing a tumor in a subject to an amount of anti-cancer therapy is provided, the method comprising administering to the subject an amount of low intensity focused ultrasound (LOFU) effective to sensitize the tumor in the subject to the amount of anti-cancer therapy before, during, or after the anti-cancer therapy. In one embodiment, the anti-cancer therapy comprises chemotherapy, radiation therapy, or immunotherapy, or targeted therapy, or surgery. In one embodiment, the anti-cancer therapy comprises chemotherapy. In one embodiment, the anti-cancer therapy comprises immunotherapy. In one embodiment, the anti-cancer therapy comprises radiation therapy. In one embodiment, the anti-cancer therapy comprises surgery, for example, to remove the tumor. The method may further comprise administering the anti-cancer therapy to the subject. Sensitizing the tumor to the amount of anti-cancer therapy renders the tumor susceptible to the treatment. For example, a parameter by which tumor treatment can be measured, such as reduction in tumor volume, is greater for a given amount of anti-cancer therapeutic administered to a sensitized tumor compared to the same amount of anti-cancer therapeutic administered to a non-sensitized tumor of comparable mass, vascularity, location, and type in the same or comparable subject. In one embodiment, the amount of LOFU effective to sensitize a subject's tumor to an amount of anti-cancer therapeutic and the anti-cancer therapeutic are synergistic.

[0069] In any of the methods described herein, the subject is a mammal. In one embodiment, the subject is a human.

[0070] The tumor referred to in the method may be a tumor of the prostate, breast, nasopharynx, pharynx, lung, bone, brain, salivary gland, stomach, esophagus, soft tissue, testis, ovary, uterus, endometrium, liver, small intestine, appendix, colon, rectum, bladder, gallbladder, pancreas, kidney, bladder, cervix, vagina, vulva, prostate, thyroid, or skin, head and neck, or may be a glioma, or a soft tissue sarcoma. In one embodiment, the tumor is prostate cancer. In one embodiment, the tumor is a soft tissue sarcoma. In one embodiment, the primary tumor is treated. In one embodiment, the secondary tumor is treated and may include, for example, metastasis or recurrent tumor. In one embodiment, the treatment of the tumor reduces the likelihood of a secondary tumor. In one embodiment, the metastasis includes one or more lung metastases.

[0071] The term "tumor," as used herein, unless otherwise specified, refers to a proliferation of neoplastic cells, including precancerous and cancerous cells and tissues. Tumors usually appear as a lesion or lump. In one embodiment, the tumor is a malignant neoplasm.

[0072] As used herein, "metastasize" (or grammatical equivalents), in reference to a cancer or tumor, means the spread of the cancer or tumor from one organ or tissue of a subject to another organ or tissue of the subject that is spatially distant from the first organ or tissue.

[0073] As used herein, "treating" a tumor means that one or more symptoms of the disease, such as the tumor itself, the tumor's vascularization, or other parameters by which the disease is characterized, are reduced, ameliorated, inhibited, placed in remission, or maintained in remission. "Treating" a tumor further means that one or more characteristics of the tumor may be eliminated, reduced, or prevented by treatment. Non-limiting examples of such characteristics include uncontrolled degradation of the basement membrane and proximal extracellular matrix, migration, division, and organization of endothelial cells into new functional capillaries, and the persistence of such functional capillaries. In one embodiment, treating a tumor means reducing the size or volume of the tumor.

[0074] As used herein, "inhibiting metastasis" of a tumor in a subject means that one or more symptoms or one or more other parameters that characterize metastatic disease are reduced, ameliorated, or inhibited. Non-limiting examples of such parameters include uncontrolled degradation of the basement membrane and proximal extracellular matrix, migration of tumor cells through the bloodstream or lymphatics, invasion, dysregulated adhesions, and proliferation at a second site, either distal or local. In one embodiment, treating metastasis means reducing the occurrence or inhibiting the progression of metastasis.

[0075] Radiation therapy is well known in the art. Radiation therapy as encompassed herein includes medical therapeutic radiation delivered by a machine outside the body (external beam radiation therapy), medical therapeutic radiation delivered from a radioactive material placed in the body near the cancer cells (internal beam radiation therapy), or total body radiation therapy. Radiation therapy as encompassed herein includes three-dimensional conformal radiation therapy (3DCRT), intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), external beam radiation therapy (EBRT), and tomotherapy. Radiation therapy can also be part of stereotactic radiosurgery or stereotactic body radiation therapy (SBRT). Delivery by any particle beam known in the art includes, for example, proton therapy, carbon ion therapy, or other charged particle beams.

[0076] In one embodiment, the radiation therapy is guided by CT imaging. In one embodiment, the radiation therapy is hypofractionated cone-beam CT imaging guided radiation therapy. All combinations of the various elements described herein are within the scope of the present invention, unless otherwise indicated herein or otherwise clearly contradicted by the context.

[0077] There are various chemotherapeutic agents that can be used in the present invention. Examples of chemotherapeutic agents include: tamoxifen; apalutamide; hormonal therapy agents; alkylating agents (e.g., trabectidin ((1'R,6R,6aR,7R,13S,14S,16R)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydrospiro[6,16-(epithiopropano-oxymethano)-7,13-imino-6aH-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinoline 1-5-yl) acetate); mustard gas derivatives (e.g., mechlorethamine, cyclophosphamide, chlorambucil, melphalan, and ifosfamide); ethylenimines (e.g., thiotepa and hexamethylmelamine); alkyl sulfonates (e.g., busulfan); hydrazines and triazines (e.g., altretamine, procarbazine, dacarbazine, and temozolomide); nitrosureas (e.g., carmustine, lomustine, and streptozocin); metal salts (e.g., carboplatin, cisplatin, and oxaliplatin); plant alkaloids (e.g., vinca alkaloids such as vincristine, vinblastine, and vinorelbine, taxanes such as paclitaxel and docetaxel, etoposide and teniposide, podophyllotoxins such as doxorubicin, camptothecan analogues such as irinotecan and topotecan (topoisomerase inhibitors); antitumor antibiotics (e.g., anthracyclines: doxorubicin, daunorubicin, epirubicin, mitoxantrone, and idarubicin; chromomycins: dactinomycin and plicamycin; various ones such as mitomycin and bleomycin); antimetabolites (e.g., folate antagonists: methotrexate; pyrimidine antagonists: 5-fluorouracil, foxuridine, cytarabine, capecitabine, and gemcitabine; purine antagonists: 6-mercaptopurine and 6-thioguanine; adenosine deaminase inhibitors: cladribine, fludarabine, nelarabine, and pentostatin);Topoisomerase inhibitors (e.g., irinotecan, topotecan; amsacrine, etoposide, etoposide phosphate, teniposide); proteasome inhibitors; chemotherapy NSAIDs; and other antineoplastic agents (e.g., ribonucleotide reductase inhibitors: hydroxyurea; corticosteroid inhibitors: mitotane; enzymes: asparaginase and pegaspargase; antimicrotubule agents: estramustine; retinoids: bexarotene, isotretinoin, tretinoin (ATRA);

[0078] Chemotherapeutic agents that cause endoplasmic reticulum (ER) stress and / or endoplasmic reticulum stress response (UPR) in cells are known in the art. For example, proteasome inhibitors, such as bortezomib (Velcade®; formerly known as PS-341), induce ER stress response. Proteasome inhibitors, such as bortezomib, also induce UPR. Histone deacetylase (HDAC) inhibitors induce ER stress response. Chemotherapeutic NSAIDs, such as indomethacin, diclofenac, and celecoxib, can induce ER stress response and induce UPR. Estrogen receptor alpha inhibitor, BHPI (1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl-2H-indol-2-one), can activate UPR. Platinum-containing anticancer drug: cisplatin is known to induce ER stress response. Taxane family of drugs: Paclitaxel is known to induce ER stress response. Anthracyclines such as doxorubicin are known to induce ER stress. Cyclophosphamide is known to induce ER stress. See also Table 2 of Hetz et al., Nature Reviews, Drug Discovery, 12:703-719 (Sept., 2013), incorporated herein by reference.

[0079] The endoplasmic reticulum (ER) is the site of synthesis and folding of secreted membrane-bound proteins and some organelle-targeted proteins. The ER regulates cellular energy levels, redox state, or Ca 2+ ER is highly sensitive to stresses that disrupt its concentration. Such stresses can reduce the protein folding capacity of the ER, resulting in the accumulation and aggregation of unfolded proteins, and / or an imbalance between the load of endogenous and transport proteins in the ER and the organelle's ability to handle the load. This condition is referred to herein and in the art as "ER stress". The ER stress response can promote cell repair and sustained survival by reducing the load of unfolded proteins through a global attenuation of protein synthesis and / or the upregulation of ER chaperones, enzymes, and structural components that enhance protein folding. This response is collectively named the unfolded protein response (UPR). The accumulation of unfolded proteins causes the dissociation of GRP78 from PERK, ATF6, and IRE1, thereby initiating the UPR.

[0080] [Table 1-1]

[0081] [Table 1-2]

[0082] [Table 1-3]

[0083] [Table 1-4]

[0084] [Table 2]

[0085] The HSP targeting agent may include, for example, an antibody or a targeting protein.

[0086] In some embodiments, exemplary agonists (activating antibodies) are anti-CD40, anti-CD27, and anti-OX40.

[0087] In some embodiments, exemplary antagonists (inhibitory or blocking antibodies) are anti-CTLA4, anti-PD1, anti-PDL1, anti-VISTA, and anti-TIM3.

[0088] In some embodiments, exemplary adjuvants are STINGL, RIGI helix inhibitors, CpG olives, and TLR agonists.

[0089] In some embodiments, exemplary cytokines are IL-2, IL-7, IL-12, IL15, IFNγ.

[0090] In an embodiment of the method, the chemotherapeutic agent is an HSP90 inhibitor. An example of an HSP90 inhibitor is 17AAG (tanespimycin or 17-N-allylamino-17-demethoxygeldanamycinan). In one embodiment, the chemotherapeutic agent is an alkylating agent. In one embodiment, the chemotherapeutic agent is trabectedin. In one embodiment, the chemotherapeutic agent is a mustard gas derivative. In one embodiment, the chemotherapeutic agent is a metal salt. In one embodiment, the chemotherapeutic agent is a plant alkaloid. In one embodiment, the chemotherapeutic agent is an antitumor antibiotic. In one embodiment, the chemotherapeutic agent is an antimetabolite. In one embodiment, the chemotherapeutic agent is a topoisomerase inhibitor. In one embodiment, the chemotherapeutic agent is a proteasome inhibitor. In one embodiment, the chemotherapeutic agent is a chemotherapeutic NSAID. In one embodiment, the chemotherapeutic agent is one of the various antineoplastic agents listed above.

[0091] Other non-limiting examples of chemotherapeutic agents or drugs encompassed by the present invention include anthracyclines, maytansinoids, alkylating agents, antimetabolites, plant alkaloids or terpenoids, and cytotoxic antibiotics, unless otherwise stated. In one embodiment, the chemotherapeutic agent is cyclophosphamide, bleomycin, etoposide, platinum agents (cisplatin), fluorouracil, vincristine, methotrexate, taxol, epirubicin, leucovorin (folinic acid), or irinotecan.

[0092] Anti-tumor immunotherapies encompassed herein include: (i) monoclonal antibodies (naked, chemo-, radio-, or toxin-conjugated antibodies, and bispecific antibodies), associated antigen-binding fragments thereof, e.g., fragments comprised of Fab fragments or scFv fragments, that bind with high affinity to biomolecular targets associated with cancer; (ii) those that are non-specific with respect to tumor cells and tumor cell antigens; anti-tumor immunotherapies, e.g., cytokines, interleukins, interferons, Flt3L, CD40L, GM-CSF, ligands and agonists, RIG1 helicase activator, anti-CD40, NKG2D ligands, anti-CSF1R, anti-TLR. The immunotherapy includes TLR ligands, INF-α, TNF-β, anti-Tie2, small organic molecules (e.g., 1,500 daltons or less) or other drugs that bind to cytokines or cytokine receptors; and checkpoint targeting agents, including, but not limited to, CTLA-4, PD-1, PDL-1, and any other small organic molecules, peptides and aptamers that target immune responses. In one embodiment, immunotherapy as used herein excludes bacteria-based anti-cancer or anti-tumor immunotherapy. In one embodiment, immunotherapy as used herein excludes Listeria-based immunotherapy.

[0093] In one embodiment, increasing the efficacy of a treatment refers to an increase in the extent of the therapeutic effect achieved relative to the extent achieved with the same amount of treatment (e.g., a given treatment dose) in the absence of the application of the efficacy-enhancing method.

[0094] There is further provided an acoustic stimulation therapy device, the device comprising: a control system for generating a frequency waveform; and a frequency waveform of 1-1000 W / cm at a treatment area. 2 The spatial peak time-averaged acoustic power intensity (I spta ), where the ultrasound is applied continuously to the treatment zone for a time period ranging from 0.5 to 5 seconds, the ultrasound frequency is in the range of 0.01 to 10 MHz, and the mechanical index of any beam is less than 4.

[0095] In one embodiment of the device, each of the one or more transducers has a center frequency in the range of 0.05 to 5 MHz and a power of 20 to 1000 W / cm 2 The ultrasonic beam is configured to generate an ultrasonic beam based on a frequency waveform having an acoustic output intensity of

[0096] In one embodiment of the device, each of the one or more transducers has a center frequency in the range of 0.5-1.5 MHz and a power of 20-1000 W / cm 2 The ultrasonic beam is configured to generate an ultrasonic beam based on a frequency waveform having an acoustic output intensity of

[0097] In one embodiment of the device, each transducer is configured to generate a cylindrical ultrasound wave such that the -3 dB beam profile waist is 5 mm or greater at the treatment zone.

[0098] In one embodiment of the device, one or more of the beams are mechanically moved during the procedure.

[0099] In one embodiment of the device, one or more transducers are operated sequentially or simultaneously to produce an average spatial peak of 250 W / cm in the treatment zone during the treatment period. 2 The ultrasonic transducer includes two or more transducers configured to generate ultrasonic waves of less than 100 Hz.

[0100] In one embodiment of the device, the one or more transducers are configured to generate ultrasound waves having a frequency in the range of 10 kHz to 300 kHz.

[0101] In one embodiment of the device, the one or more transducers are configured to generate ultrasound waves having a frequency in the range of 300 kHz to 3 MHz.

[0102] In one embodiment of the device, one or more transducers operate at a frequency between 300 kHz and 3 MHz, and one or more transducers operate at a frequency between 30 and 300 kHz.

[0103] In one embodiment of the device, two or more ultrasound transducers generate ultrasound beams through the treatment zone, each beam having an output of 10-500 W / cm 2 In the intersection zone in the range of I spta has.

[0104] In one embodiment of the device, treatment time is less than 5 seconds per cubic centimeter of tumor.

[0105] In one embodiment of the device, two transducers generate intersecting ultrasound beams within the treatment zone, each beam having an output of 50-500 W / cm 2 In the intersection zone in the range of I spta has.

[0106] In one embodiment of the device, three transducers generate ultrasound beams through the treatment zone, each beam having an output of 50-500 W / cm 2 In the intersection zone in the range of I spta has.

[0107] In one embodiment of the device, one or more transducers generate ultrasound beams that are substantially in phase with each other within the treatment zone.

[0108] In one embodiment of the device, two ultrasound beams emitted by separate ultrasound transducers are substantially in phase and intersect within the treatment zone, each beam having an intensity of 70-100 W / cm 2 The ultrasound has an acoustic power spatial peak intensity in the crossing zone in the range of 1 to 5 seconds.

[0109] In one embodiment of the device, three ultrasound beams emitted from separate ultrasound transducers are substantially in phase and intersect within the treatment zone, each beam delivering 50-70 W / cm 2 The ultrasound has an acoustic power spatial peak intensity in the crossing zone in the range of 1 to 5 seconds continuously.

[0110] In one embodiment of the device, the ultrasound beams generated by the separate transducers each have an intensity of about 100-1000 W / cm at the treatment zone. 2 I in the range spta Generate.

[0111] In one embodiment of the device, at least one transducer generates an ultrasound beam having a high intensity diameter substantially larger in size than the treatment zone and is oriented so that the treatment zone is entirely within the beam.

[0112] In one embodiment of the device, a focused treatment zone is formed where two or more ultrasound beams intersect in a path, the focused treatment zone being about 1 cm or more perpendicular to the direction of transmitted energy and about 1 cm or more parallel to the transmitted direction.

[0113] In one embodiment of the device, the acoustic pressure applied to the treatment zone from each transducer is between 0.1 and 10 MPa.

[0114] In one embodiment of the device, the number of transducers providing the focused ultrasound treatment zone is between 1 and 1000.

[0115] In one embodiment of the device, ultrasound from one or more transducers is applied continuously for the treatment period.

[0116] In one embodiment of the device, ultrasound waves are generated with a duty cycle ranging from 1 on time unit to 0-9 off time units.

[0117] In one embodiment of the device, the transducer is configured to generate ultrasonic single frequency tones or multi-frequency chirps.

[0118] In one embodiment of the device, the one or more transducers operate sequentially in time.

[0119] In one embodiment of the device, the total energy delivered to the target tissue and a desired perimeter around the target tissue during the entire course of application is greater than the total energy delivered to the surrounding tissue. In one embodiment of the method, the one or more transducers are configured such that the frequency of the ultrasound is swept during application. In one embodiment of the device, the one or more transducers include a two-dimensional phased array. In one embodiment of the device, the one or more transducers include an annular array. In one embodiment of the device, the one or more transducers include a three-dimensional phased array. In one embodiment of the device, the one or more transducers are incorporated into one or more endoscopy devices. In one embodiment of the device, the one or more transducers are incorporated into a magnetic resonance imaging machine. In one embodiment of the device, the one or more transducers are incorporated into a radiation therapy machine.

[0120] In one embodiment of the device, when ultrasound is applied to the treatment zone for about 2 seconds or less, the one or more transducers are configured to generate ultrasound such that the maximum temperature reached in the treatment zone during treatment is less than 45° C. In one embodiment of the device, when ultrasound is applied to the treatment zone for about 2 seconds or less, the one or more transducers are configured to generate ultrasound such that the maximum temperature reached in the treatment zone during treatment is less than 50° C.

[0121] In one embodiment of the device, the one or more transducers are configured to generate ultrasound waves such that when ultrasound waves are applied to the treatment zone for about 2 seconds or less, the maximum temperature reached in the treatment zone is less than 55°C during treatment.

[0122] A system is further provided, the system including: an acoustic stimulation therapy device, the acoustic stimulation therapy device including: a control system for generating a frequency waveform; and a frequency waveform of 1-1000 W / cm2 in a treatment area. 2 The spatial peak time-averaged acoustic power intensity (I spta ), where the ultrasound is applied continuously to the treatment zone for a time period in the range of 0.5 to 5 seconds and the ultrasound frequency is in the range of 0.01 to 10 MHz; a radiation therapy machine; and a control system configured and operable to control the acoustic stimulation therapy device and the radiation therapy machine such that a first amount of ultrasound and a second amount of radiation therapy are administered to the subject, where both the first amount and the second amount are sufficient to treat a tumor in the subject.

[0123] A system is further provided, the system including: an acoustic stimulation therapy device, the acoustic stimulation therapy device including: a control system for generating a frequency waveform; and a frequency waveform of 1-1000 W / cm2 in a treatment area. 2 The spatial peak time-averaged acoustic power intensity (I spta ), wherein the ultrasound is continuously applied to the treatment zone for a time period ranging from 0.5 to 5 seconds, and the ultrasound frequency is in the range of 0.01 to 10 MHz; and the acoustic stimulation therapy device is used in combination with chemotherapy such that a first amount of ultrasound and a second amount of chemotherapy are administered to the subject, wherein both the first and second amounts are sufficient to treat a tumor in the subject.

[0124] A system is further provided, the system including: an acoustic stimulation therapy device, the acoustic stimulation therapy device including: a control system for generating a frequency waveform; and a frequency waveform of 1-1000 W / cm2 in a treatment area. 2 The spatial peak time-averaged acoustic power intensity (I spta ), where the ultrasound is applied continuously to a treatment zone for a time period ranging from 0.5 to 5 seconds, and the ultrasound frequency is in the range of 0.01 to 10 MHz; and the acoustic stimulation therapy device is used in combination with immunotherapy such that a first amount of ultrasound and a second amount of immunotherapy are administered to the subject, where both the first and second amounts are sufficient to treat a tumor in the subject.

[0125] <Example 1> B16 melanoma tumors suppress IL-2 and IFNγ production by tumor-specific CD4+ T cells. To determine how melanoma cells modulate tumor-induced effector CD4+ T cell responses, three different mouse models were used. First, B16-F1 melanoma tumors were induced in C57B1 / 6J mice by subcutaneous injection of B16 cells into the lumbar flank. Tumors were allowed to grow to a size of 7–8 mm, after which CD4+ T cells were isolated from both the ipsilateral inguinal draining lymph nodes (DLN) and the distal contralateral non-draining cervical lymph nodes (NDLN). T cells were also obtained from control mice that did not bear any tumors. CD4+ T cells isolated from tumor DLNs produced significantly less IL-2 when stimulated ex vivo with anti-CD3 and anti-CD28 antibodies than cells isolated from the distal contralateral NDLN of the same mice or from lymph nodes of control tumor-free mice. A similar, but less pronounced, effect was observed with IFNγ (Fig. 1, A and B).

[0126] To confirm these data, we used the B16-F1 melanoma cell line, stably transfected to express OVA as a surrogate tumor antigen. These cells were subcutaneously injected into OT-II mice, mice with T cells expressing a transgenic MHC class II-restricted TCR that recognizes the OVA323-339 peptide. T cells were harvested from these mice as described and stimulated ex vivo using splenocytes loaded with the OVA323-339 peptide. Regenerated CD4+ T cells from ipsilateral DLN produced significantly reduced amounts of IL-2 and IFNγ compared to cells from contralateral NDLN or tumor-free mice (Figure 1C and D).

[0127] These results were further confirmed in a third model using Tyrp1 mice, which are deficient in tyrosinase-related protein 1 and have T cells expressing MHC class II-restricted TCRs specific for the TRP-1113-127 peptide of this endogenous melanocyte differentiation antigen. They were injected with B16-F1 cells. As in the previous two models, IL-2 and IFNγ production by CD4+ T cells harvested from ipsilateral DLN was significantly reduced compared to cells harvested from contralateral NDLN or tumor-free mice (Figure 1E and F). Collectively, these results suggest that melanoma tumors induce hyporesponsiveness of tumor antigen-specific CD4+ T cells, which results in a reduced ability to produce effector cytokines after restimulation.

[0128] Treatment of primary B16 melanoma with LOFU overcomes tumor-induced resistance in CD4+ T cells: HIFU is currently used to predominantly induce tumor ablation by generating high thermal doses inside tumor tissues to induce coagulation necrosis. Although HIFU is a highly effective and non-invasive ablative procedure to achieve local tumor control, it destroys vasculature and tissue infrastructure almost instantaneously, thereby limiting the infiltration of dendritic and immune cells for antigen presentation and recognition. We investigated whether administering LOFU induces non-lethal thermal / mechanical stress in tumor tissues that generates new tumor antigens and / or induces the expression of stress-induced proteins that can increase tumor immunogenicity and overcome tumor-induced resistance in CD4+ T cells. To investigate this possibility, primary B16-F1 melanoma tumors grown on separate groups of C57Bl / 7J mice were left untreated or treated with LOFU. Thirty-six hours after LOFU treatment, DLN- and NDLN-resident CD4+ T cells were isolated from both groups of mice and restimulated ex vivo with anti-CD3 and anti-CD28 antibodies. CD4+ T cells from DLN of mice treated with LOFU produced significantly more IL-2 compared to cells from the group of mice in which tumors were left untreated. In contrast, T cells from the corresponding NDLN produced comparable amounts of IL-2 in treated and untreated mice (Figure 2A). A similar but less pronounced effect was observed for IFNγ production in these same experimental groups of mice (Figure 2B). Overall, these results indicate that LOFU treatment of B16 melanoma tumors appears to overcome the state of hyporesponsiveness induced by the melanoma tumor microenvironment in favor of CD4+ T cells, suggesting improved activation and reduced tumor-induced T cell tolerance.

[0129] Melanoma tumors can induce an NFAT1-dependent program of gene expression that produces a set of proteins that interfere with TCR signaling and directly inhibit cytokine expression, leading to the establishment of functional anergy in CD4+ T cells. To determine the possibility that LOFU treatment may inhibit tumor-induced T cell tolerance by preventing anergy induction and be responsible for the increased cytokine expression observed in DLN-resident CD4+ T cells after treatment with LOFU, we first monitored the expression of anergy-related genes in CD4+ T cells isolated from the DLN of B16 tumor-bearing mice and compared it to the expression of genes in T cells taken from the NDLN of the same mice. T cells from the DLN of tumor-bearing mice expressed higher levels of anergy-related genes, including the E3 ubiquitin ligases Grail, Cbl-b, and Itc, as well as the transcription factor Egr2 (Figure 2C). However, no differences in Foxp3 expression were observed between DLN and NDLN T cells from tumor-bearing mice, suggesting that the increased presence of regulatory T cells is unlikely to be due to a decrease in CD4+ T cell responses under the conditions used in this study (Figure 2C).

[0130] We then determined whether treatment of B16 melanoma with LOFU had an effect on the expression of those anergy-related genes in T cells. To evaluate responses induced by endogenous tumor antigens, B16 tumors growing on Tyrp1 mice were left untreated or treated with LOFU. CD4+ T cells were isolated from DLN and NDLN, and the expression of various anergy-related genes was evaluated. DLN-derived T cells showed varying degrees of upregulation of six of the seven anergy genes analyzed, including Grail, Itch, and Cblb, as well as the transcription factors Egr2 and Grg4, and the protease Caspase3 (Figure 2D). Another transcription factor (Ikaros), which is also upregulated in various in vitro and in vivo T cell anergy models, was not significantly upregulated in this melanoma model of tumor-induced anergy, and its levels remained similar in both DLN- and NDLN-derived T cells (Fig. 2D). Interestingly, when tumors were treated with LOFU, the expression of five of those genes (Grail, Itch, Cblb, Egr2, and Grg4) in T cells isolated from DLN was not upregulated, showing levels comparable to the expression of these genes in NDLN (Fig. 2D), supporting that LOFU treatment inhibited the induction of anergy-inducing gene expression in tumor antigen-specific CD4+ T cells.

[0131] Melanoma tumors treated with LOFU were able to reactivate anergic tumor antigen-specific T cells: the results supported that tumor-induced T cell tolerance could be overcome after LOFU treatment. This observation was substantiated by the fact that the expression of various anergy-related genes was decreased in T cells derived from tumor DLN after LOFU treatment at the tumor site, while activation-induced cytokine expression was restored to levels close to those detected in T cells isolated from the distal NDLN or from control tumor-free mice.

[0132] We investigated whether LOFU not only prevents the induction of tumor antigen-specific T cell anergy, but also reverses established anergy and generates productive effector responses in previously tolerized T cells. Naive CD4+ T cells were isolated from the spleens and lymph nodes of Tyrp1 mice, differentiated into TH1 cells in vitro, and anergized by activating them via partial stimulation with anti-CD3 antibodies in the absence of costimulation. T cells became hyporesponsive and showed a severe reduction in IL-2 production after restimulation with anti-CD3 and anti-CD28 antibodies (Figure 3A). These anergic cells were then reactivated with CD11c+ dendritic cells loaded with lysates derived from either untreated or LOFU-treated melanoma tumors. Anergic Tyrp1 T cells stimulated with dendritic cells loaded with tumor lysates from untreated B16-F1 melanoma produced negligible amounts of IL-2. However, when dendritic cells were challenged with tumor lysates prepared from LOFU-treated tumors, previously anergized T cells produced significantly more IL-2 than those activated with untreated lysate (Figure 3B). These results indicate that LOFU treatment of melanoma tumors results in the production of immunogenic molecules, which enable dendritic cells to deliver activation signals capable of breaking tolerance and enabling otherwise anergic T cells to respond to re-encounter with antigen and generate a productive response.

[0133] Treatment of melanoma with LOFU induced changes in the expression and intracellular distribution of molecular chaperones calreticulin and Hsp70 in melanoma tumor cells: Activation of melanoma-specific T cells by dendritic cells is a critical event in determining their fate. A successful antigen-presenting event capable of eliciting an effector T cell response is highly dependent on the activation state of dendritic cells conveying tolerogenic stimuli. The results show that treatment of melanoma tumors with LOFU led to an increase in CD4+ T cell activation as a result of the interference with tumor-induced T cell tolerance. This could potentially be attributed to the generation of a more immunogenic dendritic cell population. To test the effect of LOFU on the ability of dendritic cells to efficiently present antigens to T cells, total cells from DLN of tumor-bearing mice were first isolated, untreated or treated with LOFU, and immunostained to measure the expression of B7.1, B7.2, and MHCII on the CD11c+ dendritic cell population by flow cytometry. No significant enhancement of the expression of these proteins in mice treated with LOFU was detected (FIG. 4A).

[0134] Transport of tumor antigens by molecular chaperones, including calreticulin and Hsp70, is also important for subsequent productive presentation of antigens to T cells. Both in vivo and in vitro methods were utilized to detect membrane calreticulin and Hsp70 in untreated and LOFU-treated B16 melanoma tumors. Tumors either left untreated or treated with LOFU were harvested from tumor-bearing mice, made into single cell suspensions, and stained with live / dead markers to assess cell viability. No differences in cell viability were observed in response to LOFU treatment, supporting the idea that the low-energy form of FUS did not directly induce tumor cell death (Figure 4B). B16 melanoma tumors were left untreated or exposed to LOFU treatment, and tumor tissue sections were placed on slides. Slides were stained with anti-Hsp70 or anti-calreticulin antibodies for subsequent detection by immunofluorescence. Immunofluorescence analysis of LOFU-treated melanoma confirmed that LOFU induced an increase in the expression of Hsp70 (Figure 4C). Interestingly, compared to untreated cells, LOFU-treated cells also showed an altered distribution of calreticulin, which appeared to accumulate at discrete sites of the plasma membrane on B16 cells (Figure 4C). To determine whether the increase in Hsp70 expression also correlated with an increased membrane presence of this protein, non-permeabilized CD45-TRP-1+B16 melanoma cells were stained for Hsp70 and cell surface expression after LOFU treatment was assessed by FACS. This analysis confirmed that LOFU treatment of B16 melanoma caused an increased membrane presence of Hsp-70 in tumor cells (Figure 4D).

[0135] LOFU treatment of melanoma tumors enhances dendritic cell-mediated tumor antigen presentation to induce stronger CD4+ T cell responses: To determine the possibility that LOFU treatment of tumors may result in an increased stimulatory capacity of endogenous dendritic cells, we directly tested whether lysates prepared from LOFU-treated tumors induce increased stimulation of antigen-specific T cells to generate more robust effector responses. For this experiment, B16-F1-OVA melanoma cells were used to induce tumors in C57BL / 6 mice. Lysates were prepared from untreated and LOFU-treated tumors. Splenic dendritic cells and responder naive CD4+ T cells were isolated from C57BL / 6 and OT-II tumor-free mice, respectively, and cocultured in the presence or absence of the different tumor lysates described above. Although OVA containing tumor lysates could serve as a source of tumor antigens to stimulate responder T cells, exogenous OVA323-339 peptide was also added to ensure uniform loading of dendritic cells with this peptide under all conditions to more precisely determine the tolerogenic or activating properties of the different tumor lysates.

[0136] Control responder OT-II T cells showed a strong response with high levels of IL-2 production after activation with dendritic cells loaded with OVA323-339 peptide. However, lysates from untreated tumors significantly inhibited OT-II responses, resulting in a severe reduction in IL-2 production, even when exogenous OVA323-339 peptide was added to the cultures (Figure 5A). Interestingly, contrary to untreated lysates, lysates from LOFU-treated tumors not only had no negative effect on the response of OT-II cells to OVA323-339, but were also able to induce a strong activation of OT-II responder T cells even in the absence of exogenous peptide (Figure 5A). These results extended further support for the observation that LOFU treatment of B16 melanoma tumors prevents the negative effects on the T cell stimulatory capacity of dendritic cells that normally occur in the intratumoral microenvironment.

[0137] We next determined whether resident antigen-presenting cells of tumor DLN were functionally more effective in activating target T cells after LOFU treatment of melanoma tumors. To this effect, B16-F1 melanoma was induced in C57BL / 6 mice and left untreated or treated with LOFU. DLN cell suspensions were depleted of T cells and used to test the ability of DLN antigen-presenting cells to activate tumor antigen-specific live T cells. Thus, T cell-depleted DLN cells were co-cultured for 24 h with naive Tyrp1 CD4+ T cells and lysates prepared from in vitro cultures of B16. IL-2 production was measured by ELISA to monitor the stimulation of responder T cells. Cells isolated from DLN of tumor-bearing mice treated with LOFU showed a significantly increased ability to activate Tyrp1 CD4+ T cells compared to cells isolated from untreated mice (Figure 5B). These data support that LOFU treatment of B16 melanoma results in the generation of antigen-presenting cells that are functionally more effective in activating tumor antigen-responder T cells.

[0138] LOFU followed by tumor ablation with hypofractionated IGRT results in enhanced T cell-mediated control of primary melanoma lesions: To further validate the observation that LOFU treatment can modulate tumor immunogenicity and enhance antitumor immune responses, a series of in vivo treatment strategies to evaluate primary tumor control was performed using a combination of LOFU with or without tumor ablation using daily hypofractionated IGRT of 10 Gy to a total dose of 30 Gy per mouse bearing an established B16-M1 tumor located subcutaneously in the right dorsal hind limb. 3 Treatment was initiated in all mice when tumor volume reached 62 days. Tumor volumes in each group were then measured three times a week for up to 62 days (Figure 7A). Untreated C57BL / 6, or mice treated with LOFU alone, continued to experience rapid primary tumor growth, reaching ≥300 mm within 10 days of treatment. 37A, at which point a below-the-knee amputation (BKA) was performed (Figure 7A). In contrast, mice in the hypofractionated IGRT or LOFU+IGRT groups experienced significant growth delay for up to 3 weeks after treatment, after which mice treated with IGRT alone began to show primary tumor regrowth, reaching ≥300 mm in approximately 5 weeks. 3 7A. Of note, mice in the LOFU+IGRT group had a sustained response, with tumor growth limited for more than 6 weeks after treatment. The reduction in tumor volume in the groups receiving LOFU+IGRT or IGRT was statistically significant until day 25 compared to the untreated group or the LOFU only group (P<0.05). Furthermore, the reduction in tumor volume in the LOFU+IGRT group was statistically significant until day 35 compared to IGRT only, and remained statistically significant throughout the duration of the experiment (P<0.05). (FIG. 7A). In addition, mice in the LOFU+IGRT group demonstrated tumor regression from baseline measurements, with complete tumor-free responses confirmed in 4 of 5 mice.

[0139] To confirm the immunomodulatory effect of LOFU, similar experiments were performed using an immunocompromised BALB / c nude model. In these mice, B16-M1 tumors grew very rapidly, reaching ≥300 mm approximately 1 week faster than in C57BL / 6 mice. 3 The overall treatment response was similar, with no treatment and LOFU alone not resulting in significant primary tumor control, whereas IGRT and LOFU+IGRT delayed primary tumor growth (Fig. 7B). However, in both IGRT and LOFU+IGRT treatments, the primary control was temporary. In fact, BKA was required less than 2 weeks after the start of treatment in the IGRT group and less than 3 weeks in the LOFU+IGRT group. In addition, LOFU+IGRT in immunocompromised mice did not result in statistically significant primary tumor control when compared with IGRT alone (Fig. 7B).

[0140] LOFU followed by hypofractionated IGRT results in increased recurrence-free survival and reduced lung metastases: Based on the data, the enhanced antitumor T cell response induced by LOFU may augment therapeutic IGRT to achieve better control of not only local disease but also microscopic disease and distant metastases. B16-F10 is an aggressive cell line that grows rapidly to unacceptable sizes if not treated, so the tumor size >300 mm 3 Mice bearing primary tumors of 100-2000 required BKA. Notably, by the time BKA was performed, cells from the primary tumor had already spread to the draining popliteal LNs (data not shown). Within the following weeks, the draining popliteal LNs grew rapidly and became visibly larger, while the more distal inguinal LNs became clearly palpable. Once the tumors reached this point, no procedures could be performed to alleviate the discomfort, and these mice were sacrificed. Consequently, overall survival cannot be adequately assessed in mice with large tumor burdens. It was therefore decided to evaluate two other parameters: recurrence-free survival, in which animals that died naturally or were sacrificed with excessive local recurrent tumor burden were recorded as positive events; and progression of pulmonary metastases.

[0141] The combination of LOFU+IGRT conferred a statistically significant (P=0.04) recurrence-free survival advantage compared to either treatment alone in C57BL / 6 mice (Figure 7C). Notably, in all groups except C57BL / 6 LOFU+IGRT, local metastases to the draining popliteal or inguinal LNs frequently necessitated the use of sacrifice. Furthermore, mice treated with LOFU+IGRT showed strict control of pulmonary metastases, whereas in the other three groups, even animals with relatively small local recurrences eventually succumbed to overwhelming pulmonary metastases (Figure 7D).

[0142] Mice: 6-8 week old C57BL / 6, B6.Cg-Rag1 tm1MomTyrp1B-wTg(TcraTcrb)9Rest / J (Tyrp1) and B6.Cg-Tg(TcraTcrb)425Cbn / J (0T-II) mouse strains were purchased from The Jackson Laboratory. BALBc / nude mice were obtained from the National Cancer Institute via Charles River. All mice were housed and maintained in a pathogen-free facility.

[0143] B16 cell lines and primary CD4+ T cell culture: B16-F1 and B16-F10 melanoma cell lines were purchased from the American Type Culture Collection (ATCC). A highly aggressive subclone of B16-F10 (B16-M1) was generated by isolating and expanding a metastatic clone that arose in C57BL / 6 mice 6 weeks after surgical resection of an established primary tumor. The B16-OVA melanoma cell line was kindly provided by E. M. Lord (University of Rochester Medical Center, Rochester, NY). Expression of OVA by B16-OVA cells was confirmed by real-time PCR. All melanoma cells were cultured in DMEM (Thermo Scientific) supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, and 250 IU penicillin / streptomycin.

[0144] CD4+ T cells were isolated using anti-CD4-conjugated magnetic Dynabeads (Life Technologies) according to the manufacturer's protocol. As indicated herein, CD4+ T cells were cultured with plate-bound anti-CD3Σ (clone 2C11; 0.25 μg / ml) in the presence of mouse IL-12 (10 ng / mL) (eBioscience), anti-mouse IL-4 antibody (clone 11C.11; 10 μg / ml), and 10 U / mL recombinant human IL-2 (Biological Resources Branch of the National Cancer Institute).

[0145]

number

[0146]

number

[0147] Tumor model: 3 × 10 cells suspended in Hank's balanced salt solution (Invitrogen) 5 B16-F1 melanoma cells were injected subcutaneously into the lumbar flank of the mice. 2 × 10 5 Melanoma tumors were induced in the footpad by injecting B16-M1 cells.

[0148] Tumor growth monitoring: Primary B16-M1 melanoma dorsal hindlimb tumors were measured three times a week using a vernier caliper. Tumor volume was calculated using the ellipsoid formula: V = (π / 6 × length × width × height). Primary dorsal hindlimb tumors ranged from 30 to 50 mm. 3 Phase I volume, 90-150 mm3 Phase II volume of 300-500 mm 3 It shows Golpenz growth with a phase III volume of 90-150 mm. 3 Treatment efficacy was determined by assessing tumor growth delay (TGD) from 300 to 500 mm, where tumors were in log phase II. 3 Tumors reaching the endothelial cell mass of ≥ 300–500 mm3 begin to enter phase III due to anatomical and vascular limitations. As a result, tumors reaching the endothelial cell mass of ≥ 300–500 mm3 are treated according to an IACUC-approved protocol. 3 Tumor-bearing mice underwent below-knee amputation.

[0149] ELISA: 1.5–2.5 × 104 T cells were either resting or stimulated with anti-CD3Σ+ anti-CD28 antibodies, T cell-depleted splenocytes loaded with OVA peptide 323-339 (OVA323-339) at a T cell:splenocyte ratio of 1:5, or CD11c+ purified dendritic cells (using CD11c- beads; Miltenyi Biotech) loaded with OVA323-339 or melanoma tumor lysate at a dendritic cell:T cell ratio of 1:3. Culture supernatants were typically harvested 24 hours after stimulation, and IL-2 or IFN levels were measured by sandwich ELISA (BD Biosciences).

[0150] Tumor lysates: Tumors were excised from tumor-bearing mice, cut into 1-2 mm pieces, and then lysed for 40 min.

[0151]

number

[0152] Immunofluorescence staining Tumor tissues were isolated, washed in PBS, and embedded in OCT compound (Electron Microscopy Sciences). Tissue sections (total) were prepared, permeabilized with acetone for 5 min, and incubated with goat serum for 30 min to block nonspecific protein-protein interactions. Tissue sections were incubated overnight with the following antibodies: anti-calreticulin (Pierce, PAS-25922), anti-Trp1 (Abeam, ab3312; clone TA99), and anti-Hsp70 (Novus Biologicals, NBP1-77455). Appropriate secondary antibodies were used for 30 min at room temperature. Nuclei were detected using DAPI (Invitrogen). At least 10 fields / sample were analyzed blindly on an Inverted Olympus IX81 fluorescent microscope.

[0153] Focused Ultrasound Therapy System. A treatment and imaging probe system (TIPS, Philips Research North America, Briarcliff Manor, NY, USA) was utilized for all ultrasound exposures. The system is capable of delivering focused and spatiotemporally controlled ultrasound energy and consists of a treatment control workstation, an RF generator and control electronics, an eight element spherical shell annular array ultrasound transducer (80 mm radius of curvature, 80 mm bore), and a motion stage that allows transducer motion in-plane and precise positioning perpendicular to the ultrasound beam axis. The focused ultrasound beam can also be steered approximately ±15 mm out-of-plane using electronic deflection of the focal spot. The ultrasound beam is spread perpendicularly to the target through a thin (25 pm) circular plastic membrane, with acoustic coupling provided by degassed water. During treatment, the system allows adjustment of acoustic power, ultrasound exposure duration, duty cycle, and ultrasound frequency.

[0154] In vivo focused ultrasound (FUS) therapy. Mice were anesthetized with a continuous flow of 1.5 liters / min of 1.5% isoflurane in pure oxygen. The cancer-bearing leg or lumbar lateral spine was carefully shaved to ensure proper acoustic coupling. Once the animal was positioned for treatment, the tumor was acoustically coupled to the TIPS system using degassed water and ultrasound gel. The center of the tumor was then placed at a focal distance of 80 mm from the transducer. Ultrasound exposure was delivered to the tumor using a 1 mm grid pattern that extended throughout the tumor volume. Two layers of grid points (spaced 5 mm apart) were placed in each tumor, resulting in approximately 160 discrete foci per tumor and a 5 minute exposure period. The ultrasound transducer was operated at 1.0 MHz, resulting in an elliptical focus of approximately 1.5 mm in diameter and 12 mm in length (at -6 dB pressure) as measured along the elliptical axis. Ultrasound exposure was delivered to the tumor using a 1 mm grid pattern extending across the entire tumor volume. Prior to treatment, the tumor volume was measured to calculate the grid size for the specific treatment. The duration of the ultrasound exposure at each grid point was 1.5 seconds, after which the transducer was automatically positioned on the next grid point and the procedure was repeated until the entire tumor volume was covered. Two layers of grid points were provided for each tumor. The therapeutic ultrasound device was operated in continuous wave mode with a specific acoustic power / pressure regime: acoustic power 3 W, peak negative pressure = 2.93 MPa (focal length of 80 mm) / 3.81 MPa (focal length of 85 mm) to result in non-ablative low energy FUS (LOFU). The resulting in situ intensity at the focal point (I spta ) at a depth of 4 mm in tissue at 550 W / cm 2 The total energy deposition in the tumor was estimated to be approximately 900 J.

[0155] In vivo hypofractionated cone-beam computed tomography image-guided radiation therapy (IGRT): All radiation was delivered using Xstrahl Limited's Small Animal Radiation Research Platform (SARRP) to deliver a dose of 10 Gy to the target tumor in 341 seconds. Anesthetized animals were placed on a stage attached to a motorized platform, and the tumor-bearing right hind limb was extended, elevated, and immobilized to a 1.5 cm adhesive platform to minimize external tissue exposure. Once immobilized, cone-beam computed tomography (CBCT) was performed, and data were opened in 3DSlicer for tissue segmentation and treatment planning. For a total hypofractionated dose of 30 Gy, 10 Gy was delivered on three consecutive days. In the combined therapy group, LOFU was performed 2-4 hours before CBCT.

[0156] Assessment of pulmonary metastases: Lungs were isolated from animals that died spontaneously, were euthanized, or were sacrificed at the end of the 8-week experiment. 1 mL of Fekete's solution (ethanol, glacial acetic acid, and formaldehyde-based bleach-fix solution) was insufflated into the lungs. The trachea was then clamped, and the lungs and heart were removed en bloc and washed with PBS. The lungs were then placed in Fekete's solution and bleached for 48 h before analysis. The left lung and the four lobes of the right lung were separated and nodules were counted using a dissecting microscope. Indistinct or confluent nodules could not be reliably counted; therefore, lungs were labeled as too numerous to count and assigned an arbitrary number of metastases of 250. Statistical analysis was performed using the nonparametric Kruskal-Wallis test, followed by Dunn's test for multiple comparisons.

[0157] Recurrence-free survival: The following events were scored as positive events in our recurrence-free survival analysis: spontaneous death due to necropsy confirmation of tumor lesions, euthanasia due to extensive regional metastasis to draining popliteal or inguinal lymph nodes, or euthanasia due to moribundity indicating extensive systemic tumor burden. The following non-tumor-dependent deaths were treated as censored data: death within 24-48 hours of amputation or sacrifice of animals at the end of the 8-week experiment. To prevent selective sacrifice of control or treated animals, cages were labeled using alphanumeric codes so that the animal laboratory veterinarians were blinded from the treatment and control groups. Recurrence-free survival was analyzed using the Mantel-Cox test, and statistical significance was defined as P<0.05.

[0158] Real-time PCR: Total RNA was extracted from cells using the RNeasy Micro kit (Qiagen) and cDNA was synthesized using qScript cDNA supermix (Quanta Biosciences). cDNA samples were subjected to real-time PCR using PowerSYBR (Applied Biosystems) as the reporter dye on a StepOnePlus real-time PCR system (Applied Biosystems). Expression of the tested transcripts was normalized to beta-actin. The primer sets used are:

[0159] actinb:F-GTGACGTTGACATCCGTAAAGA (SEQ ID NO:1), R-GCCGGACTCATCGTACTCC (SEQ ID NO:2);Cblb:F-GCAGCATCATTGACCCTTTCA (SEQ ID NO:3), R-ATGTGACTGGTGAGTTCTGCC (SEQ ID NO:4); NO:5), R-GTGCGCAGCTGAAGCTTTCCAATA (SEQ ID NO:6);Icharos:F-GCTGGCTCTCGGAGGAG (SEQ ID NO:7), R-CGACTTGTACACCTTCAGC(SEQ ID NO:8); R-CTTTGCGTGGAAAGTGGAGT (SEQ ID NO:10);Egr2:F-TCAGTGGTTTTATGCACCAGC (SEQ ID NO:11), R- GAAGCTACTCGGATACGGGAG (SEQ ID NO:12); NO:14);Itch:F-GTGTGGAGTCACCAGACCCT (SEQ ID NO:15), R-GCTTCTACTTGCAGCCCATC (SEQ ID NO:16);Foxp3:F-GGCCCTTCTCCAGGACAGA (SEQ ID NO:17);

[0160] Flow cytometry: Cells were preblocked with Fc-blocking (CD16 / CD32) antibody before immunostaining. The following fluorochrome-conjugated antibodies were used: anti-B7.1, B7.2, CD11c, MHC-II, CD45 and their respective isotype control antibodies (eBiosciences); anti-Hsp70 (Novus Biologicals) and anti-TRP1 (Abcam). Dead cells were detected by using UV LIVE / DEAD Fixable Dead Cell Stain kit (Invitrogen). Immunostained cells were analyzed on an LSR-II Flow Cytometer (Becton Dickinson) and post-acquisition analysis was performed using FlowJo software.

[0161] <Example 2> A hypoxic tumor microenvironment results in oxidative endoplasmic reticulum (ER) stress, which in turn leads to protein misfolding and the unfolded protein response (UPR). The UPR induces several molecular chaperones, including heat shock protein 90 (HSP90), which correct protein misfolding and improve cancer cell survival and resistance to tumoricidal treatment, whereas prolonged activation of the UPR induces cell death. The HSP90 inhibitor, 17AAG, has shown promise against various solid tumors, including prostate cancer (PC). However, therapeutic doses of 17AAG elicit systemic toxicity. A new paradigm is disclosed herein, where combination therapy of non-ablative and non-invasive low-energy focused ultrasound (LOFU) with non-toxic low doses of 17AAG causes synthetic lethality and significant tumoricidal effects in mouse and human PC xenografts. LOFU induces ER stress and UPR in tumor cells without inducing cell death. Treatment with a non-toxic dose of 17AAG further increased ER stress in LOFU-treated PCs and switched the UPR from a cytoprotective response to an apoptotic response in tumors, resulting in significant induction of apoptosis and tumor growth retardation. LOFU-induced ER stress renders ultrasound-treated tumors more sensitive to chemotherapeutic agents such as 17AAG. LOFU-induced chemosensitization is a new treatment that can be used against tumors, e.g., locally advanced and recurrent tumors.

[0162] Treatment plan and toxicity of LOFU and 17AAG treatment: For each grid location, LOFU was administered for 1.5 seconds using a 100% duty cycle, acoustic power of 3 W, and an ultrasound frequency of 1 MHz. The protocol consisted of 270 W / cm 2This resulted in an approximate in situ spatial-peak temporal average acoustic intensity of 17AAG, resulting in a predicted mean intratumoral temperature increase of 3.2°C. There were no signs of normal tissue toxicity, such as hair loss, thermal damage, or skin wounds, following treatment. Preclinical pharmacokinetic studies in mice showed that 17AAG is widely distributed and undergoes extensive hepatic metabolism. Systemic administration of 17AAG is known to be associated with significant hepatotoxicity, characterized by increases in transaminases and bile acids, and drug-related histopathological lesions in the gallbladder, common bile duct, and gastrointestinal tract. Therefore, a dose of 17AAG that was non-toxic to our treatment was determined. C57Bl / 6 mice were treated with intraperitoneal injections of 17AAG (25-75 mg / kg body weight) three times per week. Control mice were injected with an equivalent volume of the vehicle DMSO, which was used to make 17AAG soluble. Higher doses of 17AAG (50-75 mg / kg of body weight) treatment achieved significant tumor growth retardation compared to untreated controls (untreated tumors, 1879 ± 98.65 mm, respectively). 3 17AAG 75mg / kg body weight (bw), 485±24.25mm 3 , p<0.003 and 50 mg / kg bw, 964 mm 3 and p<0.007), but the Kaplan-Meier method showed 50% death of mice after 21 days of treatment at a dose of 75 mg / kg of body weight.

[0163] The low doses of 17AAG that were found to be non-toxic were 25 mg / kg in C57Bl / 6 mice and 14 mg / kg in Balb / c nude mice. Therefore, these dose levels were selected for the current study. The aim was to combine two sub-therapeutic, but non-toxic, treatments to test whether the combination could be therapeutic. Combined treatment of LOFU+17AAG amplifies ER stress: accumulation of misfolded proteins in the ER triggers a stress response with induction of chaperone proteins that help correct protein misfolding. To detect the level of ER stress, the expression levels of ER chaperones, ERp44, ERp57, and ERp72, were quantified among the different treatment groups. ERp44 is responsible for oxidative protein folding. ERp57 is an ER-resident thiol-disulfide oxidoreductase, whereas Erp72 is a disulfide isomerase. All these proteins are involved in the mechanism of protein folding in the ER. Immunoblot analysis demonstrated a significant increase in the expression of protein levels of ERp78 (p<0.03, Fig. 9D and E), ERp44 (p<0.05, Fig. 9D and G), and ERp57 (p<0.04, Fig. 9D and F) in tumor tissues after combination therapy with LOFU+17AAG compared with tumor tissues from animals that received no treatment or only LOFU or 17AAG, suggesting that 17AAG-mediated inhibition of HSP90 may increase the unfolded protein load in the ER, thereby prolonging ER stress.

[0164] LOFU+17AAG activates the proapoptotic pathway of the UPR and induces apoptosis in mouse and human prostate cancer tissues: ER stress simultaneously activates the three arms of the UPR, thereby simultaneously generating antagonistic cytoprotective and apoptotic signals. The fate of a cell depends on the ability of its protein corrective mechanisms to reduce ER stress, thereby attenuating the UPR. If ER stress persists, the cytoprotective pathways are eventually overwhelmed with chronic activation of the PERK-mediated apoptotic pathway, which causes cell death.

[0165] Since phosphorylation of PERK at Thr98O serves as a marker for its activation state, immunoblot analysis was performed and showed a significant increase in pPERK levels in tumor tissues after treatment with 17AAG (Figure 10A). Phosphorylated PERK levels were absent in untreated and LOFU-treated tumors. However, LOFU+17AAG combination therapy showed the highest levels of PERK phosphorylation (Figure 10A). Since prolonged PERK activation attenuates protein synthesis in response to ER stress via phosphorylation of translation initiation factor eIF2α at serine 51, the levels of phosphorylated eIF2α were determined. Treatment of RM1 tumors with 17AAG induced phosphorylation of eIF2α above the basal levels of untreated controls. LOFU treatment resulted in a slight decrease in phosphorylated eIF2α levels. However, the highest levels of phosphorylated eIF2α were found in tumors that received combination therapy with LOFU+17AAG (Figure 10B), demonstrating the highest activation of PERK phosphorylation in these tumors compared to the other groups.

[0166] Phosphorylated eIF2α reduces the translation of most cellular proteins, including pro-survival and anti-apoptotic proteins, but increases the translation of ATF4, a transcription factor responsible for inducing the transcription of pro-apoptotic genes, such as CCAAT / enhancer-binding protein homologous protein (CHOP), thereby preparing cells for programmed cell death if misfolded proteins are not repaired and ER stress persists. LOFU treatment did not induce CHOP levels (1.6±0.7-fold) relative to untreated controls. In contrast, treatment with 17AAG alone induced CHOP transcription levels by 14.8±2-fold, which was further increased by 25±1.3-fold (p<0.006) in the LOFU+17AAG combination therapy group compared to untreated controls (Figure 10C).

[0167] To examine whether downstream apoptotic genes were expressed after CHOP induction by LOFU+17AAG combination therapy, mouse UPR qRT-PCR Array was used on total RNA isolated from tumor tissues of various treatment groups. Heatmap analysis demonstrated that proapoptotic target genes, such as Bax, Vcp, Pdia3, Armet, Ddit3, Mapk8, Mapk9, and Mapk10, were induced several-fold after LOFU+17AAG combination therapy compared to untreated controls (Figure 10D). Treatment with LOFU alone or 17AAG alone resulted in minimal induction of proapoptotic genes. This result indicates that LOFU+17AAG combination therapy activates PERK, induces CHOP, and switches on the proapoptotic pathway of UPR. Indeed, TUNEL staining demonstrated that LOFU induced minimal apoptosis over untreated controls. Treatment with 17AAG induced significant apoptosis in prostate tumors, which was further increased by LOFU (p<0.004) (Figure 8E). Thus, 17AAG-mediated inhibition of HSP90 and activation of CHOP by the combination of LOFU+17AAG switched on apoptotic cell death in prostate tumors. LOFU+17AAG inhibits chaperone-mediated autophagy (CMA) in tumor cells.

[0168] Degradation of misfolded proteins is mediated by the proteosome pathway and autophagy. Autophagy is implicated in the tumorigenesis process in a context-dependent role, where it may provide amino acids and other essential nutrients to the metabolic pathways of nutrient-starved, hypoxic tumors. In fact, increased CMA activity has been found in a wide variety of human tumors, and CMA has been implicated in tumor cell survival, proliferation, and metastasis. Therefore, we quantified the levels of two key proteins involved in autophagy, namely Beclin, a marker of macroautophagy, and LAMP-2A lysosomal receptor, a marker of CMA, in tumor tissues of different treatment cohorts. As shown in Figure 10, Beclin levels remained unchanged with LOFU or 17AAG, or combination therapy (Figure 9A and C), indicating that macroautophagy was not altered with ultrasound therapy. However, LOFU alone or 17AAG alone induced the expression of LAMP-2A (Figure 11A and B), indicating a compensatory increase in CMA after treatment that increases the load of misfolded proteins in the ER. Interestingly, the combination of LOFU+17AAG inhibited the levels of LAMP-2A below the basal levels seen in these tumors. This suggests that the combination therapy reduces tumor cell proliferation and induces apoptosis by increasing ER stress while suppressing CMA.

[0169] LOFU sensitizes human and mouse prostate cancer xenografts to non-toxic low doses of 17AAG: treatment with LOFU alone or low doses of 17AAG (25 mg / kg body weight) alone showed no toxic effects on normal tissues but failed to inhibit tumor growth. However, combination therapy of LOFU+17AAG reduced the growth of murine RM1 tumors (Figure 10B). The mean estimated tumor growth was 5% (p<0.0001), 9% (p<0.0001), and 11% (p<0.0001) slower in the LOFU, 17AAG, and LOFU+17AAG cohorts compared to the control group. Tumor size 2000 mm in control, LOFU, and LOFU+17AAG 3The median times to achieve this size were 18, 22, and 42 days, respectively. All animals in the 17AAG group achieved that size within the time interval of 26 to 30 days.

[0170] A similar degree of chemosensitization was observed in human PC3 tumors in BalbC nu / nu mice by applying LOFU together with a non-toxic low dose of 17AAG (14 mg / kg of body weight), achieving significant tumor growth retardation (p<0.007) without immediate adverse side effects (Figure 5C).

[0171] LOFU+17AAG treatment reduces prostate cancer stem cell population in tumor tissue: The effect of LOFU+17AAG-induced ER stress on PC stem / progenitor population was assessed by flow cytometry analysis of PC stem / progenitor cell surface markers. The percentage of cells expressing cell surface SCA1 (Figure 13A and B) (p<0.004), CD44 (Figure 13A and C) (p<0.003), CD133 (Figure 13A and D) (p<0.007), and α2β1 integrin (p<0.005) (Figure 11A and E) was significantly reduced in the combination therapy group compared to control or single treatment cohorts. The mean fluorescence intensity (MF1) of all these markers remained unchanged in all three groups. qRT-PCR arrays of stem cell transcription factors demonstrated increased (>2-fold) mRNA levels of TIx3, Hoxall, Pcna, Gli2, Runxl, Foxa2, Sp1, Tbx5, HoxalO, Nfatcl, Gata6, and Notch2 (FIG. 13F), indicating that LOFU induces PC stem cell transcriptional signaling. Treatment with 17AAG also increased the expression of several transcription factor mRNAs present in LOFU-treated tumors, such as FoxPl, Nrf2f, and Pou5fl. However, tumors treated with LOFU+17AAG downregulated the expression of these genes, suggesting that maximizing ER stress by combination therapy may decrease the PC stem / progenitor cell population in tumors.

[0172] The results demonstrate that the combination of LOFU and chemotherapy reprograms the expression of pro-apoptotic genes in tumors and induces widespread apoptosis in tumor xenografts, resulting in significant tumor growth retardation in mouse and human PC tumors. In some embodiments, LOFU can improve resistance to chemotherapy and achieve chemosensitization.

[0173] Animals: Five- to six-week-old male C57Bl / 6 (NCI-Fort Dietrich, MD, USA) and athymic nude (BalbCnu / nu mice, Jackson Laboratory, Bay Harbor, ME, USA) mice were maintained ad libitum and all studies were performed under the guidelines and protocols of the Institutional Animal Care and Use Committee of the Albert Einstein College of Medicine.

[0174] Tumor Models and Treatments 1 × 10 5 RM-1 (mouse prostate cancer cell line) and 1 × 10 6 Cells of PC3 (a human prostate cancer cell line) were injected subcutaneously. Approximately 10 days later, when tumors were palpable (3-5 mm in diameter), LOFU treatment was initiated. Mice were divided into four groups (n=5 / group): no treatment, LOFU, 17AAG (InvivoGen, San Diego, CA, USA), and 17AAG+LOFU. Palpable tumors were treated with LOFU every 3-4 days for five fractions administered over a 2-week period. Animals received 17AAG three times a week during this time. Measurements of tumor volume were performed twice weekly using calipers, along with simultaneous physical assessment of signs of systemic toxicity (malaise and diarrhea).

[0175] <Example 3>

[0176] Ablative procedures such as high intensity focused ultrasound (HIFU), radiofrequency ablation (RFA), and cryotherapy have the potential to release tumor-derived proteins that may, in some cases, become available for uptake by dendritic cells (DCs) and other professional antigen-presenting cells (APCs) of the immune system. Clinical HIFU uses high temperatures that reach 95-100 °C within minutes at the focal point, which instantly kills tumor cells and destroys tissue architecture and vasculature. This can prevent the infiltration of immune cells in HIFU-treated tumors. Tumor cells do not have time to respond to the thermal stress and trigger stress proteins such as HSPs for immune activation. HIFU-induced coagulation necrosis can release large amounts of denatured tumor proteins, but may induce antigen tolerance from antigen loading, and denatured cell proteins require further antigen processing and cross-presentation by DCs for T cell activation. Pretreatment of tumors with low-energy focused ultrasound (LOFU), which induces sonic stress by increasing the temperature to 42-45°C without killing cells, can result in cytoplasmic protein denaturation, endoplasmic reticulum (ER) stress, and increased expression of molecular chaperones such as heat shock proteins (HSPs). Antigen processing mechanisms ultimately process misfolded proteins as antigenic peptides presented on the cell surface MHC for T cell recognition. Subsequent exposure of LOFU-treated tumors to HIFU 1-2 days later results in tumor cell death and release of HSP-tumor-peptide complexes into the extracellular compartment and bloodstream, autologous in situ tumor vaccination. Thus, sequential application of LOFU and HIFU provides a source of tumor antigens and endogenous "danger" signals for DC activation, thereby inducing a tumor-specific systemic immune response that enhances the efficacy of therapeutic ultrasound to control both local and systemic disease.

[0177] Three human prostate cancer cell lines (DU145, PC3, and LNCap), two mouse prostate cancer cell lines (RM-1 and Tramp-C1), and a mouse model were tested for the efficacy of combined HIFU and LOFU therapy. Induction of HSPs was measured by ELISA, immunofluorescence staining, and flow cytometry. Cell proliferation and number were determined by ELISPOT assay.

[0178] Pretreatment with non-ablative LOFU allows tumor cells to process misfolded proteins, and subsequent treatment with HIFU 1 day later allows HSP peptide complexes to be released from dead tumor cells for DC uptake and induction of T cell immunity. RM1-OT tumors expressing palpable OVA were sequentially treated with LOFU followed by HIFU 1 day apart, and animals were sacrificed on days 3, 7, and 14 after LOFU treatment. Meanwhile, tumor-specific T cell responses were not detected in one cycle of LOFU and HIFU treatment, but there was a modest increase in the total number of IFN-γ-producing cells (stimulated by PMA and ionomycin) on day 3 (110±5 / 2.5×105 cells LOFU and 66±16 / 2.5×105 cells HIFU vs. untreated, p<0.05, FIG. 14A), indicating that LOFU and HIFU treatment could skew the immune response toward a Th1 phenotype. However, the number of IFNγ-secreting cells decreased to pretreatment levels at 7 and 14 days without statistical differences among the various groups (data not shown). Thus, repeated treatment of tumors with LOFU and HIFU could promote the release of HSPs and tumor antigens for periodic immunization and simulate a vaccination schedule for the induction of tumor-specific immune responses.

[0179] Palpable RM1-OT tumors were treated three times with weekly cycles of successive LOFU and HIFU administered one day apart, and animals were sacrificed one week after the last HIFU treatment. The frequency of tumor-specific T cells in splenocytes was analyzed by IFN-γ ELISPOT assay to detect the cytotoxic function of these tumor-reactive T cells. When splenocytes from mice treated with LOFU and HIFU were co-cultured with irradiated RM1-OT cells, the number of IFN-γ-secreting RM1-OT-reactive T cells increased (432 ± 65 cells per 2.5 × 105 splenocytes after LOFU and HIFU vs. 15 ± 6 cells per 2.5 × 105 splenocytes after HIFU alone; Fig. 14B). The frequency of tumor-specific IFN-□-releasing T cells in mice treated with LOFU and HIFU was 0.17 ± 0.03%. These tumor-reactive splenocytes were found to specifically recognize both the OVA-derived MHC class I-restricted peptide, OVA257-264 (149±28 cells per 2.5×105 total splenocytes) and the MHC class II-restricted peptide, OVA323-339 (132±32 cells per 2.5×105 total splenocytes) when co-cultured with these peptides. In contrast, no significant immune response was detected in mice treated with either LOFU or HIFU alone (15±6 cells per 2.5×105 total splenocytes in both groups). These results indicate that the combination therapy of LOFU+HIFU can induce both CD4 and CD8 T cell responses against OVA, a surrogate cytoplasmic tumor antigen. HIFU treatment alone induced cell death and release of HSPs in tumor tissues but did not induce significant antitumor cellular immunity.

[0180] Tumor-specific cytotoxic T lymphocytes (CTLs) were assessed by CD107a recruitment assay, measuring the presence of cell surface CD107a on splenocytes after culture with irradiated RM1-OT cells. CD107a is a membrane protein of perforin / granzyme B vesicles that becomes transiently recruited to the cell surface during the cytotoxic degranulation process by CTLs. Although CTLs were present in all treatment groups, tumor-specific CD107a+ T cells were highest in mice treated with LOFU and HIFU (27.88±4.80% in LOFU and HIFU treated mice vs. 7.5±1.2% in untreated mice, p<0.05; FIG. 14C). The percentage of CD8+ T cells that were reactive to a surrogate tumor antigen (OVA) was quantified by H-2b / OVA257-264 tetramer staining (FIG. 14D). Although untreated or single treatment cohorts had negligible OVA-reactive CD8 T cells, these cells increased after LOFU and HIFU treatment (0.12% LOFU and HIFU vs. <0.01% untreated), further confirming the presence of tumor-specific T cells in vivo.

[0181] Finally, to examine whether pretreatment with non-ablative LOFU enhances the therapeutic effect of HIFU, tumor volumes in mouse models were measured over multiple days (FIG. 14E). The time interval for HIFU exposure was kept the same between treatment groups. Tumor sizes in various groups were not significantly different after one cycle of ultrasound therapy, but growth delay was observed after two cycles. Tumor growth rate was not altered with LOFU treatment alone compared to untreated controls (p>0.05). HIFU alone significantly inhibited tumor growth compared to LOFU cohorts and untreated cohorts (p<0.05). Pretreatment with LOFU enhanced the tumor-destructive effect of HIFU treatment as shown by the relative mouse photographs (FIG. 14E, upper panel) (LOFU and HIFU vs. HIFU, p<0.01; LOFU and HIFU vs. LOFU or no treatment (NT), p<0.001).

[0182] LOFU system: A treatment and imaging probe system (TIPS, Philips Research North America, Briarcliff Manor, NY, USA) was utilized for all ultrasound exposures. The system includes an 8-element spherical shell annular array transducer (80 mm radius of curvature, 80 mm aperture) and a translation stage that allows for transducer movement and precise positioning. The transducer was operated at 1.0 MHz, resulting in a focal spot approximately 1.5 mm in diameter and 12 mm long (-6 dB pressure).

[0183] LOFU Treatment Protocol: On the day of treatment, animals were anesthetized with ketamine and xylazine (7:1 mg / ml for 100 μl / mouse, intraperitoneally (ip)). Once positioned for treatment, tumors were acoustically coupled to the TIPS system using degassed water and ultrasound gel.

[0184] Ultrasound exposure parameters were as follows: 270 W / cm at a sonication depth of 3 mm in tissue, assuming an attenuation coefficient of 0.5 dB cm−1 MHz−1. 2 Approximate in situ spatial peak temporal average intensity (I spta ), with an acoustic power of 3 W and a duty cycle of 100%. Ultrasound exposure was delivered to the tumor using a 2 mm grid pattern extending across the entire tumor volume. Before LOFU, the tumor volume was measured to calculate the grid size for a particular treatment. The duration of LOFU exposure at each grid point was 1.5 seconds, after which the transducer was automatically positioned over the next grid point and the procedure was repeated until the entire tumor volume was covered. This resulted in non-uniform energy delivery to the tumor.

[0185] In vitro temperature rise prediction: Prediction of intratumoral temperature by invasive means may unnecessarily modulate the therapeutic effect of combined treatments. Therefore, to predict intratumoral temperature rise using the above setup and treatment protocol, ultrasound exposures were performed within a 6 mm x 6 mm area in a tissue-mimicking phantom, in which a T-type thermocouple (200 pm diameter) was embedded at a depth of 3 mm. These in vitro exposures were repeated five times and the results were averaged.

[0186] Detection of apoptosis in situ: Apoptotic cells were detected in situ by performing TUNEL (TdT-mediated digoxigenin-labeled dUTP nick end labeling) staining. Briefly, paraffin-embedded sections were deparaffinized, rehydrated through graded alcohols, and stained using the ApopTag kit (Intregen Co, Norcross, GA, USA). The apoptosis rate in tumor cells was quantified by counting the percentage of apoptotic cells in each high-power field.

[0187] Immunoblot analysis: 24 hours after LOFU, tumor cells were harvested, washed with phosphate-buffered saline, and lysed using TPER (Thermo Fisher Scientific, Rockford, IL, USA). Cell lysates were subjected to SDS-PAGE, transferred to polyvinylidene difluoride membranes, and immunoblotted with primary antibodies against PERK, pPERK, eIF2, peIF2, ERp72, ERp44, ERp57, Beclin (Cell Signaling, Danvers, MA, USA), Lamp2a (Abcam, Cambridge, MA, USA), and horseradish peroxidase-conjugated secondary antibodies. Blots were developed using an ECL kit (GE Healthcare, Piscataway, NJ, USA). Densitometric analysis of the immunoreactive bands of each blot was photographed, and then the images were digitized and analyzed by using a Gel Doc XR system (Bio-Rad, Hercules, CA, USA).

[0188] Real-time PCR analysis of UPR target genes. Twenty-four hours after LOFU treatment, RM1 tumor cells were lysed using RLT buffer mixed with 1% β-mercaptoethanol from the RNeasy Mini kit (Qiagen, Valencia, CA, USA).

[0189] RNA was isolated from tumor lysates using Qiagen's protocol for the RNeasy Mini kit with on-column DNA digestion. RNA samples were stored at -80°C before further use. The isolated RNA was subjected to cDNA synthesis using the SuperScript™ First-Strand Synthesis System (Invitrogen, Grand Island, NY, USA). Splicing of XBP1 RNA was detected using the following primer pair 5'-ACTCGGTCTGGAAATCTG-3' (SEQ ID NO:19) and 5'-TAGCCAGGAAACGTCTAC-3' (SEQ ID NO:20) (Fisher Scientific, Pittsburg, PA, USA). Real-time PCR was performed in a Light Cycler real-time PCR machine (Bio Rad Laboratories, Hercules, CA, USA) using Absolute QPCR SYBER Green Mix (ABgene, Rochester, NY, USA) according to standard ABgene protocols. To confirm the specificity of primer amplification, melting curves were generated at the end of PCR, and different samples containing the same primer pairs showed consistent amplicon melting temperatures.

[0190] Primers used for real-time PCR included GRP78 5'TTGCTTATGGCCTGGATAAGAGGG3' (SEQ ID NO:21) and 5'TGTACCCTTGTCTTCAGCTGTCAC3' (SEQ ID NO:22); EDEM 5' TCATCCGAGTTCCAGAAAGCAGTC 3' (SEQ ID NO:23) and 5' TTGACATAGAGTGGAGGGTCTCCT 3' (SEQ ID NO:24) (Fisher Scientific). All qRT-PCR and real-time PCR experiments were repeated three times. qRT-PCR and PCR arrays for apoptotic genes and stem cell transcription factors were performed by SA Biosciences PCR array system (Frederick, MD, USA) according to the manufacturer's protocol. In brief, RT 2 cDNA was prepared from purified total RNA using the First Strand kit (Qiagen), and then PCR arrays were performed using the SA Bioscience PCR array kit. Data were analyzed by web-based PCR array data analysis software from SA Biosciences.

[0191] Flow cytometry analysis: Flank tumors were treated with LOFU, 17AAG, and LOFU+17AAG in various cohorts. 24 hours after treatment, tumor cells were isolated by collagenase digestion and analyzed by flow cytometry for expression of prostate cancer stem cell markers, SCA1, CD44, and CD133. Isolated tumor cells were stained with anti-SCA1 conjugated with FITC (BD Biosciences, La Jolla, CA, USA), anti-CD133 conjugated with pacific blue (eBioscience, San Diego, CA, USA), and anti-CD44 conjugated with PE (BD Biosciences, La Jolla, CA, USA). Data acquisition was performed using an LSRII (BD Biosciences) and analyzed by FlowJo v.7.1 (Treestar Inc, Ashland, OR, USA) software.

[0192] Kaplan-Meier method: Mouse survival / mortality in the different treatment groups was analyzed by the Kaplan-Meier method according to radiation dose using Sigma-Plot and GraphPad Prism (version 4.0 for OS X, San Diego, CA, USA) software.

[0193] Statistical Analysis: For digital images, sampling areas were randomly selected for digital acquisition for data quantification. Digital image data were evaluated in a blinded manner for all treatments. A two-tailed Student's t-test was used to determine significant differences (p<0.05) between experimental cohorts with representative standard error of the mean (SEM).

[0194] <Example 4>

[0195] FIG. 17 illustrates an acoustic stimulation therapy (APT) device, generally designated by reference character (1), according to an exemplary embodiment of the present invention. The APT device (1) is powered by a power source (not shown) and includes a control system (10), an amplifier (12), a matching transformer (14), and a transducer (16). To provide treatment, the ultrasound transducer (16) may be positioned near or within an area of ​​the patient's body (1000). Using a function generator in the control system (10), a clinician may make appropriate adjustments to the frequency and duration of the ultrasound pulses delivered by the transducer (16). When the ultrasound transducer (16) is excited, the transmission faces of the transducer elements generate pressure waves in the bodily fluid surrounding the ultrasound transducer (16). The pressure waves then propagate through the fluid and tissue within the patient's body (1000) and ultimately reach the target site, thereby causing non-ablative acoustic stress to the target tissue. As described in further detail herein, sonic stress delivered to tissue can have many therapeutic applications, for example, in the case of cancer treatment, such stress of cancer cells in a tumor can result in modulation of immunogenicity, radiosensitization, and chemosensitization. The ultrasound transducer (16) may be repositioned to an adjacent area of ​​the patient's body for further treatment.

[0196] The matching transformer (14) provides an impedance transformation between the power source and the ultrasonic transducer.

[0197] The amplifier 12 generates a transducer drive signal for driving the transducer 16 based on the output signal of the control system 10. In an exemplary embodiment, the amplifier 12 may be a switched resonant power amplifier, an example of which is disclosed in U.S. Patent No. 7,396,336, the contents of which are incorporated herein by reference in their entirety. In another embodiment, a low impedance ultrasonically driven transducer system may be used.

[0198] The transducer (16) delivers 10-1000 W / cm at the treatment zone. 2 The spatial peak time-averaged intensity (I spta ) of acoustic output. The ultrasound is applied continuously for a time period ranging from 0.5 seconds to 5 seconds, where the frequency is in the range of 0.01 to 10 MHz. In some embodiments, the minimum diameter of any ultrasound beam at the treatment zone is about 1 cm.

[0199] FIG. 17 illustrates an acoustic stimulation therapy (APT) device, generally designated by reference character (1), according to an exemplary embodiment of the present invention. The APT device (1) is powered by a power source (not shown) and includes a control system (10), an amplifier (12), a matching transformer (14), and an ultrasonic transducer (16). To provide treatment, the ultrasonic transducer (16) may be positioned near or within an area of ​​a patient's body (1000). Using a function generator in the control system (10), a clinician may make appropriate adjustments to the frequency and duration of the ultrasonic pulses delivered by the transducer (16). When the ultrasonic transducer (16) is excited, the transmission faces of the transducer elements generate pressure waves in the bodily fluid surrounding the ultrasonic transducer (16). The pressure waves then propagate through the fluid and tissue within the patient's body (1000) and ultimately reach the target site, thereby causing non-ablative sonic stress to the target tissue. As described in further detail herein, sonic stress delivered to tissue can have many therapeutic applications, and in the case of cancer treatment, for example, such stress in tumors can result in modulation of immunogenicity, radiosensitization, and chemosensitization of cancer cells. The ultrasound transducer (16) may be repositioned to adjacent areas of the patient's body for further treatment.

[0200] The matching transformer (14) provides an impedance transformation between the power source and the ultrasonic transducer (16).

[0201] The amplifier 12 generates a transducer drive signal for driving the transducer 16 based on the output signal of the control system 10. In an exemplary embodiment, the amplifier 12 may be a switched resonant power amplifier, an example of which is disclosed in U.S. Patent No. 7,396,336, the contents of which are incorporated herein by reference in their entirety. In another embodiment, a low impedance ultrasonically driven transducer system may be used.

[0202] The transducer (16) delivers 10-1000 W / cm at the treatment zone. 2 The spatial peak time-averaged intensity (I spta ) of acoustic output. The ultrasound is applied continuously for a time period ranging from 0.5 seconds to 5 seconds, where the frequency is in the range of 0.01 to 10 MHz. In some embodiments, the minimum diameter of any ultrasound beam at the treatment zone is about 1 cm.

[0203] 17, the frequency of the ultrasound generated by the APT device (1) is in the range of about 10 kHz to about 300 kHz. However, an APT device according to the present invention may generate higher frequencies, such as frequencies in the range of about 300 kHz to about 3 MHz.

[0204] As shown in Figure 18, one embodiment of such an APT device, generally designated by reference numeral (100), may include a control system (110), an amplifier (112), a matching transformer (14), and a transducer (116), such components having the same functions and structures as those described with respect to Figure 17. In an embodiment, the transducer (116) may be a planar or concave piston-type transducer comprised of single or multiple elements that convert another type of energy into acoustic energy.

[0205] As shown in FIG. 19, APT device (1) and APT device (100) may be integrated into a single system generally designated by reference number (200) to provide improved efficacy and / or lower overall energy input. The integrated system (200) provides focused low frequency and collimated high frequency beams for APT treatment. In some embodiments, the low frequency ultrasound is substantially focused according to what is achievable for a given frequency or range of frequencies, and the intermediate frequencies are collimated. In some embodiments, the transducer used to generate the low frequency is concave and the transducer used to generate the intermediate frequency is planar.

[0206] As shown in FIGS. 20-22, the APT devices (1), (100), (200) may cooperate with an ultrasonic monitoring system generally designated by reference character (300). The ultrasonic monitoring system (300) may be powered by a power source (not shown) and includes a control system (310), an amplifier (312), and a pulse receiving system (314). The ultrasonic monitoring system (300) may be used to monitor the target tissue and / or provide imaging of the target tissue before, during, and / or after an APT procedure, in particular, the pulse receiving system (314) may include a transducer that receives pressure waves reflected from or generated by or from within the target tissue, and the amplifier (312) generates an electrical signal corresponding to the received pressure waves. The control system (310) generates an output based on the electrical signal that may be used by a clinician to determine a treatment status and / or other parameters. Although the ultrasound monitoring system (300) is shown as a separate component from the APT devices (1), (100), (200), it should be appreciated that monitoring and APT delivery may be performed by a single system.

[0207] In some embodiments, the ultrasound monitoring system (300) is used to provide information regarding the location of the tissue being treated. One or more non-therapeutic ultrasound transmit and receive subsystems may be used to monitor the APT treatment and the effects of the treatment on the tissue.

[0208] In some embodiments, data collected and used to plan radiation therapy is also used, at least in part, to plan ultrasound treatment. In some embodiments, data collected for or planning an APT treatment is used to plan radiation therapy. In some embodiments, data collected for planning radiation therapy is used for planning an APT treatment.

[0209] In some embodiments, data collected during an APT treatment is used to plan radiation therapy.

[0210] In some embodiments, ultrasound is administered at a lower frequency to treat specific locations identified in part by ultrasound imaging performed at a higher frequency.

[0211] A variety of ultrasound-based imaging and monitoring modalities may be used to monitor power deposition in tissue during an APT procedure. In some embodiments, tissue temperature may be monitored by acoustic means.

[0212] In some embodiments, ultrasound elastography is used to monitor the treatment. In some embodiments, harmonic imaging is used to monitor the treatment. In some embodiments, thermal strain is measured. In some embodiments, the system is comprised of one or more ultrasound transmit and receive transducer subsystems that are used to measure tissue strain. The tissue strain information may be used to direct the treatment ultrasound beam to the desired tissue and, in some embodiments, prior to applying full treatment power to the treatment transducers. For example, in one embodiment, power is applied to one or more of the treatment transducers for 1-3 seconds at 10-50% of the planned treatment power and the target tissue strain is measured using ultrasound feedback. The treatment intensity, application time, or both of the APT transducers can be adjusted, or the transducers can be physically or electronically repositioned or effectively directed to the target tissue based on strain imaging. In some embodiments, the full power planned for the treatment is applied from one or more transducers, but for a time that is less than the time used for therapeutic effect during the strain measurement period until the desired targeting is confirmed.

[0213] In some embodiments, thermometry is used to monitor treatment. Temperature on or within the patient may be measured using a variety of methods, including but not limited to thermocouples, fiber optic probes, certain MRI pulse sequences, and ultrasound thermal strain imaging.

[0214] Each transducer of the APT systems (1), (100), (200) may be a single transducer or a series of multiple transducers. FIG. 23 is a perspective view of a transducer, generally designated by reference character (400), according to an exemplary embodiment of the present invention. The transducer (400) includes a series of transducer elements (402). Any number of the transducer elements (402) may be arranged in series along an azimuthal axis. The transducer elements (402) are supported on a backing block (404). As is well known, signal leads couple to electrodes of each transducer element (402) and transmitting and receiving circuitry. The transducer elements (402) convert electrical signals provided by transmitting circuitry into pressure waves.

[0215] In some mid-frequency embodiments (about 300 kHz to about 3 MHz), two or more ultrasound transducers generate intersecting ultrasound beams within a treatment zone, referred to herein as the intersecting zone, with each beam generating between 10 and 500 W / cm. 2 In the intersection zone in the range of I spta In an embodiment, the two transducers generate intersecting ultrasound beams within the treatment zone, each beam having an intensity of 20-200 W / cm. 2 In the intersection zone in the range of I spta In an embodiment, three transducers generate intersecting ultrasound beams within the treatment zone, each beam having an intensity of 20-300 W / cm. 2 In the intersection zone in the range of I spta has.

[0216] In some embodiments, the beams are substantially in phase with each other. In some embodiments, two ultrasound beams emitted from separate ultrasound transducers are substantially in phase and intersect within the treatment zone, each beam having an output of 20-100 W / cm. 2and the ultrasound is administered for 1-5 seconds in succession. In some embodiments, three ultrasound beams emitted from separate ultrasound transducers are substantially the same frequency and in phase, intersect within the treatment zone, and each beam has an acoustic power spatial peak intensity in the range of 50-70 W / cm 2 The ultrasound has an acoustic power spatial peak intensity in the intersection zone in the range of 1 to 5 seconds continuously.

[0217] In some embodiments, the beams generated from the individual transducers or transducer elements each have a power of approximately 300 W / cm in the treatment zone. 2 I spta In some embodiments, the beams generated from the separate transducers or transducer elements each generate between 10 and 100 W / cm in the treatment zone. 2 I spta Generate.

[0218] In some embodiments, the diameter of at least one transducer, and the ultrasound beam emitted from said transducer, is substantially larger than the treatment zone. The use of one or more such large transducers in combination with smaller transducers advantageously allows for less precise targeting of high power, large volume beams while achieving effective and faster treatment.

[0219] In some embodiments, where two or more beams intersect each other, a focused treatment zone is formed, the focused treatment zone being about 1 cm or more perpendicular to the direction of the transmitted energy and also about 1 cm or more parallel to the transmitted direction.

[0220] In some embodiments, the acoustic pressure applied to the treatment zone from each transducer is between 0.1 and 10 MPa.

[0221] In some embodiments, the number of transducers providing the focused ultrasound treatment zone is between 1 and 1000.

[0222] In some embodiments, one or more center frequencies are utilized during treatment with center frequencies ranging from about 100 kHz to 20 MHz.

[0223] In some embodiments, ultrasound from a given transducer is applied continuously. In some embodiments, ultrasound emitted from a given transducer is applied in pulses of alternating on and off time units, known as a duty cycle. The duty cycle can range from 1 on time unit to 9 off time units.

[0224] In some embodiments, the transducer transmits a single frequency sound or a multi-frequency chirp.

[0225] In some embodiments, the transducers are operated sequentially such that the total energy delivered to the target tissue during the entire course of application is greater than the total energy to the surrounding tissue.

[0226] In some embodiments, the frequency is swept during application to partially reduce zones of unnecessarily high intensity in zones near the transducer.

[0227] In some embodiments, the transducer comprising the treatment head is mechanically vibrated.

[0228] In some embodiments, the transducers are configured as a two-dimensional phased array, an annular array, and / or a three-dimensional phased array.

[0229] In some embodiments, one or more ultrasound transducers are incorporated into one or more endoscopic devices.

[0230] The APT treatment systems disclosed herein provide reduced thermal doses compared to thermal dosing schemes common to hyperthermia and ablative thermal therapies. In some embodiments, the maximum temperature reached in the treatment zone is about 45° C. or less for a treatment lasting about 2 seconds or less. In some embodiments, the maximum temperature reached in the treatment zone is about 45° C. or less for a treatment lasting about 3 seconds or less. In some embodiments, the maximum temperature reached in the treatment zone is about 50° C. or less for a treatment lasting about 2 seconds or less. In some embodiments, the maximum temperature reached in the treatment zone is about 50° C. or less for a treatment lasting about 3 seconds or less.

[0231] Considering the thermal mass, it is expected that the therapeutic effect is achieved in part by a thermal mechanism. Without wishing to be bound by theory, mechanical effects coupled with thermal effects may partially explain the observed effects of treatment using the disclosed devices, systems and methods.

[0232] In some embodiments, a couplant is used between the transducer and the patient's body to efficiently transmit ultrasound and, in some embodiments, to provide a desired distance between the transducer and the treatment zone. In some embodiments, the couplant is circulated to cool the transducer and / or the patient's body during treatment. Additional fluids may be used for the purposes of transmitting ultrasound, providing spacing, and cooling the patient and system components.

[0233] Without being bound by theory, APT treatment using the system described herein can promote the interaction between cells and between cells and matrix proteins. The interaction between cancer cells and immune cells, and the interaction between immune cells, for example, between T cells and DCs.

[0234] In some embodiments, APT treatment may disrupt a protein complex, for example a protein folding complex.

[0235] For patients with diseases that benefit from treatment with multiple modalities, penetration throughout targeted treatment zones and lesions within these zones, moderate application of each modality as well as short duration of treatment is desired.

[0236] Various other aspects of APT treatment devices and APT treatment modalities according to exemplary embodiments of the present invention will now be described:

[0237] <Positioning device> In some embodiments, the transducer applicator is designed so that it can be carried by a clinician or caregiver. In some embodiments, the applicator is mounted on a mechanical positioning device, such as the positioning device (500) shown in FIG. 24. The positioning device (500) can be manually operated or robotically controlled. In this embodiment, the positioning device (500) is an arcuate rail along which the transducer travels; in particular, the transducer may be mounted on a cable-driven carriage that in turn rides on the rail. The rail itself may be rotatable so that the transducer may be positioned in three dimensions. The positioning device (500) may be large enough so that the patient can fit under the transducer and within its target range. Although FIG. 24 shows only one transducer positioned on the rail, it should be appreciated that more than one transducer may be placed on the rail and / or other rails may be provided that support one or more other transducers. In some embodiments, a Stewart platform, sometimes called a hexapod, may be used in the positioning device. Computer programming may be used to set treatment parameters and operate the positioning device.

[0238] Equipment and patient cooling In some embodiments, the treatment system includes a patient cooling mechanism for cooling skin exposed to the ultrasound or other energy.

[0239] [Table 3]

[0240] <Audio stimulation system> In some embodiments, Acoustic Pstimulation Therapy (APT) has the potential to transform current treatments into highly effective in situ vaccines. For example, the combination of hypofractionated radiotherapy and AP can reverse T cell tolerance and eliminate melanoma metastases, for example to the lungs in animal or human melanoma models and cancer in patients. The animal model can be a canine or mouse animal model, and humans can be treated similarly. In some instances, APT is combined with radiotherapy (RT) to reduce overall toxicity, reduce ionizing radiation dose, and generate stronger and unique immunogenic tumor microenvironment (TME) damage patterns different from those that can be achieved with RT alone. In some instances, TME treatment can be achieved and metastasis and vascular niche can be modified. Although the combination effect mechanism is yet to be elucidated, treatment begins with damage-induced reprogramming at the level of the cell by tumor cell ER stress induction (mainly AP), DAMPs (AP and RT), and ROS & DNA damage (mainly RT). DC activation, migration lymph nodes, cytotoxic T cell activation, and migration to the tumor bed may follow.

[0241] Damage-induced reprogramming at the cellular level can be induced in many ways using energy treatments, such as non-ablative energy treatments. Each of the energies shown in Table 3 can be used to induce reprogramming at the cellular level, and this treatment can be combined with any of the treatments shown in Table 2, and combinations thereof. For example, dendritic cell targeting therapy, effector T cell targeting, or immune checkpoint inhibition can be combined with irreversible electroporation (IRE), microwave, low-intensity focused ultrasound (LOFU), high-intensity focused ultrasound (HIFU), radiofrequency energy, or cryotherapy, and combinations thereof.

[0242] The dendritic cell targeted therapy may include a material selected from the group consisting of Flt3L, CD40L, GM-CSF, ligands and agonists, RIG1 helicase activator, anti-CD40, NKG2D ligands, anti-CSF1R, anti-TLR, TLR ligands, INF-α, TNF-β.

[0243] The effector T cell target may comprise a material selected from the group consisting of anti-OX40, 4-1BBL, anti-foxp40 TGF-β inhibitor, anti-CD137, artificial immune synapse for T cell activation, anti-CD47, anti-CD27, and anti-GD2.

[0244] Immune checkpoint inhibition includes materials selected from the group consisting of anti-CTL4, anti-PD1, anti-VISTA, tim3, and IDO inhibitors (e.g., norharman, rosmarinic acid, COX-2 inhibitors, 1-methyltryptophan, epacadostat, navoximide).

[0245] In some embodiments, an acoustic stimulation (AP) system is configured to generate a range of ultrasonic fields. Possible relevant features consist of wide transverse field dimensions, low intensity, and multiple frequencies. The AP-1 system comprises a four channel unit that can be configured to deliver one to four frequencies with up to 16 transducer elements in the range of 0.1 to 4 MHz. In other examples, the AP-1 system may comprise two transducers. A dual frequency configuration may be used with one transducer operating at 1 MHz or higher and one transducer operating at 250 kHz. Intensity may range from 100 to 500 W / cm in the treatment zone. 2 The AP system may include a 5-15 mm transverse beam for use on a treatment volume of a mouse tumor model or other modalities, such as a tumor in a human patient. The control treatment volume may overlap with a variable frequency or incoherent non-ablative ultrasound (US) field. The AP system may be configured to use 1-4 transducers per channel. Treatment times may consist of 1-3 seconds per treatment volume, with multiple volumes scanned to treat the tumor. In some instances, a large amount of beam intersection focal area can reduce the overall treatment time. For example, a 1.2 cm wide by 2.0 cm long ellipsoid can result in a treatment zone of 1.5 cc volume. In another example, a 110 cc (diameter ~6 cm) tumor can be treated in approximately 220 seconds.

[0246] 25 illustrates an acoustic stimulation (AP) system according to an embodiment. The AP system includes a user interface, e.g., a computer display coupled to a computer, such as a laptop computer. The laptop computer can be coupled to a controller. The controller can be coupled to a linkage, such as a robotic arm. One or more ultrasound transducers described herein can be attached to the end of the linkage, such as a robotic arm, to control the placement of the ultrasound transducers on the patient.

[0247] The AP system can be configured for clinical treatment of humans and large animal models and can incorporate CT-based treatment planning. For example, a graphical user interface (GUI) can be provided on the display of the acoustic stimulation system of FIG. 25. FIG. 26 shows CT-based treatment planning for soft tissue sarcomas, such as canine soft tissue sarcomas. The AP system includes US elastography-based treatment monitoring that can be attached to a linkage, such as a robotic arm. For example, a dose monitoring feedback control system may be specifically designed for non-ablative AP treatments. Treatment temperature can be analyzed using thermal strain imaging and maintained, for example, below 50°C. The non-ablative nature of the treatment may not require as high precision in alignment and deposition. The simplified hardware design can create a substantially lower cost product and a user-friendly design.

[0248] The AP system can be configured for use in the treatment of solid surface or malignant tumors up to 8 cm deep that are candidates for an initial course of radiation therapy or are recurrent or progressive despite conventional therapy. The unit can target US energy with specific desired frequencies and spatiotemporal parameters as described herein to the lesion to modulate the lesion environment. In the case of cancer, acoustic stimulation therapy (APT) combined with stereotactic radiation therapy (SRT) and / or possibly with other modalities can activate antitumor components and the function of the innate and adaptive immune systems, ultimately alleviating cancer-related dysfunction. The advantages of APT include being fast, non-invasive, transfusion-free, and "point on click" to utilize the patient's tumor to generate a potent in situ vaccine against disseminated disease. The system described herein can deliver ultrasound with desired intensity, frequency, and focal size parameters and has been used in mouse cancer models or other treatment modality testing, e.g., in large animals and humans.

[0249] In some embodiments, a prototype unit can be built and used for bench testing, toxicity testing, and tumor treatment on companion animals or human cancer patients. The companion animal can be a dog. A conceptual diagram of the unit used for treatment planning and a GUI displaying CT segmentation data can be seen in Figure 26 (the treatment table is not part of the system).

[0250] In some embodiments, the acoustic stimulation treatment system may include an ultrasound treatment subsystem, a robotic subsystem, and an ultrasound diagnostic subsystem. The ultrasound treatment subsystem may include generator electronics and a transducer to generate a treatment zone of approximately 10 mm in the lateral direction and 20 mm in the axial dimension. There are at least two different transducer elements that generate ultrasound waves at two different frequencies, one low frequency less than about 400 kHz and the other high frequency greater than about 400 kHz. In some examples, a computer-controlled motorized robotic subsystem may be used to generate a treatment zone of the treatment beam that is smaller in volume than a typical tumor being treated, and to further manage exposure of healthy tissue outside the treatment zone.

[0251] The ultrasound diagnostic subsystem may consist of a transducer "probe" separate from that used for treatment generation. In another example, such a subsystem can position the treatment head and use elastography to monitor the effect of the treatment on the applied tissue. In another example, the CT DICOM data can be segmented for treatment planning.

[0252] Hardware and software architectures are provided in Figures 27 and 28. As shown in Figure 29, subsystems may include a positional scanning robot delivering ultrasound therapy, ultrasound diagnostic image analysis algorithms for treatment planning, intra-treatment motion tracking and intra-treatment dose delivery verification / measurement. Treatment modulation using ultrasound elastography can be integrated into the system architecture. Specific software tasks, such as bench testing of US treatment and thermal strain peck tracking subsystems, integration code for robot registration and transfer to acoustic stimulation treatment system software, design and code treatment algorithms using CT segmentation-based treatment planning, integrate all acoustic stimulation treatment system software modules into the working system, integrate ultrasound peck tracking system closed-loop algorithms, define spatial resolution and temperature sensitivity of strain imaging, develop deep learning algorithms incorporating localized treatment of tumors, may be designed. In other examples, components such as (i) construction and segmentation of 3D ultrasound images for use in treatment planning and monitoring, (ii) tumor vasculature imaging, and (iii) development of machine learning algorithms that combine biomarker data including imaging, tumor biopsy, liquid biopsy, and acoustic stimulation treatment system data into adaptive treatment plans during the course of treatment may be generated.

[0253] In some embodiments, the acoustic stimulation treatment system unit includes the following general operating environment and can be described with other components described herein: The acoustic stimulation treatment system may treat unwanted tissue within about 10 centimeters of the body surface. The targeted tissue may include the unwanted tissue as well as the margins surrounding the unwanted tissue. The acoustic stimulation treatment system may include a power source and controller to generate ultrasound, a delivery tool, and a motorized robot to position and move the delivery tool. The acoustic stimulation treatment system may include a stand-alone system capable of performing surgery and may include the necessary displays, operator controls, and ultrasound delivery systems. In some examples, the acoustic stimulation treatment system unit may include a centralized electronic control system, allowing a physician to control the treatment. The acoustic stimulation treatment system may include a controller means capable of administering the treatment while maintaining a safe temperature of the patient's healthy tissue, such as the skin. The temperature monitoring software may record the thermal readings of each temperature probe throughout the treatment. The GUI and software may be used to input patient information, treatment plan information, treatment parameters, and track the surgery. As known to those skilled in the art, all materials that come into contact with the patient may have established biocompatibility.

[0254] In some embodiments, the acoustic stimulation treatment system unit may include an ultrasound treatment subsystem, an ultrasound applicator, a central cart, a robotic subsystem, an irradiation instrument, and an ultrasound diagnostic subsystem. The ultrasound generation subsystem includes appropriate ultrasound signal generation and power to produce desired field parameters including intensity, frequency, and duty. In some embodiments, the components of the acoustic stimulation treatment system may be transported by a central cart or attached to a patient table. The central cart may include wheels to facilitate transportation. The wheels may be fixed to prevent the cart from accidentally moving during surgery. The cart may include four-wheel steering to facilitate maneuvering. In other examples, the cart cannot easily tip over. The system may be equipped with a minimum 12-foot hospital-grade power cord. The power source can be used in countries with different standard voltages by switching cables without switching power schemes. The cart provides a means to store the power cord on the back of the cart or within the cart. The unit may further include a support arm. The support arm provides support and allows the robot to be positioned as needed close to the patient. The support arm may include all necessary electrical and water lines and connections. In other examples, the support arm may include vertical height adjustment so that the lowest surface of the treatment head can be adjusted, for example, between 80-160 cm from the floor to treat a patient positioned on a treatment table. In some examples, the support arm is on swivel casters and can be steered closer to and further away from the treatment table.

[0255] In other embodiments, the unit may include a linkage such as a robotic arm. The robotic arm may include a support weight for the irradiation tool. The robotic arm may allow the focal region of the ultrasound treatment beam to be moved and positioned as desired. The robotic arm may move at a speed of 100 mm / sec in any linear direction. In some embodiments, the unit may include an irradiation tool. The irradiation tool may provide a means for proper positioning of the irradiation tool to treat the targeted tissue. In some examples, the irradiation tool may not compress the patient's tissue excessively so that the tissue moves unnecessarily, as confirmed by CT or ultrasound imaging. The treatment head may contain one or more US treatment transducers. The irradiation tool may apply ultrasound such that the targeted tissue does not exceed 55°C for 3 consecutive seconds. The irradiation tool may apply ultrasound such that the tissue outside the desired treatment zone does not exceed 45°C for 3 consecutive seconds. All surfaces of the irradiation tool that may come into contact with the patient may be made of a biocompatible material. An ultrasound transmission material may be provided between the irradiation tool and the skin. The material can function to cool the skin as needed so that the skin temperature does not exceed 43°C in one minute. The irradiation instrument can be ergonomically designed to support the treatment of a particular anatomical structure and part of the body, for example, human breast, human prostate, human applicator, and neck. The transducer in the irradiation instrument can be operated at 100% duty for a minimum of 10 minutes, and this cycle can be repeated a minimum of 1000 times. The irradiation instrument can be liquid cooled. In another example, the irradiation instrument can be water-based, with degassed water provided. The total weight of the irradiation instrument may not exceed, for example, 1 kg. In another embodiment, the unit may include a power source. The power source may include an RF power source. The RF power source may have an input bus for external control. The duty cycle may be adjustable from 0.05 to 1.0. The pulse width may be adjustable from 1 microsecond to 1 millisecond.

[0256] In some embodiments, the unit may include a temperature measurement control circuit. The control circuit may include a fiber optic or thermocouple temperature probe readout with overheat or "alarm" output capability for each channel. The control circuit may include a temperature probe for monitoring the temperature of critical components. The control circuit may include a temperature probe for monitoring surface temperature and ensuring patient comfort. The control circuit may include a temperature probe for insertion into the patient in areas of high ultrasound intensity to prevent tissue overheating. The control circuit may include at least one calibrated alternating magnetic field (AMF) probe for monitoring AMF amplitude where its relationship to the field map is documented and calibrated and can be used to monitor AMF amplitude in the treatment area prior to treatment. The control circuit may include circuitry for accepting the voltage output of the AMF probe, allowing for the designation of "alarm" points and outputting an "alarm" signal when a preset value is exceeded. The control circuit may include a CPU that monitors all temperature and AMF amplitude "alarm" outputs and sends an appropriate signal to the RF power supply to shorten the treatment. In other embodiments, the unit may include a temperature measurement system. The temperature measurement system may include a fiber optic temperature probe controller with over-temperature or "alarm" output capabilities for each channel. The system controller may include an output bus for sending logic signals when predetermined conditions are met. The temperature measurement system may provide an output for controlling AMF amplitude based on the temperature around the tumor. Two temperature probes may be used in the procedure. The probes may be applied to the target tissue as well as the surrounding tissue, for example in the form of a hypodermic needle. The surface texture of the temperature probe may be smooth to the touch. The connecting wires of the temperature probe may have a kink-resistant and kink-free 5" radius. The temperature probe may be temperature durable at 48°C and fully flex without distorting the set value. The temperature probe may be packaged in a sterilization-compatible pouch (e.g., a Tyvek bag) for protection. The temperature probe may be verified with two complete sterilization cycles.The temperature probe must meet biocompatibility requirements. In other embodiments, the unit may include a cooling system. The cooling system may have a means for directing cooling directly adjacent to the target tissue. The patient surface temperature may be maintained at or below 43°C. Patient contact parts of the cooling system must meet biocompatibility requirements. The cooling system may be constructed of non-metallic materials.

[0257] In some embodiments, the unit may include an irradiation tool that delivers ultrasound to the patient. In some configurations, the irradiation tool may be a treatment head. An ultrasound transducer may be attached to the applicator to generate the intersection of ultrasound waves from the treatment transducer. The ultrasound transducer may include one low frequency transducer (<400 kHz) and / or one high frequency transducer (>400 kHz). In some embodiments, the applicator may include one US image imaging probe. The applicator may be small enough to be placed to treat any body part, but large enough in size to allow intersection of the beam at the desired patient treatment zone. Maximum dimensions may be 150 mm diameter x 150 mm length. Maximum weight may be 1000 grams. In some embodiments, patient ergonomic considerations may include companion animals and humans, as well as anatomical location. The applicator must not interfere with or facilitate patient body surface temperature control for superficial tumors. A maximum surface temperature of 45°C may be applied for 3 seconds. Transducer cooling and transducer-to-patient couplant can be water with an acoustically transparent gel. Acoustic impedance matching from the transducer to the patient can include a water-filled, recirculated, degassed (<2 ppm O2) bolus / coupling cone. Coupling of ultrasound waves exiting the patient's body with sound absorbing material can be utilized.

[0258] In some embodiments, the ultrasound treatment power subsystem may include a power supply with multiple channels for powering the multi-beam transducer array. The subsystem may further include an ultrasound generator-controller unit with a serviceability requirement of 108-132 VAC, 48-66 Hz. The maximum power output from the power supply / generator to the individual transducers / transducer elements may be 100 W / channel. The ultrasound treatment power subsystem may include specific settings that are determined in collaboration with the ultrasound supplier. In some instances, depending on the anatomy being treated, a beam with a lateral dimension of 10 mm and a maximum focal length of 20-120 mm from the exit plane may be desired. In other instances, the array design and beam characteristics may be specified for the treatment algorithm.

[0259] In some embodiments, CT can be used prior to the acoustic stimulation treatment system to image the lesion and surrounding tissue during image-guided treatment planning and monitoring. Later systems can use ultrasound imaging with one or more diagnostic probes. Segmentation software and user GUI requirements can include 3DSlicer as a platform for open source segmentation on which LOFU segmentation can be based. During treatment planning, working dose and safety specifications are 100-500W / cm2 for 1-5 seconds through the treatment zone (lesion + 10mm margin). 2 US of 100 J, energy less than 50 J applied to soft tissue volumes outside the treatment zone, and energy less than 50 J applied to bone volumes outside the treatment zone. Fiducials may be used for RT to be used to position the delivery tool. During monitoring of the ultrasound dose, the effect on the tissue may be determined using B-mode peck tracking and elastography methods.

[0260] In another example, algorithms defining the motion of the robotic treatment head can be used to optimize for shorter treatment times and avoidance of healthy tissue. In some embodiments, the robotic positioning and scanning of the treatment head can include robot controlled position and movement to (1) treat lesions larger than the focal treatment zone of the treatment head beam and (2) treat lesions larger than the focal treatment zone of the head beam and (3) reduce exposure of healthy tissue. Specifications can include continuous motion or scanning in steps of 0.1-1 cm for tumors with a focal zone (-3 dB) of 1 cm wide and 1.5 cm long, scanning speeds of up to 100 mm / sec in any direction, and positioning accuracy of + / - 0.1 mm. The treatment head can treat lesion sizes of 10 cm in any dimension parallel to the body surface and 10 cm deep (perpendicular to the body surface). The treatment head can include rotations of up to 360 degrees, as well as rotations used in part to reduce radiation dose outside the desired focal treatment volume and in healthy tissue. Tissue locations can be treated on the patient's treatment bed. Maximum payload can be ≥ 2 kg. The robot architecture under consideration is primarily a 6DoF arm with rotating head, Stewart platform, and C-arm rotation under consideration. Selection may be based on specifications, features, and cost analysis. 6DOF may allow for C-arm motion when the base is mounted on a vertical surface and may be the preferred form of implementation. In some examples, the robot may be mounted on a surgical arm or other manually operated device, allowing the operator to position the robot as desired close to the tissue to be treated. Robot motion algorithms may be optimized to minimize treatment time and limit exposure to healthy tissue to a safe level. Visual guides and fiducial registration may be used to position the treatment head during preparation for the treatment.

[0261] In some embodiments, the hardware components include and can be described with other components described herein. The computer controller can be a Dell Precision 7510 core i7 8gb RAM with SDD and a laptop running windows 10. The computer provides sufficient performance and connection ports for the ultrasound and robot hardware. The ultrasound diagnostic / diagnostic probe is comprised of an Interson high performance USB connected linear probe and windows compatible hardware. In some examples, a linear probe with a scanning depth of 10 cm can be selected. In addition, access to RF data may be allowed that is very useful for ultrasound strain imaging that will be developed to monitor the dose of LOFU. The two probes can be used in two separate systems. The robot for positioning and scanning can be equipped with multiple commercially available 6DOF arms and can meet the desired range of motion, payload requirements, and positioning accuracy for clinical applications. The ultrasound treatment subsystem can include a dedicated transducer power generation system, and an assembly of a specific combination of signal generators and RF amplifiers. The subsystem includes transducer power electronics, signal generators and amplifiers, AWG generators, and DDS; B&K Precision manufactures CE marked IEC 60601 certified signal generators. The unit may include at least two amplifiers, one for each transducer. The linear amplifiers include class a / b broadband modular units provided by E&I, with no tuning required. This is important in a modular system where a variety of transducers can be used, such as with the use of certain imaging probes. In some cases, Apex's opamp-based configuration may be preferred, as hardware costs can be much lower compared to the E&I solution. In this example, DC power supplies and other requirements may be evaluated and integrated.

[0262] The integrated ultrasound generating system may include BioSono and Sonic Concepts units. The system may provide a 4-channel, 75 watts / ch US generator in the AP-1 unit. In other instances, a dedicated 2-channel system with the desired voltage and frequency specifications may be used. In some instances, custom boards may be used, requiring up-front engineering, but may ultimately be the preferred choice due to their bespoke, small size, and substantially lower cost. Precision acoustics includes high-power transducers constructed of piezoelectric ceramics and can be used at 200 kHz or higher with short focal regions useful for treating superficial tumors. The irradiation instrument auxiliary components include a water coupling degassing transducer system, water coupling temperature control, treatment head housing and mounting components, patient-specific transducer frames and coupling devices, electrical wiring, water tubing, and harness components. In some embodiments, other components of the system may include thermocouples, water degassing systems, and power meters and oscilloscopes for electrical characterization of the system components.

[0263] In some embodiments, the software may include medical imaging and software system integration for image-guided treatment, treatment modules, control of system components, and GUI interfaces in research prototypes. The architecture is modular, allowing for rapid integration of subsystems and specific firmware. Source control can be used to manage the code. The main treatment planning interface may be incorporated into customized 3DSlicer applications. The treatment module may control the robotic positioning system, therapeutic transducers, and thermocouple inputs. For US treatment monitoring, the PLUS library may interact with diagnostic ultrasound probes and may use operating system environments and design software such as Visual Studio 2013. A 7.5 MHz, 10 cm scanning depth linear probe with a USB interface may be used. Inferno may provide an SDK written on the existing Slicer code base written in C#; C++, and a C++ wrapper for the SDK may be written.

[0264] In some embodiments, treatment algorithm development for the acoustic stimulation treatment system unit can be implemented as follows and explained with other components described herein. A raster scan pattern generated from a treatment plan using CT segmentation can be used. Raster scans can be performed at each treatment volume defined by the ultrasound field pattern, such as receiving 2-3 seconds of ultrasound, LOFU may be intended to be substantially non-ablative and generate temperatures below 50°C. Diagnostic ultrasound can be used during treatment delivery to confirm dose delivery and examine the effect of the dose on the tissue. At each raster location, a low "scout" dose, for example 30% of the expected treatment dose, is first applied to evaluate the thermal and mechanical response. Among the various elastography measurements that can perform ultrasound-based monitoring, a speckle tracking method identified as thermal strain imaging (TSI) can be first examined for LOFU dose monitoring. The temperature effect of the scout dose under control can be used to adjust the treatment power using a treatment algorithm.

[0265] In some embodiments, a prototype unit may be designed under a lean target quality system suitable for use in dogs or other planned cancer treatment modalities and its data submitted to the FDA, as well as early feasibility testing. The acoustic stimulation treatment system unit may be expected to be manufactured, bench tested, and ready for in vivo testing. In addition, three units may be produced with modifications from the first prototype, based in part on the use of the first unit. The units may be suitable for use in treating companion animal cancer patients and for use of data obtained from dog clinical trials submitted to the FDA. In addition, the units may involve risk analysis, software architecture evaluation, engineering tasks to complete the prototype for dog and human testing, selection and procurement of transducers, amplifiers, positioning robots, design and manufacture of irradiation instruments, procurement of cart specifications / designs (including mounting components for the robot), selection of water degassing system, and development of software architecture.

[0266] Although reference is made to prototypes for in vivo animal testing, the systems described herein can be used to treat human patients.

[0267] The AP unit may include a combination of frequencies that can be used in the acoustic stimulation treatment system unit. The prototype may include a modular design that can facilitate the integration of various transducers. The AP system may include up to about 30, up to about 25, up to about 20, up to about 15, up to about 10, or up to about 5 transducers operating at various frequencies ranging from about 100 kHz to 4 Mz. The AP system may include multi-frequency operation, such as the simultaneous use of low and high frequency components. Multi-frequency operation may result in multiple benefits, including reduced power requirements to achieve the desired acoustic stimulation effect, and may generate field-specific immunogenic patterns. A reduction in the field strength required to generate APT may be achieved with an increased treatment volume.

[0268] The shape, size, and orientation of two or more transducer elements in the treatment head can be used to create focal treatment zones of approximately 6-10 millimeters in diameter and 10-20 mm along the beam axis. For each focal zone, the transducer can be activated for 1-5 seconds to generate tissue temperatures in the range of 40°C-50°C. Positioning and scanning robots can be used to treat tumors that are larger than the focal zone of the ultrasound field of the acoustic stimulation treatment system. In some examples, a robotic subsystem that allows scanning of the focal zone over the lesion and surroundings may be incorporated into the acoustic stimulation treatment system device. The robotic subsystem may include a robotic arm with 4-6 degrees of freedom (DoF).

[0269] FIG. 30 shows the desired motion and 6 DoF robot for treating a representative large surface tumor, typical of soft tissue sarcomas in mammals such as dogs. The motion can include translational motion, rotational motion, and combinations thereof. The robot can rotate the treatment head in a circular or other pattern to reduce exposure to healthy tissue. FIG. 30 shows such a robot arm according to some embodiments. In some examples, the robot can be used to treat large tumors that cannot be treated in one shot for evaluation of the robot. Diagnostic ultrasound can be used in the lesion mapping and treatment planning process to verify the location and, for example, to plan treatment without using CT data. During US image segmentation, a precision robot may be provided and attached to an arm with a treatment ultrasound transducer. 2D to 3D reconstruction from a scanning ultrasound probe can benefit from knowing the exact location and orientation of each 2D slice relative to a common frame of reference. The robot may be calibrated to remove errors on the order of a few millimeters. The robot can be highly accurate, with a positional accuracy of 5 microns. The robot may not require adjustments because parts of the robot are precision machined from a single piece of aluminum, all distances and angles are precisely known, and integration into the acoustic stimulation treatment system is planned. The robot may further include a multi-beam treatment head, which rotates to increase the dose to the focal zone relative to the surrounding tissue, as shown in FIG. 31. The transducers may be of the same or different frequencies. The robot arm may include a wrist and fingers, with a transducer attached to the end of each finger to control the orientation and position of each of the multiple transducers.

[0270] Ultrasound diagnostic and treatment monitoring subsystem In some embodiments, real-time treatment monitoring and temperature measurement can be achieved using a variety of methods, including intratumoral temperature measurement using thermocouple probes, US-guided imaging or MRI-guided imaging, and thermal strain imaging. Diagnostic ultrasound probes and strain imaging can be used to quantify ultrasound absorption in tissue, providing useful verification of the desired volume being treated, and can also be used as a means of monitoring and adjusting treatment dose. Tumor extent can be examined to calibrate temperature-elevated strain, and correlate strain imaging with validity. Thus, the effect of ultrasound on strain as a function of tumor fluidity, vascularity, and mutation load can be determined.

[0271] Ultrasound strain imaging methods further allow non-invasive monitoring of ultrasound treatments. Tissues can respond as damped oscillators to the compression and rarefaction pressure waves generated by ultrasound. AP can provide unique spatiotemporal ultrasound intensity and frequency profiles to probe tissue properties. In some instances, elastography-based assessments before, during, and after AP treatments may provide unique opportunities for imaging, treatment planning, treatment monitoring, and identification of biomarkers of the tumor environment. Ultrasound-guided ultrasound therapy may provide direct monitoring of treatment modalities. In other instances, US-based tumor characterization can reduce the frequency and number of biopsies and increase the information obtained from biopsies and blood tests. Compared to MRI used to monitor thermal ablation HIFU treatments, US-guided US treatments require much less expensive equipment and smaller infrastructure, and can be administered to patients more quickly.

[0272] In some examples, a 7.5 MHz, 10 cm scanning depth linear probe can be integrated onto the constructed acoustic stimulation treatment system, e.g., a robotic arm, and speckle tracking experiments can be performed. In other examples, the temperature change induced in the LOFU treatment can be determined by measuring the local thermal strain. The local thermal strain can be a nominal strain caused by the variation in sound speed based on temperature. By determining the temperature change, a temperature map of the entire treatment area can be non-invasively generated, in contrast to one or more invasive thermocouples embedded in tissue, which only yield one or more discrete points. The thermal strain can be evaluated by tracking the displacement of the speckles in the raw RF data. The thermal strain imaging design can be initialized using a lock matching algorithm to calculate the motion between frames of the RF data. For each block of the image at the current time, the algorithm can search the surrounding neighborhood for the most matching block. The vector between the block and its maximum match can provide the displacement of such block. Normalized cross-correlation may be used as the similarity metric. Iterative Bayesian regularization interpolation can identify ideal displacements to provide sub-sample accuracy to reduce noise in the displacement image. Displacements may be used to calculate thermal strain based on the thermal properties of the tissue. The measurement method is valid up to 50°C, which is not appropriate for HIFU but is advantageously compatible with temperature increases in acoustic stimulation applications where thermal expansion of tissue can overwhelm thermal strain. Temperature changes due to treatment application (5-15°C) may be sufficient to generate useful thermal strain images (1-2% total strain). A normalized cross-correlation implementation can be determined, which is used to track the raw ultrasound (radiofrequency) signal with local tissue temperature changes. A two-dimensional normalized correlation between the matching kernel and the search region can form a locally matching metric image. Peak values ​​in such a matching metric image can be used to determine local signal displacement.A US power system can be integrated and treatment monitoring can be developed in the gel phantom.

[0273] <Control system> As used herein, a control system is a component of the system embodiments described herein that is configured to operate certain functions of the system embodiments described herein. The control system comprises a processor.

[0274] <Preclinical testing of the acoustic stimulation treatment system> Based on the teachings provided herein, one of skill in the art can conduct animal studies and develop systems for treating humans as described herein.

[0275] In some instances, clinical development times may be shortened and immunotherapy devices may be rapidly and widely commercialized to treat certain cancers in animals and humans.Soft tissue sarcomas occur approximately five times more frequently in dogs than in humans and can arise in easily accessible superficial locations on the dog's limbs.

[0276] In some instances, neoadjuvants may include debunking and activation of immune responses. Post-treatment resection can provide an early direct assessment of treatment effects on the TME. Because TME engineering is a primary strategy, the use of neoadjuvants can be particularly beneficial in establishing local effects and in determining whether these effects can generate a systemic immune response. Neoadjuvant treatments, biopsies, blood samples, and data derived therefrom can be used to facilitate use in other indications and in treating gross disease without surgical resection. Breast tumors can be treated using neoadjuvant stereotactic body radiation therapy (SBRT) regimens prior to lumpectomy. The first method can include optimizing the LOFU dose to generate an immunomodulatory effect in spontaneous primary cancers. The tumors can be selected from the group consisting of localized nonmetastatic soft tissue sarcoma, melanoma, and breast tumors. Three dose levels of LOFU can be tested with six patients per dose level. Tumor tissue samples may be taken pre-LOFU and post-LOFU to determine the immunophenotype and determine the immunomodulatory effect of LOFU in the TME, and blood samples may be taken to evaluate systemic changes. The method may be selected from the group consisting of biopsy primary tumor and collection of blood and peripheral blood mononuclear cells (PBMCs), external LOFU treatment, biopsy or resection of primary tumor and draining lymph nodes, collection of PBMCs before and after LOFU treatment, and standard of care therapy for the patient. Readout of the method may include determining the immunophenotype of tissues before and after LOFU. Samples may include immunohistochemistry / immunofluorescence (IHC / IF) of tumor and dLN samples, flow cytometry of tumor and PBMC samples, and RNASeq of tumor samples. IHC / IF of tumor and dLN samples may be selected from standard known markers such as hematoxylin-eosin (H&E), CD3, FOXP3, and HLA-DR.Flow cytometry of tumor and PBMC samples may be performed for T cell activation markers (cytokine production), dendritic cells (activation markers), and myeloid cells and macrophages. RNASeq may be performed on one or more tumor components and may be selected from T cell activation profiles, IFNs, ISGs, anergy genes, HSPs and chaperones, and immunosuppressive genes.

[0277] The second method may include optimizing LOFU in combination with radiation therapy and immunotherapy to generate immunomodulatory effects in spontaneous primary cancers. The tumor type may be selected from the group consisting of localized non-metastatic soft tissue sarcoma, melanoma, and breast tumor. Four regimens and six patients may be tested using LOFU and hypofractionated RT, LOFU and immunotherapy (e.g. anti-PD-(L)1), hypofractionated RT (HyRT) and immunotherapy, and LOFU and hypofractionated RT and immunotherapy, and immunotherapy (anti-PD-1 or anti-PD-L1). LOFU tumor tissue biopsy samples may be taken before and / or after the regimen to determine the immunophenotype and determine the immunomodulatory effects of LOFU in the TME and systemic circulation. The method used may be selected from the group consisting of biopsy primary tumor and draining lymph nodes with collection of PBMCs, LOFU, and / or RT intervention, biopsy or resection of primary tumor and draining lymph nodes with collection of PBMCs, and standard of care therapy. The readout can be determining the immunophenotype of the tissue pre-LOFU and / or post-LOFU.

[0278] In some embodiments, the treatment can be HyRT and a combination of HyRT and a neoadjuvant acoustic stimulation treatment system prior to surgical resection to activate the immune system. HyRT can be 3x10Gy. In other examples, the process can include LOFU and a triple dose of 10Gy with the use of dual frequency LOFU and HyRT. The output of such treatment can include histology and flow cytometry of the resected tissue, e.g., tumor infiltrating lymphocytes and myeloid cells, DAMP markers and exosomes, survival, local recurrence, distant metastases-lung examination by CT, analysis of blood for neutrophil / lymphocyte ratio, immunological response (cytokines (IFN-γ)), and T cell receptor diversity profiling by ImmunoSEQ TCR deep sequencing on timpanist TBD.

[0279] <Human clinical development> Ultrasound and multiparametric MRI can provide image-guided staging and treatment, allowing UR and TR energy to be localized to PC lesions with increased precision.

[0280] Device design for specific indications: In some instances, the specifications of the treatment head and robot of the AP device can be modified to treat various tumors based on the size and location of the tumor with respect to depth, adjacent organs, and other tissues including bone and gas bodies and body contours that absorb and reflect ultrasound energy, and susceptibility to treatment-induced toxicity. The acoustic stimulation treatment system can be used to treat various cancers such as soft tissue sarcomas. A treatment head design with an independently movable transducer within the irradiation instrument can be used for prostate cancer and transperineal treatment of patients. Independent transducer movement within the head may require less movement of the entire treatment head by the robot to perform a given treatment and may appear to be useful for transperineal applications. The acoustic stimulation treatment system can be used in the treatment of melanoma tumors. Diagnostic and irradiation instruments may be utilized for the treatment of breast cancer. Finally, a combined instrument including ultrasound and electron radiation can be used to simultaneously administer AP and RT treatments.

[0281] Optimization of ultrasound treatment parameters and regimens in a mouse model The acoustic stimulation unit described herein can be configured in many ways and can include a power source with four channels that can deliver ultrasound coherently or incoherently. The AP unit can be configured to generate frequencies from 100 kHz to 4 MHz and can be configured to transmit ultrasound simultaneously from two high-power transducers, one of which operates at around 400 kHz. In some examples, the AP unit can be augmented with a scanning robot (e.g., 2 DoF) to treat larger tumors and scan a larger treatment volume using articulation motion. In other examples, multi-frequency AP can be combined with radiation therapy (RT) to induce (i) cancer cell stress with demonstrated links to MHC peptide-display T cell activation and reversal of T cell anergy, (ii) changes to tumor vasculature tumor perfusion, and (iii) reprogramming of the tumor environment to drive CTL-mediated acute and memory responses. In some embodiments, the combination treatment can include ultrasound or RT with appropriate timing sequences and dose parameters, as well as bioactivation chemistries or immune checkpoints. Studies may be performed to elucidate the effects of ultrasound frequency and timing and intensity of RT dose used in combined AP and RT therapy.

[0282] <Combination Therapy Sequence> In some embodiments, an administration sequence of AP and RT can be utilized that is safe, immunogenic, and facilitates use in radiation oncology facilities and patient compliance. An effective means for generating cancer antigen-specific systemic CD8+ T cell-mediated immune responses can be created. LOFU can be given as a neoadjuvant approximately 2-4 hours after high dose radiation. Timing can be a result of logistics associated with separate locations of LOFU and RT equipment. Additionally, studies related to embodiments suggest that LOFU can reduce STAT3 phosphorylation approximately 2-6 hours after LOFU treatment. In some instances, STAT3 phosphorylation induced by RT and chemotherapy can regulate multiple survival functions such as Nf-KB as well as IL-6 production. RT administered during the post-LOFU transitional period of low STAT3 activation can increase radiation injury. In elucidating and optimizing immunogenicity patterns associated with treatment, IL-6 / STAT3 and Nf-kB pathways following various combination treatments can be characterized and adjunctive ablative treatments can be planned accordingly.

[0283] For combined AP and RT treatments, it may be advantageous to administer AP treatments before or minutes after radiation therapy to reduce anesthesia time and total procedure time. It can be determined whether acoustic stimulation administered close to radiation has an efficacy and therapeutic index equivalent to or even greater than dose regimens in which AP and RT are separated by several hours. Changes in DAMP patterns, ROS damage, other stress markers, and tumor immune cell denizens can be examined. Initially, 1-3 treatments of doses of APT and RT given over 5 days in initial clinical trials may be implemented. As with certain hypofractionated RT schemes, local administration can be completed within 5 days to effectively stimulate the immune system.

[0284] The timing and sequence of RT and AP application, as well as dose modulation of RT and AP between treatments, during the 5-day tumor microenvironment (TME) engineering window between local toxic treatment and arrival of tumor antigen-specific CTLs, as illustrated by the cycle concept of cancer immunity, may be determined. Development categories may include (i) US and RT intensity and sequence, and (ii) bioactivity combinations.

[0285] <Incorporating materials into energy treatment: AMP> In some embodiments, acoustic amplification and microparticles (AMPs) can be incorporated into AP regimens to increase tumor localized immunogenic damage followed by delivery of bioactive agents. In some examples, AMPs can be crafted to specific sizes, compositions, architectures, and stability. AMPs can be tested for efficacy in activating DCs and tumor antigen specific effector T cell responses in tumor-bearing mouse models. AMP agents can be examined via intravenous (IV) and intramural (IT) routes of administration. In some examples, AMPs may be developed with essentially the same AP power sequence as currently utilized without AMPs. In other examples, particles may be formulated to transduce energy at up to about 10-fold lower power compared to those currently used in APT. The result may be the generation of cancer-specific immunogenic patterns that generate robust innate and adaptive responses that are effective against phenotypically heterogeneous cancer cell populations. Such a pattern is generated by radiation synergy using one or more components selected from the group consisting of DAMPS generation, stimulation of tumor vasculature, and reduction of STAT3 phosphorylation. In some embodiments, AP treatment utilizing AMPs can be combined with RT. In another example, a radiosensitizer can be incorporated into the AMP particle.

[0286] AP multi-frequency structural devices may be designed to vary the amount of mechanical and thermal stress. As the ultrasound frequency decreases, mechanical disruption of both the particle and the surrounding tissue may increase. In some instances, particle size insensitivity may be produced, including small particles that rupture under low frequency US. Materials and Fabrication Methods: Particle size may correspond to nanodroplet formulations, as known to those skilled in the art. Particles may include, for example, echogenic liposomes less than 200 nm in diameter and microbubbles (1-3 microns).

[0287] <Timing of AP application after particle administration> Ultrasound application can be utilized immediately after IV injection of AMPs and up to 24 hours later. AMPs, when used in conjunction with administration of a bioactive agent, can form particles that can focus ultrasound energy into tumor vasculature and perivascular spaces, mechanically disrupting such spaces.

[0288] The particles may include perfluorinated molecules selected from the group consisting of perfluoropropane, perfluorobutane, perfluoropentane, perfluorohexane, and perfluorooctyl bromide (perflubron). Perflubron may provide contrast across CT, MRI, and ultrasound modalities. A variety of lipids may be used, including phospholipids. Nanoliposomes incorporating ceramides may be used as RT-induced ceramide production and subsequent apoptosis of cancer cells and tumor vasculature may be associated with anti-cancer mechanisms of radiation. Formulations may be tested in cell viability and assays, and DAMPS signaling assays using passive cavitation detection (PCD). Particle formulation capabilities may be determined as a basis for bioactive loading and surface functionalization with tumor targeting molecules.

[0289] <Incorporating Materials into Energy Treatments: Bioactive Agents> In some embodiments, multi-modal treatments can be developed to induce strong tumor-specific CTL-mediated responses using tumor-localized treatments that generate strong immunogenic patterns and processes. Bioactive agents can be selected from the group consisting of immune checkpoint inhibitors (ICIs), including PD-(L)1 axis blockers, and those that activate or otherwise engage components of the innate and adaptive immune systems. CD40 agonist antibodies, CD27 agonist antibodies, and FLT3L can be used in bimodal and trimodal combinations in combination with RT. Small molecule immune modulators can be selected, for example, from the group consisting of STING activators, and agonists of TLRs. Chemotherapeutic and targeted therapeutic agents whose mechanism of action is substantially directed at cancer cells can generate immunogenic patterns and can directly interact with innate and adaptive immune cells. In some embodiments, agents can be selected to promote a systemic anti-cancer immune response. The agent can be a PARP inhibitor or an epigenetic modulator. Dosing regimens can be determined and treatments identified that result in complete primary tumor regression in treated tumors, reverse CD8+ T cell anergy, and provide effective immune memory to impede tumor growth. Trimodal induction of immunogenicity can be determined, in part, by a combination of APT, RT, and bioactive agents, by DAMPs.

[0290] <STINGアゴニスト> The presence of DNA in the cytosol can be indicative of diseased or otherwise damaged cells. Cyclic dinucleotides (CDNs) can be produced by the DNA sensor cyclic GMP-AMP synthase (cGAS) sensing of circular DNA and by bacteria. Stimulator of interferon genes (STING) is an ER transmembrane protein that is activated by CDA and triggers the production of type 1 interferon. In some instances, inflammation can include type 1 IFN, including increased CTL activation and NK cell cytotoxicity. RT can be effective in part due to the circular DNA sensing STING pathway in APCs. In other instances, local inflammation of type 1 interferon can be effective in combination with the pattern generated by AP treatment, and antigen releasing treatments including radiation. Although there is some overlap with the radiation therapy mechanism, STING can be combined with radiation and AP. The STING agonist can be 5,6-dimethylxanthenone-4-acetic acid (DMXAA). In some instances, the STING agonist can be administered locally to avoid systemic toxicity.

[0291] In some instances, AMPs can be incorporated into AP regimens to increase tumor-localized immunogenic damage followed by delivery of bioactive agents. AMPs can be made to specific sizes, compositions, structures, and engineered for efficacy in activating tumor antigen-specific effector T cell responses in DCs, tumor-bearing animal, or human models.

[0292] Combinations of energy-based therapies with pharmaceutical and biotechnological materials can be used to treat cancer patients. These combination treatments, including "energy-stimulated immunity," can address a variety of cancers and are initially guided by the clinical use of a given bioactive agent. The bioactive agent may be selected from the group consisting of inflammatory damage / danger sensing agents, including CTLA-4 and PD-(L)1 axis, myeloid growth factor Flt3L, CD27, Toll-like receptor (TLR) agonists, agents that modulate myeloid cells, such as CSF-1R inhibitors, circular DNA sensing pathway STING agonists, and other cell surface proteins, including chaperones, PDI, calnexin, calreticulin, CD74, Hsp54, Hsp60, Hsp70, Hsp72, BiP, Hsp90, Gp96, clusterin, and CD47. The mechanism may stem in part from the ability of APT to disrupt cellular processes and induce the UPR, which may also partially explain the synergistic effect of RT and AP. Thus, in addition to immune checkpoint inhibitors, the therapeutic agents used in treatment may include agents selected from the group consisting of PARP inhibitors and protease inhibitors.

[0293] <Digital Processing Device> In some embodiments, the platforms, systems, media, and methods described herein include a digital processing device or use thereof. In further embodiments, the digital processing device comprises one or more hardware central processing units (CPUs), general purpose graphic processing units (GPGPUs), or field programmable gate arrays that perform the functions of the device. In further embodiments, the digital processing device further comprises an operating operating system configured to execute executable instructions. In some embodiments, the digital processing device is optionally connected to a computer network. In further embodiments, the digital processing device is optionally connected to the Internet to access the World Wide Web. In further embodiments, the digital processing device is optionally connected to a cloud computing infrastructure. In other embodiments, the digital processing device is optionally connected to an intranet. In other embodiments, the digital processing device is optionally connected to a data storage device.

[0294] In accordance with the description disclosed herein, suitable digital processing devices include, by way of non-limiting example, server computers, desktop computers, laptop computers, notebook computers, subnotebook computers, netbook computers, netpad computers, set-top computers, handheld computers, Internet appliances, mobile smart phones, tablet computers, personal digital assistants, video game consoles, and vehicles. Those skilled in the art will recognize that many smart phones are suitable for use in the systems described herein. Those skilled in the art will recognize that selected televisions, video players, and digital music players, with optional computer network connections, are suitable for use in the systems described herein. Suitable tablet computers include those having booklet, slate, and convertible configurations known to those skilled in the art.

[0295] In some embodiments, the digital processing device comprises an operating system configured to execute instructions. An operating system is software, including programs and data, that controls the hardware of the device and provides services for the execution of applications, for example. Those skilled in the art will recognize that suitable server operating systems include, by way of non-limiting examples, FreeBSD, OpenBSD, NetBSDR, Linux, Apple Mzc OS X Server, Oracle Solaris, Windows Server, and Novell NetWare. Those skilled in the art will recognize that suitable personal computer operating systems include, by way of non-limiting examples, UNIX-like operating systems, such as Microsoft Windows, Apple Mac OS X, UNIX, and GNU / Linux. In some embodiments, the operating system is provided by cloud computing. Those skilled in the art will also recognize that suitable mobile smartphone operating systems include, by way of non-limiting examples, Nokia® Symbian® OS, Apple® iOS®, Research In Motion® BlackBerry OS®, Google® Android®, Microsoft® Windows Phone® OS, Microsoft® Windows Mobile® OS, Linux®, and Palm® WebOS®.Those skilled in the art will also recognize that suitable media streaming device operating systems include, by way of non-limiting examples, Apple TV®, Roku®, Boxee®, Google TV®, Google Chromecast®, Amazon Fire®, and Samsung® HomeSync®. Those skilled in the art will also recognize that suitable video game console operating systems may include, by way of non-limiting examples, Sony® PS3®, Sony® PS4®, Microsoft® Xbox 360®, Microsoft Xbox One, Nintendo® Wii®, Nintendo® Wii U®, and Ouya®.

[0296] In some embodiments, the device comprises a storage device and / or a memory device. A storage device and / or a memory device is one or more physical devices used to temporarily or permanently store data or programs. In some embodiments, the device is a volatile memory and requires power to maintain the stored information. In some embodiments, the device is a non-volatile memory and retains the stored information when power is not provided to the digital processing device. In further embodiments, the non-volatile memory comprises a flash memory. In some embodiments, the non-volatile memory comprises a dynamic random access memory (DRAM). In some embodiments, the non-volatile memory comprises a ferroelectric random access memory (FRAM®). In some embodiments, the non-volatile memory comprises a phase change random access memory (PRAM). In other embodiments, the device is a storage device, including, by way of non-limiting examples, CD-ROM, DVD, flash memory device, magnetic disk drive, magnetic tape drive, optical disk drive, and cloud computing based storage device. In further embodiments, the storage device and / or the memory device is a combination of devices such as those disclosed herein.

[0297] In some embodiments, the digital processing device includes a display for transmitting visual information to a user. In some embodiments, the display is a cathode ray tube (CRT). In some embodiments, the display is a liquid crystal display (LCD). In further embodiments, the display is a thin film transistor liquid crystal display (TFT-LCD). In some embodiments, the display is an organic light emitting diode (OLED) display. In various further embodiments, the OLED display is a passive-matrix OLED (PMOLED) or active-matrix OLED (AMOLED) display. In some embodiments, the display is a plasma display. In other embodiments, the display is a video projector. In still further embodiments, the display is a combination of devices such as those disclosed herein.

[0298] In some embodiments, the digital processing device comprises an input device for receiving information from a user. In some embodiments, the input device is a keyboard. In some embodiments, the input device is a pointing device, including, by way of non-limiting example, a mouse, a trackball, a trackpad, a joystick, a game controller, or a stylus. In some embodiments, the input device is a touch screen or a multi-touch screen. In other embodiments, the input device is a microphone for capturing voice or other sound input. In other embodiments, the input device is a video camera or other sensor for capturing motion or visual input. In further embodiments, the input device is a Kinect, Leap Motion, or the like. In still further embodiments, the input device is a combination of devices, such as those disclosed herein.

[0299] In a particular embodiment, referring to FIG. 32, an exemplary digital processing device (101) is programmed or otherwise configured to operate the energy stimulation device described herein. The digital processing device (1601) can coordinate various aspects of the energy stimulation device of the present disclosure, e.g., perform processing steps. In this embodiment, the digital processing device (1601) comprises a central processing unit (CPU, also referred to herein as "processing unit" and "computer processing unit") (1605), which may be a single-core or multi-core processing unit, or multiple processing units for parallel processing. The digital processing device (1601) also comprises memory or storage locations (1610) (e.g., random access memory, read-only memory, flash memory), electronic storage (1615) (e.g., hard disk), communication interfaces (1620) (e.g., network adapters) for communicating with one or more other systems, and peripherals (1625), such as cache, other memory, data storage, and / or electronic display adapters. The memory (1610), storage (1615), interface (1620), and peripherals (1625) communicate with the CPU (1605) via a communication bus (solid lines), such as a motherboard. The storage (1615) may be a data storage (or data repository) for storing data. The digital processing device (1601) is operatively connected to a computer network ("network") (1630) using the communication interface (1620). The network (130) may be the Internet and / or an extranet, an intranet and / or an extranet in communication with the Internet. In some cases, the network (1630) is a telecommunications and / or data network. The network (1630) may include one or more computer servers, which may enable distributed computing, such as cloud computing.The network (1630), in some cases with the aid of the digital processing device (1601), may implement a peer-to-peer network, which may enable devices coupled to the digital processing device (1601) to act as clients or servers.

[0300] With continued reference to FIG. 32, the CPU (1605) executes a series of machine-readable instructions, which may be embodied in a program or software. The instructions may be stored in a memory location, such as the memory (1610). The instructions may be directed to the CPU (1605), which may then program or otherwise configure the CPU (1605) to perform the methods of the present disclosure. Examples of operations performed by the CPU (1605) include fetch, decode, execute, and writeback. The CPU (1605) may be part of a circuit, such as an integrated circuit. One or more other components of the digital processing device (101) may be included in the circuit. In some cases, the circuit is an application specific integrated circuit (ASIC) or a field programmable gate array (FPGA).

[0301] 32, the storage device (1615) can store files such as drivers, libraries, and saved programs. The storage device (1615) can store user data, such as user preferences and user programs. In some embodiments, the digital processing device (1601) includes one or more additional data storage devices that are external, such as located on a remote server communicating over an intranet or the Internet.

[0302] 32, the digital processing device (1601) can communicate with one or more remote computer systems via a network (1630). For example, the digital processing device (1601) can communicate with a user's remote computer system. Examples of remote computer systems include a personal computer (e.g., a portable PC), a slate or tablet PC (e.g., Apple® iPad®, Samsung® Galaxy Tab), a phone, a smartphone (e.g., Apple® iPhone®, Android-enabled device, Blackberry®), or a personal digital assistant.

[0303] The methods described herein can be implemented by machine (e.g., computer processor) executable code stored in an electronic storage location of the digital processing device (1601), such as memory (1610) or electronic storage (1615). The machine executable or machine readable code can be provided in the form of software. In use, the code can be executed by the processor (1605). In some cases, the code can be retrieved from storage (1615) and stored in memory (1610) for immediate access by the processor (1605). In some situations, the electronic storage (1615) can be omitted and the machine executable instructions are stored in memory (1610).

[0304] <Non-transitory computer-readable storage medium> In some embodiments, the platforms, systems, media, and methods disclosed herein include one or more non-transitory computer-readable storage media encoded with a program, including instructions executable by an operating system of an optionally networked digital processing device. In further embodiments, the computer-readable storage medium is a tangible component of the digital processing device. In yet further embodiments, the computer-readable storage medium is optionally removable from the digital processing device. In some embodiments, the computer-readable storage medium includes, but is not limited to, CD-ROMs, DVDs, flash memory devices, solid-state storage devices, magnetic disks, magnetic tape drives, optical disk drives, cloud computing systems and services, and the like. In some cases, the programs and instructions are encoded on the medium permanently, nearly permanently, semi-permanently, or non-transitoryly.

[0305] <Computer Program> In some embodiments, the platform, system, medium, and method disclosed herein include at least one computer program or the use thereof. A computer program is executable by a CPU of a digital processing device and includes a set of instructions written to perform a specific task. Computer-readable instructions may be implemented as program modules, such as functions, objects, application programming interfaces (APIs), data structures, etc., that perform a specific task or extract a specific data type. In light of the disclosure provided herein, those skilled in the art will recognize that computer programs can be written in various versions of various languages.

[0306] The functionality of the computer readable instructions may be combined or distributed as desired in various environments. In some embodiments, the computer program comprises one sequence of instructions. In some embodiments, the computer program comprises multiple sequences of instructions. In some embodiments, the computer program is provided from one location. In other embodiments, the computer program is provided from multiple locations. In various embodiments, the computer program comprises one or more software modules. In various embodiments, the computer program comprises, in part or in whole, one or more web applications, one or more mobile applications, one or more standalone applications, one or more web browser plug-ins, extensions, add-ins, or add-ons, or combinations thereof.

[0307] <Web application> In some embodiments, the computer program comprises a web application. In light of the disclosure provided herein, one skilled in the art will recognize that a web application, in various embodiments, utilizes one or more software frameworks and one or more database systems. In some embodiments, the web application is created on a software framework such as Microsoft® .NET or Ruby on Rails (RoR). In some embodiments, the web application utilizes one or more database systems, including, by way of non-limiting examples, relational, non-relational, object-oriented, associative, and XML database systems. In further embodiments, suitable relational database systems include, but are not limited to, Microsoft® SQL Server, mySQL™, and Oracle®. One skilled in the art will recognize that a web application, in various embodiments, is written in one or more versions of one or more languages. A web application may be written in one or more markup languages, presentation definition languages, client-side scripting languages, server-side coding languages, database query languages, or combinations thereof. In some embodiments, the web application is written to some extent in a markup language such as HyperText Markup Language (HTML), Extensible HyperText Markup Language (XHTML), or Extensible Markup Language (XML). In some embodiments, the web application is written to some extent in a presentation definition language such as Cascading Style Sheets (CSS). In some embodiments, the web application is written to some extent in client-side scripting such as Asynchronous Javascript and XML (AJAX), Flash® Actionscript, Javascript, or Silverlight®.In some embodiments, the computer program is written to some extent in a server-side coding language, such as Active Server Pages (ASP), ColdFusion, Perl, Java, JavaServer Pages (JSP), Hypertext Preprocessor (PHP), Python, Ruby, Tcl, Smalltalk, WebDNA, or Groovy. In some embodiments, the web application is written to some extent in a database query language, such as Structured Query Language (SQL). In some embodiments, the web application integrates with an enterprise server product, such as IBM® Lotus Domino. In some embodiments, the web application includes a media player component. In various further embodiments, the media player component utilizes one or more of a number of suitable multimedia technologies, including, but not limited to, Adobe® Flash, HTML 5, Apple® QuickTime, Microsoft® Silverlight, Java, and Unity.

[0308] <Mobile application> In some embodiments, the computer program comprises a mobile application that is provided to the mobile digital processing device. In some embodiments, the mobile application is provided to the mobile digital processing device at the time of manufacture. In other embodiments, the mobile application is provided to the mobile digital processing device by a computer network as described herein.

[0309] Given the disclosure provided herein, mobile applications are created by techniques known to those of skill in the art using hardware, languages, and development environments known in the art. Those skilled in the art will recognize that mobile applications are written in multiple languages. Suitable programming languages ​​include, by way of non-limiting examples, C, C++, C#, Objective-C, Java™, Javascript, Pascal, Object Pascal, Python™, Ruby, VB.NET, WML, and XHTML / HTML with or without CSS, or combinations thereof.

[0310] Suitable mobile application development environments are available from several sources. Commercially available development environments include, by way of non-limiting example, Airplay SDK, alcheMo, Appcelerator®, Celsius, Bedrock, Flash Lite, .NET Compact Framework, Rhomobile, and WorkLight Mobile Platform. Other development environments are available free of charge and include, by way of non-limiting example, Lazarus, MobiFlex, MoSync, and Phonegap. Mobile device manufacturers also distribute software development kits, including, by way of non-limiting example, the iPhone® and iPad® (iOS) SDK, Android™ SDK, BlackBerry® SDK, BREW SDK, Palm® OS SDK, Symbian SDK, webOS SDK, and Windows® Mobile SDK.

[0311] Those skilled in the art will recognize that various commercial forums are available for the distribution of mobile applications, including, but not limited to, the Apple® App Store, Google® Play, Chrome® WebStore, BlackBerry® App World, the App Store for Palm devices, the App Catalog for webOS, the Windows® Marketplace for Mobile, the Ovi Store for Nokia® devices, Samsung® Apps, and the Nintendo® DSi Shop.

[0312] <Standalone application> In some embodiments, the computer program includes a standalone application, which is a program that runs as an independent computer process that is not an add-on, e.g., not a plug-in, to an existing process. Those skilled in the art will recognize that standalone applications are often compiled. A compiler is a computer program that converts source code written in a programming language into binary object code, such as assembly language or machine code. Suitable compiled programming languages ​​include, by way of non-limiting examples, C, C++, Objective-C, COBOL, Delphi, Eiffel, Java™, Lisp, Python™, Visual Basic, and VB.NET, or combinations thereof. Compilation is often performed at least in part to create an executable program. In some embodiments, the computer program includes one or more executable compiled applications.

[0313] <Web browser plug-in> In some embodiments, the computer program includes a web browser plug-in (e.g., an extension function, etc.). In computing, a plug-in is one or more software components that add specific functionality to a larger software application. Software application manufacturers support plug-ins so that third party developers can create the ability to extend the application, support easily adding new features, and reduce the size of the application. When supported, plug-ins allow customization of the functionality of the software application. For example, plug-ins are commonly used in web browsers to play videos, create interactivity, scan for viruses, and display specific file types. Those skilled in the art are familiar with various web browser plug-ins, including Adobe® Flash® Player, Microsoft® Silverlight®, and Apple® QuickTime®. In some embodiments, the toolbar includes one or more web browser extensions, add-ins, or add-ons. In some embodiments, the toolbar includes one or more explorer bars, tool bands, or desk bands.

[0314] In light of the disclosure provided herein, one of skill in the art will recognize that several plugin frameworks are available that allow for the development of plugins in a variety of programming languages, including, by way of non-limiting examples, C++, Delphi, Java™, PHP, Python™, and VB.NET, or combinations thereof.

[0315] A web browser (also called an Internet browser) is a software application designed for use with networked digital processing devices for searching, viewing, and traversing information resources on the World Wide Web. Suitable web browsers include, but are not limited to, Microsoft® Internet Explorer®, Mozilla® Firefox®, Google® Chrome, Apple® Safari®, Opera Software® Opera®, and KDE Konqueror. In some embodiments, the web browser is a mobile web browser. Mobile web browsers (microbrowsers, minibrowsers, and wireless browsers) are designed for use on mobile digital processing devices, including, by way of non-limiting examples, handheld computers, tablet computers, netbook computers, sub-notebook computers, smartphones, music players, personal digital assistants (PDAs), and handheld video game systems. Suitable mobile web browsers include, but are not limited to, Google® Android® browser, RIM BlackBerry® browser, Apple® Safari®, Palm® Blazer, Palm® WebOS® Browser, Mozilla® Firefox® for mobile, Microsoft® Internet Explorer® Mobile, Amazon® Kindle® Basic Web, Nokia® browser, Opera Software® Opera® Mobile, and Sony® PSP™ browser.

[0316] <Software module> In some embodiments, the platforms, systems, media, and methods disclosed herein include software, server, and / or database modules, or the use thereof. In view of the disclosure provided herein, the software modules are created by techniques known to those skilled in the art using machines, software, and languages ​​known in the art. The software modules disclosed herein are implemented in numerous ways. In various embodiments, the software modules include files, sections of code, programming objects, programming structures, or combinations thereof. In further various embodiments, the software modules include multiple files, multiple sections of code, multiple programming objects, multiple programming structures, or combinations thereof. In various embodiments, the one or more software modules include, but are not limited to, web applications, mobile applications, and stand-alone applications. In some embodiments, the software modules are in one computer program or application. In other embodiments, the software modules are in more than one computer program or application. In some embodiments, the software modules are hosted on one machine. In other embodiments, the software modules are hosted on more than one machine. In further embodiments, the software modules are hosted on a cloud computing platform. In some embodiments, the software modules are hosted on one or more machines in one location. In other embodiments, the software modules are hosted on one or more machines in more than one location. <Database> In some embodiments, the platforms, systems, media, and methods disclosed herein include one or more databases, or the use thereof. In view of the disclosure provided herein, one of skill in the art will recognize that many databases are suitable for storing and retrieving information. In various embodiments, suitable databases include, but are not limited to, relational databases, non-relational databases, object-oriented databases, object databases, entity-relationship model databases, associative databases, and XML databases. Further non-limiting examples include SQL, PostgreSQL, MySQL, Oracle, DB2, and Sybase. In some embodiments, the database is internet-based. In further embodiments, the database is web-based. In still further embodiments, the database is cloud computing-based. In other embodiments, the database is one or more local computer storage devices.

[0317] <Example 5> Pilot efficacy experiments typically use n=35 / up to cohort. Outputs and endpoints include tumor size (one-way ANOVA), survival (Kaplan-Meier, log-rank test), and metastasis count in lung. Additionally, tumor progression monitoring can be analyzed non-invasively using various imaging techniques including IR-783 dye and NIR imaging on IVIS instruments and PET SPECT:Inveon™ multimodal PET·SPECT·CT platform.

[0318] Final experiments included 8-12 animals per cohort; 3 were sacrificed 24 h post-treatment for histology, 3 were sacrificed 1 week after Rx for tumor immunology assays, and 5 were followed for 60 days to investigate disease progression.

[0319] Mouse cancer models include B16F10m1 melanoma, TPSA23 prostate, and 4T1 breast mouse tumor cells inoculated into C57blck6, GEM, and Balb / c mice, respectively. Both B16F10 and 4T1 can metastasize very rapidly, although more slowly metastatic models are also available.

[0320] The ultrasound and RT devices include APT and RT directed at the inoculated tumor, as well as the immediate surroundings and regions of interest (RoI) with the goal of treating the entire ROI. The ultrasound system, comprised of multiple transducers, delivers 100 to 10,000 W / cm at 1 Mhz and 250 kHz. 2 Typically, ultrasound treatment delivers 50-150 W / cm per treated cross section. 2 This is applied for 1 to 5 seconds.

[0321] Radiation was delivered using Xstrahl Limited's Small Animal Radiation Research Platform (SARRP). The SARRP unit has CT scanning and tissue segmentation and treatment planning capabilities. Survival rate, primary tumor size, and number of lung metastases are potential endpoints.

[0322] Outputs include EMT status of cancer cells (vimentin staining), quantification of circulating tumor cells, tumor infiltrating lymphocytes (TILs), and stromal cells in the tumor environment (immunohistochemistry and FACS of lysates), intercellular, cell surface, and exosomal quantification of upregulated ER stress markers, chaperones calreticulin, HSP70 and HSP90, BiP; ATP, HMGB1; hypoxia HIF-1α, and damage responders STAT3, Nf-κB (western blot, FACS, and immunohistochemistry). Outputs may further include, with respect to RT, generation of reactive oxygen species (ROS) and nitrogen species (RNS) damaged DNA, increased tumor cell antigenicity and increased release of antigen and DC activated DNA. Thus, ROS and RNS production is measured in treated tumors at various time points by using the OxiSelect™ in vitro ROS / RNS Assay Kit, a rapid and sensitive fluorescent assay.

[0323] ER stress regulators by isolating RNA from tumor treated samples and analyzing it using instruments including full RNA-seq analysis or RT2 Profiler PCR arrays provide detection of 370 key genes that recognize and respond to the accumulation of misfolded proteins in the endoplasmic reticulum and regulators involved in the endoplasmic reticulum stress response (i.e. Calr, Ero1Ib, Ppia, Scap).

[0324] Blood assays can include CBC and neutrophil to lymphocyte ratios. Serum taken before and after treatment can be analyzed for cytokines using ELISpot and, in some cases, a further detailed cytokine mouse membrane antibody array that detects up to 97 different targets, including chemokines, Th1 and Th2 cytokines, TNFα, INFγ, INFβ, IL2, IL6, IL10, IL12, TGFβ, metalloproteases, and growth factors. LN and splenocytes can be INFγ and IL2, and CD8+ T cells are exposed to tumor lysate. If memory T cell populations are warranted, inoculation into the left flank occurs at least 30 days after disappearance of primary tumor cells, and tumor growth and effector memory T cells can be quantified. All data can be compared to untreated tumor samples.

[0325] Systems such as those described herein can be configured in many ways, and can be configured, for example, to perform whole body scans using low intensity focused ultrasound by scanning the beam to multiple locations.

[0326] While preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous modifications, changes, and substitutions will occur to those skilled in the art without departing from the invention. It is understood that various alternatives to the embodiments of the invention described herein may be utilized in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents are covered thereby.

[0327] Exemplary embodiments 1. An ultrasound system for stimulating the immune system of a patient, the system comprising: a probe having a diameter of at least 0.5 cm; 3 and a beam volume of 10W / cm 2 ~900W / cm 21. The method of claim 1, further comprising: generating an ultrasound beam having an intensity within a beam volume within a range of at least about 2 cm; and a processor coupled to the ultrasound transducer, the processor configuring instructions for treating a patient at a plurality of locations with the beam. 3 at least about 0.5 cm per second over the entire tissue volume 3 and optionally, wherein the scanning speed is about 0.5 cm per second of the total volume of tissue scanned. 3 ~about 50cm 3 and optionally, the total volume of tissue is within about 2 cm 3 ~About 1000cm 3 and optionally, a total tissue volume of about 4 cm 3 ~about 500cm 3 2. The system of embodiment 1, wherein the beam volume is within a range of 0.5 cm and optionally the entire volume is scanned with an intensity within the range. 3 ~1000cm 3 and optionally, the beam volume is within 1 cm 3 ~500cm 3 and optionally, about 2 cm 3 ~about 250cm 3 4. The system of embodiment 1, wherein the intensity is in the range of about 20 W / cm 2 ~about 500W / cm 2 5. The system of embodiment 1, comprising a linkage coupled to an ultrasound transducer, the processor coupled to the linkage and configured with instructions for moving the transducer to a plurality of positions to treat a plurality of volumetric regions of tissue, each of the plurality of volumetric regions being within a range of at least 0.5 cm. 3 and 10W / cm 2 ~900W / cm 2and an intensity within a range of 0.5-1.0.0.5. The system of embodiment 1, wherein the processor is configured with instructions for overlapping the plurality of volumetric regions. 7. The system of embodiment 5, wherein the processor is configured with instructions for moving the ultrasound transducer from a first position corresponding to the first volumetric region to a second position corresponding to the second volumetric region while the ultrasound transducer is transmitting the ultrasound beam. 8. The system of embodiment 5, wherein the linkage comprises a robotic arm including a plurality of joints, each of the plurality of joints being connected to an actuator for controlling an angle of the joint, and the processor is configured with instructions for determining a plurality of angles of the plurality of joints to direct the ultrasound beam to the plurality of positions. 9. The system of embodiment 5, wherein the processor is configured to control an orientation of the ultrasound transducer at each of the plurality of positions to align the ultrasound transducer with a surface of the patient's skin at each of the plurality of positions. 10. The system of embodiment 9, wherein the processor is configured to control an orientation of the ultrasound transducer at each of a plurality of positions to align the ultrasound transducer with a surface of the patient's skin at each of the plurality of positions, optionally where each of the plurality of positions corresponds to a three-dimensional position and a three-dimensional orientation to position the ultrasound transducer in six degrees of freedom. 11. The system of embodiment 5, wherein the robotic arm comprises a plurality of fingers, the ultrasound transducer including a plurality of transducers, each of the plurality of fingers being tethered to a transducer mounted thereon, and each of the plurality of fingers being configured to control a transducer angle of an ultrasound beam from a transducer mounted on the finger to direct the ultrasound beam to a target location. 12. The system of embodiment 1, further comprising a user input for the user to specify an adjunctive therapy to be combined with the ultrasound treatment, wherein the processor is configured with instructions for recording a treatment time of the ultrasound beam to the tissue and outputting a time for the adjunctive therapy, optionally, wherein the adjunctive therapy is selected from the group consisting of radiation therapy, chemotherapy, and immunotherapy, and optionally, the output time includes a time frame for the adjunctive therapy.13. The system of embodiment 1, wherein the processor is configured with instructions to provide a user interface to the user, the user interface including an image of the patient's tumor and an input treatment location. 14. The system of embodiment 1, wherein the processor is configured to perform tissue elastography of the whole tissue volume. 15. The system of embodiment 1, wherein the processor is configured to receive a diffusion parameter as an input. 16. A method of treating a patient, the method comprising: administering an immune stimulating energy selected from the group consisting of irreversible electroporation (IRE), microwave, low intensity focused ultrasound (LOFU), high intensity focused ultrasound (HIFU), radio frequency energy, and cryotherapy; and administering an immune therapy selected from the group consisting of dendritic cell targeted therapy, effector T cell targeting, and immune checkpoint inhibition. 17. The method of embodiment 16, wherein the dendritic cell targeted therapy is selected from the group consisting of Flt3L, CD40L, GM-CSF, ligands and agonists, RIG1 helicase activator, anti-CD40, NKG2D ligands, anti-CSF1R, anti-TLR, TLR ligands, INF-α, TNF-β. 18. The method of embodiment 16, wherein the effector T cell target is selected from the group consisting of anti-OX40, 4-1BBL, anti-foxp40 TGF-β inhibitors, anti-CD137, artificial immune synapse for T cell activation, anti-CD47, anti-CD27, and anti-GD2. 19. The method of embodiment 16, wherein the checkpoint inhibition is selected from the group consisting of anti-CTL4, anti-PD1, anti-VISTA, tim3, IDO inhibitors, norharmane, rosmarinic acid, COX-2 inhibitors, 1-methyltryptophan, epacadostat, and naboximide.

Claims

1. 1. An acoustic stimulation therapy system, comprising: A processor; One or more ultrasonic transducers coupled to the processor, the ultrasonic transducers providing one or more ultrasonic beams having a frequency waveform of 10 to 900 W / cm 2 The spatial peak time-averaged acoustic power intensity (I spta ) and at least 0.5 cm 3 one or more ultrasound transducers configured to generate one or more ultrasound beams having a beam volume of a probe coupled to the processor, the probe configured to monitor a patient; and A system comprising:

2. The processor and the ultrasonic transducer are configured to operate at a rate of at least about 0.5 cm per second. 3 The system of claim 1 , configured to volumetrically scan tissue at a rate of

3. The speed of scanning the entire tissue volume is approximately 0.5 cm per second. 3 ~Approx. 50cm 3 The system according to claim 1 or 2, wherein the range is

4. The system of claim 2 or 3, wherein the entire tissue volume is scanned.

5. The total tissue volume is at least about 2 cm 3 The system according to any one of claims 2 to 4,

6. Total tissue volume was approximately 0.5 cm 3 ~Approx. 1000cm 3 The system according to any one of claims 2 to 5, wherein the range is

7. The total tissue volume is approximately 1 cm 3 ~Approx. 500cm 3 The system according to any one of claims 2 to 6, wherein the range is

8. The total tissue volume is approximately 1 cm 3 ~Approx. 250cm 3 The system according to any one of claims 2 to 7, wherein the range is

9. The intensity is about 20 W / cm 2 ~Approx. 500W / cm 2 The system according to any one of claims 2 to 8, wherein the range is

10. The system of any one of claims 1 to 9, wherein the processor is configured with instructions for overlapping multiple locations.

11. 11. The system of claim 1, wherein the processor is configured with instructions for moving an ultrasound transducer from a first position corresponding to a first volumetric measurement area to a second position corresponding to a second volumetric measurement area while the ultrasound transducer is transmitting an ultrasound beam.

12. 12. The system of any one of claims 2 to 11, further comprising a linkage coupled to the one or more ultrasonic transducers, the processor coupled to the linkage and configured with instructions for moving the one or more ultrasonic transducers to a plurality of positions.

13. 13. The system of claim 12, wherein the linkage comprises a robotic arm including a plurality of joints, each of the plurality of joints being coupled to an actuator to control an angle of the joint, and the processor is configured with instructions to determine a plurality of angles of the plurality of joints to direct the ultrasound beam to a plurality of locations.

14. 14. The system of claim 13, wherein the robotic arm comprises a plurality of fingers, each of the plurality of fingers coupled to a transducer mounted thereon, and each of the plurality of fingers configured to control an angle of an ultrasound beam from the transducer mounted on the finger to direct the ultrasound beam at a target location.

15. The system of any one of claims 2 to 14, wherein the processor is configured to control an orientation of the ultrasound transducer at each of a plurality of positions to align the ultrasound transducer with a surface of the patient's skin at each of the plurality of positions.

16. 16. The system of claim 15, wherein the processor is configured to control an orientation of the ultrasound transducer at each of a plurality of positions to align the ultrasound transducer with a surface of the patient's skin at each of the plurality of positions, optionally where each of the plurality of positions corresponds to a three-dimensional position and a three-dimensional orientation to position the ultrasound transducer in six degrees of freedom.

17. 17. The system of any one of claims 1 to 16, further comprising: a user input for a user to specify an adjunctive therapy to be combined with ultrasound treatment, wherein the processor is configured with instructions for recording a treatment time of an ultrasound beam to tissue and outputting a time for the adjunctive therapy, optionally the adjunctive therapy being selected from the group consisting of radiation therapy, chemotherapy, immunotherapy, irreversible electroporation (IRE), microwave therapy, low intensity focused ultrasound (LOFU), and high intensity focused ultrasound (HIFU), and optionally the output time includes a time frame for the adjunctive therapy.

18. The system of any one of claims 1 to 17, wherein the processor is configured with instructions for providing a user interface to a user, the user interface including an image of a patient's tumor and an input treatment location.

19. The system of any one of claims 1 to 18, wherein the processor is configured to perform tissue elastography of the whole tissue volume.

20. The system of any one of claims 1 to 19, wherein the processor is configured to receive a diffusion parameter as an input.

21. The system of any one of claims 1 to 20, wherein the probe is an imaging probe.

22. The system of any one of claims 1 to 20, wherein the probe is a thermometer.

23. The system of claim 22 , wherein the probe is a thermocouple.

24. 23. The system of claim 22, wherein the probe is a fiber optic temperature probe.

25. 25. The system of claim 23 or 24, wherein the processor is configured to provide a temperature reading.

26. 25. The system of claim 23 or 24, wherein the processor is configured to issue a temperature alarm.

27. The system of any one of claims 1 to 26, wherein the probe includes a separate transducer for measuring ultrasound.

28. 30. The system of claim 27, wherein the probe uses elastography to monitor the effect of treatment on tissue.

29. The system of any one of claims 1 to 28, further comprising a cooling system.

30. The system according to any one of claims 17 to 29, wherein the adjuvant therapy is radiation therapy.

31. 31. The system of claim 30, wherein the radiation therapy is adjuvant ablative.

32. The system according to any one of claims 17 to 29, wherein the adjunctive therapy is IRE.

33. 33. The system of claim 32, wherein the IRE is administered for a period of about 30 seconds to about 180 seconds.

34. The system of any one of claims 17 to 29, wherein the auxiliary therapy is microwave therapy.

35. 35. The system of claim 34, wherein the microwave therapy is administered for a period of about 1 second to about 60 seconds and at a power of about 1 W to about 10 W.

36. The system according to any one of claims 17 to 29, wherein the adjuvant therapy is LOFU.

37. LOFU is about 1 to 1,000 W / cm 2 The spatial peak time-averaged acoustic power intensity (I spta 37. The system of claim 36, further comprising:

38. The system of claim 36 or 37, wherein the LOFU has an acoustic power of about 3W to 32W.

39. The system of any one of claims 36 to 38, wherein the LOFU is administered for a period of about 0.5 seconds to about 5 seconds.

40. The system of any one of claims 17 to 29, wherein the adjunctive therapy is HIFU.

41. The HIFU is about 1,000 to 2,000 W / cm 2 The spatial peak time-averaged acoustic power intensity (I spta 41. The system of claim 40, further comprising:

42. The system of claim 40 or 41, wherein the HIFU has an acoustic power of about 1W to 20W.

43. The system of any one of claims 40 to 42, wherein the HIFU is administered for a period of about 1 second to about 10 seconds.

44. The system according to any one of claims 17 to 29, wherein the adjuvant therapy is chemotherapy.

45. 45. The system of claim 44, wherein the chemotherapy comprises administering a chemotherapeutic agent.

46. 46. ​​The system of claim 45, wherein the chemotherapeutic agent is a proteasome inhibitor, a PI3 kinase inhibitor, an autophagy inhibitor, an mTOT inhibitor, a PPARγ agonist, a Cox-2 inhibitor, a calcium channel inhibitor, an ER stress inducer, a CHOP modulator, a nucleoside analog, an eIF2α phosphatase inhibitor, a protein ligand, or an HSP90 inhibitor.

47. 47. The system of claim 46, wherein the chemotherapeutic agent is bortezomib, 3-methyladenine, polyphenol (green tea) epigallocatechin gallate, genistein, curcumin, resveratrol, 15,16-dihydrodanshen I (Danshen root), chloroquine, rapamycin, temsirolimus, 4-O-carboxymethyl ascochlorin, celecoxib, verapamil, ritonavir, 3-thia fatty acid, tetradecylthioacetic acid, nelfinavir, cisplatin, gemcitabine, salubrinal, cycloheximide, TRAIL, 4-phenylbutyric acid, geldanamycin, 17-alianylamino-17-demethoxy-geldanamycin (17AAG), 17-dimethylamino-ethylamino-17-demethoxygeldanamycin (17DMAG), or vacuolin.

48. The system of claim 45, wherein the chemotherapeutic agent is an HSP90 inhibitor.

49. 49. The system of claim 48, wherein the chemotherapeutic agent is 17-allylamino-17-demethoxy-geldanamycin (17AAG).

50. The system according to any one of claims 1 to 29, wherein the adjunctive therapy is immunotherapy.

51. 51. The system of claim 50, wherein the immunotherapy is selected from the group consisting of dendritic cell targeted therapy, effector T cell targeting, and immune checkpoint inhibition.

52. 52. The system of claim 51, wherein the dendritic cell targeted therapy comprises an immunotherapeutic agent of dendritic cell targeted therapy selected from the group consisting of Flt3L, CD40L, GM-CSF, RIG1 helicase activator, anti-CD40, NKG2D ligand, anti-CSF1R, anti-TLR, TLR ligand, INF-α, and TNF-β.

53. 52. The system of claim 51 , wherein the effector T cell targeting comprises a T cell targeted immunotherapeutic selected from the group consisting of anti-OX40, 4-1BBL, anti-foxp40, TGF-β inhibitor, anti-CD137, artificial immune synapse for T cell activation, anti-CD47, anti-CD27, and anti-GD2.

54. 52. The system of claim 51, wherein the immune checkpoint inhibition comprises an immune checkpoint immunotherapeutic selected from the group consisting of anti-CTL4, anti-PD1, anti-VISTA, tim3, IDO inhibitors, norharman, rosmarinic acid, COX-2 inhibitors, 1-methyltryptophan, epacadostat, and navoximod.

55. 1. A method of treating a patient, the method comprising: administering immune stimulating energy selected from the group consisting of irreversible electroporation (IRE), microwaves, low intensity focused ultrasound (LOFU), high intensity focused ultrasound (HIFU), radiofrequency energy, and cryotherapy; administering an immunotherapy selected from the group consisting of dendritic cell targeted therapy, effector T cell targeting, and immune checkpoint inhibition; A method comprising:

56. 56. The method of claim 55, wherein the dendritic cell targeted therapy comprises an immunotherapeutic agent of the dendritic cell targeted therapy selected from the group consisting of Flt3L, CD40L, GM-CSF, RIG1 helicase activator, anti-CD40, NKG2D ligand, anti-CSF1R, anti-TLR, TLR ligand, INF-α, and TNF-β.

57. 56. The method of claim 55, wherein the effector T cell targeting comprises a T cell targeted immunotherapeutic selected from the group consisting of anti-OX40, 4-1BBL, anti-foxp40 TGF-β inhibitor, anti-CD137, artificial immune synapse for T cell activation, anti-CD47, anti-CD27, and anti-GD2.

58. 56. The method of claim 55, wherein the immune checkpoint inhibition comprises an immune checkpoint immunotherapeutic selected from the group consisting of anti-CTL4, anti-PD1, anti-VISTA, tim3, IDO inhibitors, norharman, rosmarinic acid, COX-2 inhibitors, 1-methyltryptophan, epacadostat, and navoximod.